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Recent extensive efforts to understand the complicated molecular mechanisms of 
melanoma development have led to the discovery and approval of the two most 
promising therapeutic options that target the CTLA4 and BRAF gene products: 
ipilimumab and vemurafenib, respectively. Underlying molecular complexity, 
functional redundancy among survival pathways and tumor heterogeneity can lead 
to intrinsic or de novo resistance to applied therapies in melanoma. Cancer is not 
driven by a single gene, but by a combination of multiple genes that perturb the 
core cellular functions that contribute to cancer evolution, and serve to maintain 
the cancer phenotype (tumor maintenance). Targeting different aberrations 
simultaneously may decrease the chance of resistance development. In view of 
the highly heterogeneous mutational signature of melanoma and the presence of 
abnormal redundant pathways and their subsequent crosstalk, it is important to 
develop successful therapies to identify cooperating oncogenes and reconstitute 
the genomic architecture that drives their synergistic effects.  
For this study, I investigated the systems biology of a tumor’s functional 
maintenance in melanoma as defined by hardwired somatic mutations. I show that 
copy number variations supported by the involvement of chromosomal structural 
mutations play a vital role in determining the transcriptional landscape of 
cutaneous melanoma. These somatic events organize the genome in such a way 
as to simultaneously activate oncogenic modules that can sustain the tumor’s 
functional maintenance. These events often result in the coordinated and 
concomitant gain and loss of multiple cancer-promoting and anti-growth genes 
xi 
 
with functional consequences for the cancer. Comprehensive integrative analysis 
and functional validation in one melanoma patient with a complex set of tumors 
and cell lines confirmed the biological significance of these somatic events, and 
strongly suggested the presence of a functional module. A maintenance functional 
module is defined as a core set of somatic events persisting throughout the tumor 
evolution of any melanoma patient, and this is essential to sustaining the tumor’s 
functional maintenance.   
I also show that the components of a maintenance functional module perform in a 
cooperative manner with significant effect on tumor proliferation. The presence of 
synergy between components of the functional module with vemurafenib is strong 
evidence of the biological importance of hardwired genomic mutations 
constructing a network of significantly correlated genes, with at least an additive 
effect on tumor proliferation. 
Finally, I discovered a universal functional module in melanoma. The significant 
enrichment of this module on several chromosomal segments suggests the 
importance of these segments harboring blocks of hardwired and functionally 
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BUB3 BUB3 mitotic checkpoint protein 10q24 
BUD31 BUD31 homolog (S. cerevisiae) 7q22 
C10orf90 chromosome 10 open reading frame 90 10q26 
C11orf16 chromosome 11 open reading frame 16 11p15 
C12orf11 asunder spermatogenesis regulator 12p12 
C19orf71 chromosome 19 open reading frame 71 19p13 
C1GALT1 
core 1 synthase, glycoprotein-N-acetylgalactosamine 3-beta-
galactosyltransferase 1 7p21 
C1R complement component 1, r subcomponent 12p13 
C6orf218 long intergenic non-protein coding RNA 518 6p24 
C7orf13 long intergenic non-protein coding RNA 1006 7q36 
C9orf53 CDKN2A antisense RNA 1 (head to head) 9p21 
CA8 carbonic anhydrase VIII 8q12 
CADM2 cell adhesion molecule 2 3p12 
CAP2 CAP, adenylate cyclase-associated protein, 2 (yeast) 6p22 
CASP2 caspase 2, apoptosis-related cysteine peptidase 7q34 
CBL Cbl proto-oncogene, E3 ubiquitin protein ligase 11q23 
CBWD1 COBW domain containing 1 9p24 
CCDC15 coiled-coil domain containing 15 11q24 
CCDC6 coiled-coil domain containing 6 10q21 
CCL2 chemokine (C-C motif) ligand 2 17q11 
CCND1 Cyclin D1 11q13 
CCNT1 cyclin T1 12q13 
CCT6P1 chaperonin containing TCP1, subunit 6 (zeta) pseudogene 1 7q11 
CD74 
CD74 molecule, major histocompatibility complex, class II invariant 
chain 5q32 
CDC123 cell division cycle 123 10p13 
CDC27 cell division cycle 27 17q21 
CDC37L1 cell division cycle 37-like 1 9p24 
CDC40 cell division cycle 40 6q22 
CDH3 cadherin 3 16q22 
CDK1 cyclin-dependent kinase 1 10q21 
CDK13 cyclin-dependent kinase 13 7p14 
xxiii 
 
CDK2 cyclin-dependent kinase 2 12q13 
CDK20 cyclin-dependent kinase 20 9q22 
CDK4 cyclin-dependent kinase 4 12q13 
CDK5RAP1 CDK5 regulatory subunit associated protein 1 20q11 
CDKN2a cyclin-dependent kinase inhibitor 2A 9p21 
CDKN2B cyclin-dependent kinase inhibitor 2B (p15, inhibits CDK4) 9p21 
CDKN2BAS CDKN2B antisense RNA 1 9p21 
CEBPB CCAAT/enhancer binding protein (C/EBP), beta 20q13 
CENPW centromere protein W 6q22 
CEP57L1 centrosomal protein 57kDa-like 1 6q21 
CHCHD1 coiled-coil-helix-coiled-coil-helix domain containing 1 10q22 
CHEK2 checkpoint kinase 2 22q12 
CHMP4B charged multivesicular body protein 4B 20q11 
CHPF2 chondroitin polymerizing factor 2 7q36 
CHST12 carbohydrate (chondroitin 4) sulfotransferase 12 7p22 
CHTOP chromatin target of PRMT1 1q21 
CHUK conserved helix-loop-helix ubiquitous kinase 10q24 
CISD1 CDGSH iron sulfur domain 1 10q21 
CLK2 CDC-like kinase 2 1q21 
CLU clusterin 8p21 
CLU1 clusterin 8p21 
CMAS cytidine monophosphate N-acetylneuraminic acid synthetase 12p12 
C-myc v-myc avian myelocytomatosis viral oncogene homolog 8q24 
CNNM2 cyclin and CBS domain divalent metal cation transport mediator 2 10q24 
CNOT4 CCR4-NOT transcription complex, subunit 4 7q33 
CNPY4 canopy FGF signaling regulator 4 7q22 
COG5 component of oligomeric golgi complex 5 7q31 
COL11A1 collagen, type XI, alpha 1 1p21 
COL1A1 collagen, type I, alpha 1 17q21 
COL22A1 collagen, type XXII, alpha 1 8q24 
COL4A6 collagen, type IV, alpha 6 Xq22 
COL6A5 collagen, type VI, alpha 5 3q21 
COMMD7 COMM domain containing 7 20q11 
COPG2 coatomer protein complex, subunit gamma 2 7q32 
COPS6 COP9 signalosome subunit 6 7q22 
COQ3 coenzyme Q3 methyltransferase 6q21 
COX15 cytochrome c oxidase assembly homolog 15 (yeast) 10q24 
CPNE1 copine I 20q11 
CPSF4 cleavage and polyadenylation specific factor 4, 30kDa 7q22 
CRAF Raf-1 proto-oncogene, serine/threonine kinase 3p25 
CRCP CGRP receptor component 7q11 
xxiv 
 
CREB5 cAMP responsive element binding protein 5 7p15 
CRLS1 cardiolipin synthase 1 20p13 
CRTC2 CREB regulated transcription coactivator 2 1q21 
CRYAB crystallin, alpha B 11q22 
CSRP2 cysteine and glycine-rich protein 2 12q21 
CSTF2T cleavage stimulation factor, 3' pre-RNA, subunit 2, 64kDa, tau variant 10q11 
CTBP2 C-terminal binding protein 2 10q26 
CTCF CCCTC-binding factor (zinc finger protein) 16q21 
CTGF connective tissue growth factor 6q23 
CTLA4 Cytotoxic T-Lymphocyte-Associated Protein 4 2q33 
CTNNBL1 catenin, beta like 1 20q11 
CTSS cathepsin S 1q21 
CTTNBP2 cortactin binding protein 2 7q31 
CUEDC2 CUE domain containing 2 10q24 
CUL1 cullin 1 7q36 
CUL2 cullin 2 10p11 
CUL4B cullin 4B Xq23 
CUL7 cullin 7 6p21 
CUTC cutC copper transporter 10q24 
CWF19L1 CWF19-like 1, cell cycle control (S. pombe) 10q24 
CXorf30 cilia and flagella associated protein 47 Xp21 
CYB5R4 cytochrome b5 reductase 4 6q14 
CYGB cytoglobin 17q25 
CYR61 cysteine-rich, angiogenic inducer, 61 1p22 
CYSLTR2 cysteinyl leukotriene receptor 2 13q14 
DBF4 DBF4 zinc finger 7q21 
DCAF4 DDB1 and CUL4 associated factor 4 14q24 
DCAF8L1 DDB1 and CUL4 associated factor 8-like 1 Xp22 
DCT dopachrome tautomerase 13q32 
DDX27 DEAD (Asp-Glu-Ala-Asp) box polypeptide 27 20q13 
DDX6 DEAD (Asp-Glu-Ala-Asp) box helicase 6 11q23 
DENND4C DENN/MADD domain containing 4C 9p22 
DENND5B DENN/MADD domain containing 5B 12p11 
DGAT2L6 diacylglycerol O-acyltransferase 2-like 6 Xq13 
DHX32 DEAH (Asp-Glu-Ala-His) box polypeptide 32 10q26 
DHX35 DEAH (Asp-Glu-Ala-His) box polypeptide 35 20q11 
DIDO1 death inducer-obliterator 1 20q13 
DIP2C DIP2 disco-interacting protein 2 homolog C (Drosophila) 10p15 
DLAT dihydrolipoamide S-acetyltransferase 11q23 
DLG3 
membrane protein, palmitoylated 3 (MAGUK p55 subfamily member 
3) 17q12 
DLGAP2 discs, large (Drosophila) homolog-associated protein 2 8p23 
xxv 
 
DNAH14 dynein, axonemal, heavy chain 14 1q42 
DNAH5 dynein, axonemal, heavy chain 5 5p15 
DNAJA4 DnaJ (Hsp40) homolog, subfamily A, member 4 15q24 
DNAJC2 DnaJ (Hsp40) homolog, subfamily C, member 2 7q22 
DNAJC22 DnaJ (Hsp40) homolog, subfamily C, member 22 12q13 
DNAJC30 DnaJ (Hsp40) homolog, subfamily C, member 30 7q11 
DNAJC9 DnaJ (Hsp40) homolog, subfamily C, member 9 10q22 
DNAL4 dynein, axonemal, light chain 4 22q13 
DNM1L dynamin 1-like 12p11 
DNMT1 DNA (cytosine-5-)-methyltransferase 1 19p13 
DOCK1 dedicator of cytokinesis 1 10q26 
DOLPP1 dolichyldiphosphatase 1 9q34 
DOPEY1 dopey family member 1 6q15 
DPM1 
dolichyl-phosphate mannosyltransferase polypeptide 1, catalytic 
subunit 20q13 
DPP6 dipeptidyl-peptidase 6 7q36 
DPY19L3 dpy-19-like 3 (C. elegans) 19q13 
DSTYK dual serine/threonine and tyrosine protein kinase 1q32 
DTNBP1 dystrobrevin binding protein 1 6p22 
DUS4L dihydrouridine synthase 4-like (S. cerevisiae) 7q22 
DYNC1H1 dynein, cytoplasmic 1, heavy chain 1 14q32 
DYNC2H1 dynein, cytoplasmic 2, heavy chain 1 11q21 
E-Cadherin Cadherin 1, Type 1, E-Cadherin (Epithelial) 16q22 
ECE1 endothelin converting enzyme 1 1p36 
ECHDC1 ethylmalonyl-CoA decarboxylase 1 6q22 
ECHS1 enoyl CoA hydratase, short chain, 1, mitochondrial 10q26 
EDNRB endothelin receptor type B 13q22 
EEF1A1 eukaryotic translation elongation factor 1 alpha 1 6q14 
EI24 etoposide induced 2.4 11q24 
EIF3A eukaryotic translation initiation factor 3, subunit A 10q26 
EIF4EBP2 eukaryotic translation initiation factor 4E binding protein 2 10q21 
ELAVL2 ELAV like neuron-specific RNA binding protein 2 9p21 
EML5 echinoderm microtubule associated protein like 5 14q31 
EN2 engrailed homeobox 2 7q36 
ENSA endosulfine alpha 1q21 
EPB41L1 erythrocyte membrane protein band 4.1-like 1 20q11 
EPHB4 EPH receptor B4 7q22 
EPM2A epilepsy, progressive myoclonus type 2A, Lafora disease (laforin) 6q24 
ERCC6 excision repair cross-complementation group 6 10q11 
ERGIC2 ERGIC and golgi 2 12p11 
ERGIC3 ERGIC and golgi 3 20q11 
ERLIN1 ER lipid raft associated 1 10q24 
xxvi 
 
ERMP1 endoplasmic reticulum metallopeptidase 1 9p24 
ESRP1 epithelial splicing regulatory protein 1 8q22 
ESYT2 extended synaptotagmin-like protein 2 7q36 
ETV1 ets variant 1 7p22 
EZH2 enhancer of zeste 2 polycomb repressive complex 2 subunit 7q35 
EZR ezrin 6q25 
FAM115C TRPM8 channel-associated factor 2 7q35 
FAM118B family with sequence similarity 118, member B 11q24 
FAM120A family with sequence similarity 120A 9q22 
FAM120B family with sequence similarity 120B 6q27 
FAM149B1 family with sequence similarity 149, member B1 10q22 
FAM175B family with sequence similarity 175, member B 10q26 
FAM204A family with sequence similarity 204, member A 10q26 
FAM21A family with sequence similarity 21, member A 10q11 
FAM21C family with sequence similarity 21, member C 10q11 
FAM3C family with sequence similarity 3, member C 7q22 
FAM45A family with sequence similarity 45, member A 10q25 
FAM53B family with sequence similarity 53, member B 10q26 
FAM9A family with sequence similarity 9, member A Xp22 
FANCC Fanconi anemia, complementation group C 9q22 
FASTK Fas-activated serine/threonine kinase 7q35 
FBXL4 F-box and leucine-rich repeat protein 4 6q16 
FBXO18 F-box protein, helicase, 18 10p15 
FBXO25 F-box protein 25 8p23 
FBXO30 F-box protein 30 6q24 
FBXO5 F-box protein 5 6q25 
FBXW2 F-box and WD repeat domain containing 2 9q34 
FDX1 ferredoxin 1 11q22 
FDXACB1 ferredoxin-fold anticodon binding domain containing 1 11q23 
FGFR3 Fibroblast Growth Factor Receptor 3 4p16 
FIG4 FIG4 phosphoinositide 5-phosphatase 6q21 
Fos FBJ murine osteosarcoma viral oncogene homolog 14q24 
FOXI1 forkhead box I1 5q34 
FOXP4 forkhead box P4 6p21 
FPR3 formyl peptide receptor 3 19q13 
FTSJD2 cap methyltransferase 1 6p21 
FUT11 fucosyltransferase 11 (alpha (1,3) fucosyltransferase) 10q22 
FXN frataxin 9q21 
GADD45 Growth Arrest And DNA-Damage-Inducible, Alpha 1p31 
GADD45B growth arrest and DNA-damage-inducible, beta 19p13 
GALNT11 polypeptide N-acetylgalactosaminyltransferase 11 7q36 
xxvii 
 
GAPDH glyceraldehyde-3-phosphate dehydrogenase 12p13 
GAPVD1 GTPase activating protein and VPS9 domains 1 9q34 
GATAD1 GATA zinc finger domain containing 1 7q21 
GCNT2 
glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood 
group) 6p24 
GDI2 GDP dissociation inhibitor 2 10p15 
GET4 golgi to ER traffic protein 4 homolog (S. cerevisiae) 7p22 
GGT7 gamma-glutamyltransferase 7 20q11 
GHITM growth hormone inducible transmembrane protein 10q23 
GLE1 GLE1 RNA export mediator 9q34 
GLI1 GLI family zinc finger 1 12q13 
GLI3 GLI family zinc finger 3 7p13 
GLRX3 glutaredoxin 3 10q26 
GLUD1 glutamate dehydrogenase 1 10q23 
GLUT1 solute carrier family 2 (facilitated glucose transporter), member 1 1p34 
GNA11 guanine nucleotide binding protein (G protein), alpha 11 (Gq class) 19p13 
GNAQ guanine nucleotide binding protein (G protein), q polypeptide 9q21 
GOLT1B golgi transport 1B 12p13 
GON4L gon-4-like (C. elegans) 1q22 
GOPC golgi-associated PDZ and coiled-coil motif containing 6q21 
GORAB golgin, RAB6-interacting 1q24 
GPATCH4 G patch domain containing 4 1q22 
GPC5 glypican 5 13q32 
GPR98 adhesion G protein-coupled receptor V1 5q13 
GRAMD1B GRAM domain containing 1B 11q24 
GRB10 growth factor receptor-bound protein 10 7p12 
GRHPR glyoxylate reductase/hydroxypyruvate reductase 9q12 
GSK3β glycogen synthase kinase 3 beta 3q13 
GSTK1 glutathione S-transferase kappa 1 7q34 
GTF2H5 general transcription factor IIH, polypeptide 5 6q25 
GTF3C6 general transcription factor IIIC, polypeptide 6, alpha 35kDa 6q21 
GUSB glucuronidase, beta 7q11 
GXYLT1 glucoside xylosyltransferase 1 12q12 
H2AFV H2A histone family, member V 7p13 
H3F3C H3 histone, family 3C 12p11 
HACE1 
HECT domain and ankyrin repeat containing E3 ubiquitin protein 
ligase 1 6q21 
HAUS6 HAUS augmin-like complex, subunit 6 9p22 
HBP1 HMG-box transcription factor 1 7q22 
HBS1L HBS1-like translational GTPase 6q23 
HDAC1 histone deacetylase 1 1p34 
HDDC2 HD domain containing 2 6q13 
xxviii 
 
HERC2 HECT and RLD domain containing E3 ubiquitin protein ligase 2 15q13 
HERC4 HECT and RLD domain containing E3 ubiquitin protein ligase 4 10q21 
HERPUD2 HERPUD family member 2 7p14 
HGF Hepatocyte Growth Factor 7q21 
HIATL1 hippocampus abundant transcript-like 1 9q22 
HIF1AN hypoxia inducible factor 1, alpha subunit inhibitor 10q24 
HIF-1α Hypoxia Inducible Factor 1 14q23 
HIP1 huntingtin interacting protein 1 7q11 
HIPK2 homeodomain interacting protein kinase 2 7q34 
HMMR hyaluronan-mediated motility receptor (RHAMM) 5q34 
HOXA3 homeobox A3 7p15 
HOXA4 homeobox A4 7p15 
HPS6 Hermansky-Pudlak syndrome 6 10q24 
HSF2 heat shock transcription factor 2 6q22 
HSPB2 heat shock 27kDa protein 2 11q22 
HYLS1 hydrolethalus syndrome 1 11q24 
IBTK inhibitor of Bruton agammaglobulinemia tyrosine kinase 6q14 
ICAM1 intercellular adhesion molecule 1 19p13 
ID3 inhibitor of DNA binding 3, dominant negative helix-loop-helix protein 1p36 
IDE insulin-degrading enzyme 10q23 
IDUA iduronidase, alpha-L- 4p16 
IFRD1 interferon-related developmental regulator 1 7q31 
IFT81 intraflagellar transport 81 12q24 
IGF2R insulin-like growth factor 2 receptor 6q25 
IGFBP3 insulin-like growth factor binding protein 3 7p12 
IGSF11 immunoglobulin superfamily, member 11 3q21 
IL1 interleukin 1, alpha 2q14 
IL2 interleukin 2 4q26 
IL31RA interleukin 31 receptor A 5q11 
IL8 interleukin 8 4q13 
ING3 inhibitor of growth family, member 3 7q31 
INHBA inhibin, beta A 7p15 
INK4a cyclin-dependent kinase inhibitor 2A 9p21 
INPP5A inositol polyphosphate-5-phosphatase, 40kDa 10q26 
INSIG1 insulin induced gene 1 7q36 
INVS inversin 9q31 
IPO8 importin 8 12p11 
IRF1 interferon regulatory factor 1 5q23 
ITGB8 integrin, beta 8 7p15 
ITIH5L inter-alpha-trypsin inhibitor heavy chain family, member 6 Xp11 
JAM3 junctional adhesion molecule 3 11q25 
xxix 
 
JARID2 jumonji, AT rich interactive domain 2 6p24 
JHDM1D lysine (K)-specific demethylase 7A 7q34 
JTB jumping translocation breakpoint 1q21 
KANK1 KN motif and ankyrin repeat domains 1 9p24 
KBTBD2 kelch repeat and BTB (POZ) domain containing 2 7p14 
KCNIP3 Kv channel interacting protein 3, calsenilin 2q21 
KCNN4 
potassium channel, calcium activated intermediate/small conductance 
subfamily N alpha, member 4 19q13 
KDM6B lysine (K)-specific demethylase 6B 17p13 
KHDRBS3 KH domain containing, RNA binding, signal transduction associated 3 8q24 
KIAA0368 KIAA0368 9q32 
KIAA0528 C2 calcium-dependent domain containing 5 12p12 
KIAA0895 KIAA0895 7p14 
KIAA0907 KIAA0907 1q22 
KIAA1199 cell migration inducing protein, hyaluronan binding 15q25 
KIAA1279 KIF1 binding protein 10q22 
KIAA1432 RAB6A GEF complex partner 1 9p24 
KIAA2026 KIAA2026 9p24 
KIF16B kinesin family member 16B 20p11 
KIF24 kinesin family member 24 9p13 
KIT v-kit Hardy-Zuckerman 4 feline sarcoma viral oncogene homolog 4q12 
KLC1 kinesin light chain 1 14q32 
KLHL9 kelch-like family member 9 9p22 
KRAS Kirsten rat sarcoma viral oncogene homolog 12p12 
KRBA1 KRAB-A domain containing 1 7q36 
KRIT1 KRIT1, ankyrin repeat containing 7q21 
L3MBTL2 l(3)mbt-like 2 (Drosophila) 22q13 
LACE1 lactation elevated 1 6q22 
LAPTM5 lysosomal protein transmembrane 5 1p34 
LARP4 La ribonucleoprotein domain family, member 4 12q13 
LARP4B La ribonucleoprotein domain family, member 4B 10p15 
LDB1 LIM domain binding 1 10q24 
LDHB lactate dehydrogenase B 12p12 
LEF1 lymphoid enhancer-binding factor 1 4q23 
LEMD2 LEM domain containing 2 6p21 
LGALS9C lectin, galactoside-binding, soluble, 9C 17p11 
LGI3 leucine-rich repeat LGI family, member 3 8p21 
LIF Leukemia Inhibitory Factor 22q12 
LINC00174 long intergenic non-protein coding RNA 174 7q11 
LKB1 serine/threonine kinase 11 19p13 
LMBR1 limb development membrane protein 1 7q36 
LOC100128822 - 7q36 
xxx 
 
LOC100134229 - 7q34 
LOC100216545 KMT2E antisense RNA 1 (head to head) 7q22 
LOC100270746 ncRNA 6p22 
LOC154761 Family With Sequence Similarity 115, Member C Pseudogene 7q35 
LOC202781 - 7q36 
LOC401431 ATP6V0E2 Antisense RNA 1 7q36 
LOC441204 ncRNA 7p15 
LOC493754 RAB guanine nucleotide exchange factor (GEF) 1 pseudogene 7q11 
LOC646762 ncRNA 7p14 
LRP3 low density lipoprotein receptor-related protein 3 19q13 
LRRC27 leucine rich repeat containing 27 10q26 
LRRC43 leucine rich repeat containing 43 12q24 
LRRC8A leucine rich repeat containing 8 family, member A 9q34 
LSM5 LSM5 homolog, U6 small nuclear RNA associated (S. cerevisiae) 7p14 
LUC7L2 LUC7-like 2 (S. cerevisiae) 7q34 
LUZP6 leucine zipper protein 6 7q33 
LYRM2 LYR motif containing 2 6q15 
LZTS2 leucine zipper, putative tumor suppressor 2 10q24 
MAGE-A1 Melanoma Antigen Family A 1 Xq28 
MAGE-A3 Melanoma Antigen Family A 3 Xq28 
MAP1LC3A microtubule-associated protein 1 light chain 3 alpha 20q11 
MAP3K4 mitogen-activated protein kinase kinase kinase 4 6q26 
MAP7D2 MAP7 domain containing 2 Xp22 
MAPK10 mitogen-activated protein kinase 10 4q22 
MAPK8 mitogen-activated protein kinase 8 10q11 
MAPKAP1 mitogen-activated protein kinase associated protein 1 9q34 
MARCKS myristoylated alanine-rich protein kinase C substrate 6q21 
MC1-R 
Melanocortin 1 Receptor (Alpha Melanocyte Stimulating Hormone 
Receptor) 16q24 
MCAM melanoma cell adhesion molecule 11q23 
MCF2L MCF.2 cell line derived transforming sequence-like 13q34 
MCL1 myeloid cell leukemia 1 1q21 
MCMBP minichromosome maintenance complex binding protein 10q26 
MDK midkine (neurite growth-promoting factor 2) 11p11 
MDM2 MDM2 proto-oncogene, E3 ubiquitin protein ligase 12q13 
MDN1 MDN1, midasin homolog (yeast) 6q15 
MED17 mediator complex subunit 17 11q21 
MED21 mediator complex subunit 21 12p12 
MEK1 mitogen-activated protein kinase kinase 1 15q22 
MET MET proto-oncogene, receptor tyrosine kinase 7q31 
MFAP2 microfibrillar-associated protein 2 1p36 
MGC72080 pseudogene 7q21 
xxxi 
 
MGC87042 STEAP Family Member 1B 7p15 
MICALL2 MICAL-like 2 7p22 
MICU1 mitochondrial calcium uptake 1 10q22 
MITF microphthalmia-associated transcription factor 3p14 
MKLN1 muskelin 1, intracellular mediator containing kelch motifs 7q32 
MLANA melan-A 9p24 
MLANA melan-A 9p24 
MLL3 lysine (K)-specific methyltransferase 2C 7q36 
MLL5 lysine (K)-specific methyltransferase 2E 7q22 
MLLT3 
myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, 
Drosophila); translocated to, 3 9p22 
MME membrane metallo-endopeptidase 3q25 
MMS19 MMS19 nucleotide excision repair homolog (S. cerevisiae) 10q24 
MMS22L MMS22-like, DNA repair protein 6q16 
MnSOD Superoxide Dismutase 2, Mitochondrial 6q25 
MOB3B MOB kinase activator 3B 9p21 
MOSPD3 motile sperm domain containing 3 7q22 
MPP3 
membrane protein, palmitoylated 3 (MAGUK p55 subfamily member 
3) 17q12 
MRPL15 mitochondrial ribosomal protein L15 8q11 
MRPL18 mitochondrial ribosomal protein L18 6q25 
MRPS16 mitochondrial ribosomal protein S16 10q22 
MRPS17 mitochondrial ribosomal protein S17 7p11 
MRPS33 mitochondrial ribosomal protein S33 7q34 
MTAP methylthioadenosine phosphorylase 9p21 
MTERFD1 mitochondrial transcription termination factor 3 8q22 
MTHFD1L methylenetetrahydrofolate dehydrogenase (NADP+ dependent) 1-like 6q25 
MTMR10 myotubularin related protein 10 15q13 
MTO1 mitochondrial tRNA translation optimization 1 6q14 
MTPAP mitochondrial poly(A) polymerase 10p12 
MTRF1L mitochondrial translational release factor 1-like 6q25 
MTSS1 metastasis suppressor 1 8p22 
MUC5B mucin 5B, oligomeric mucus/gel-forming 11p15 
MUM1L1 melanoma associated antigen (mutated) 1-like 1 Xq22 
MXRA5 matrix-remodelling associated 5 Xp22 
NAA20 N(alpha)-acetyltransferase 20, NatB catalytic subunit 20p11 
NANOG Nanog homeobox 12p13 
NCAD Cadherin 2, Type 1, N-Cadherin (Neuronal) 18q12 
NCAPD3 non-SMC condensin II complex, subunit D3 11q25 
NCAPG2 non-SMC condensin II complex, subunit G2 7q36 
NCBP1 nuclear cap binding protein subunit 1, 80kDa 9q34 
NCOA4 nuclear receptor coactivator 4 10q11 
xxxii 
 
NDST2 N-deacetylase/N-sulfotransferase (heparan glucosaminyl) 2 10q22 
NDUFA4 NDUFA4, mitochondrial complex associated 7p21 
NDUFAF4 NADH dehydrogenase (ubiquinone) complex I, assembly factor 4 6q16 
NDUFB2 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2, 8kDa 7q34 
NDUFB6 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 6, 17kDa 9p13 
NDUFB9 NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 9, 22kDa 8q24 
NEK6 NIMA-related kinase 6 9q33 
NEU1 sialidase 1 (lysosomal sialidase) 6p21 
NFE2L3 nuclear factor, erythroid 2-like 3 7p15 
NFIB nuclear factor I/B 9p24 
NFkB1 nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 4q24 
NFRKB nuclear factor related to kappaB binding protein 11q24 
NHSL1 NHS-like 1 6q23 
NLRP2 NLR family, pyrin domain containing 2 19q13 
NOLC1 nucleolar and coiled-body phosphoprotein 1 10q24 
NOM1 nucleolar protein with MIF4G domain 1 7q36 
NPAT nuclear protein, ataxia-telangiectasia locus 11q22 
NR3C1 
nuclear receptor subfamily 3, group C, member 1 (glucocorticoid 
receptor) 5q31 
NRAS neuroblastoma RAS viral (v-ras) oncogene homolog 1p13 
NRBF2 nuclear receptor binding factor 2 10q22 
NRBP2 nuclear receptor binding protein 2 8q24 
NT5DC1 5'-nucleotidase domain containing 1 6q22 
NUB1 negative regulator of ubiquitin-like proteins 1 7q36 
NUDCD1 NudC domain containing 1 8q23 
NUDCD3 NudC domain containing 3 7p13 
NUDT2 nudix (nucleoside diphosphate linked moiety X)-type motif 2 9p13 
NUP188 nucleoporin 188kDa 9q34 
NUP43 nucleoporin 43kDa 6q25 
NUPL2 nucleoporin like 2 7p15 
OAT ornithine aminotransferase 10q26 
OBFC1 oligonucleotide/oligosaccharide-binding fold containing 1 10q25 
OCIAD2 OCIA domain containing 2 4p12 
ODC1 ornithine decarboxylase 1 2p25 
OPTN optineurin 10p14 
OR11G2 olfactory receptor, family 11, subfamily G, member 2 14q11 
OR51F1 
olfactory receptor, family 51, subfamily F, member 1 
(gene/pseudogene) 11p15 
OR6C4 olfactory receptor, family 6, subfamily C, member 4 12q14 
OR8D1 olfactory receptor, family 8, subfamily D, member 1 11q25 
ORC5 origin recognition complex, subunit 5 7q22 
OSBPL2 oxysterol binding protein-like 2 20q13 
xxxiii 
 
OSTM1 osteopetrosis associated transmembrane protein 1 6q21 
OXER1 oxoeicosanoid (OXE) receptor 1 2p22 
p27 Cyclin-Dependent Kinase Inhibitor 1B  12p13 
P2RX7 purinergic receptor P2X, ligand gated ion channel, 7 12q24 
P2RY2 purinergic receptor P2Y, G-protein coupled, 2 11q13 
p38 mitogen-activated protein kinase 14 6p21 
P53 tumor protein p53 17p13 
PADI4 peptidyl arginine deiminase, type IV 1p36 
PAFAH1B2 
platelet-activating factor acetylhydrolase 1b, catalytic subunit 2 
(30kDa) 11q23 
PAG1 
phosphoprotein membrane anchor with glycosphingolipid 
microdomains 1 8q21 
PAK1IP1 PAK1 interacting protein 1 6p24 
PAOX polyamine oxidase (exo-N4-amino) 10q26 
PARG poly (ADP-ribose) glycohydrolase 10q11 
PARVB parvin, beta 22q13 
PAX1 Paired Box Gene 3 (Waardenburg Syndrome 1) 2q36 
PAXIP1 PAX interacting (with transcription-activation domain) protein 1 7q36 
PCDHGA12 protocadherin gamma subfamily A, 12 5q31 
PCGF6 polycomb group ring finger 6 10q24 
PCMT1 protein-L-isoaspartate (D-aspartate) O-methyltransferase 6q25 
PCMTD2 
protein-L-isoaspartate (D-aspartate) O-methyltransferase domain 
containing 2 20q13 
PDCD11 programmed cell death 11 10q24 
PDCD1LG2 programmed cell death 1 ligand 2 9p24 
PDCD2 programmed cell death 2 6q27 
PDE2A phosphodiesterase 2A, cGMP-stimulated 11q13 
PDGFa Platelet-Derived Growth Factor Alpha Chain 7p22 
PDGFb Platelet-Derived Growth Factor Beta Polypeptide 22q13 
PDIA4 protein disulfide isomerase family A, member 4 7q35 
PD-L1 CD274 molecule 9p24 
PDRG1 p53 and DNA-damage regulated 1 20q11 
PDZD8 PDZ domain containing 8 10q26 
PEX3 peroxisomal biogenesis factor 3 6q24 
PEX6 peroxisomal biogenesis factor 6 6p22 
PFDN2 prefoldin subunit 2 1q23 
PFDN4 prefoldin subunit 4 20q13 
PGAM1 phosphoglycerate mutase 1 (brain) 10q25 
PGBD3 piggyBac transposable element derived 3 10q11 
PGM3 phosphoglucomutase 3 6q14 
PHF14 PHD finger protein 14 7p21 
PHF5A PHD finger protein 5A 22q13 




phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit 
alpha 3q26 
PI4K2A phosphatidylinositol 4-kinase type 2 alpha 10q24 
PIGT phosphatidylinositol glycan anchor biosynthesis, class T 20q12 
PIM3 Pim-3 proto-oncogene, serine/threonine kinase 22q13 
PITRM1 pitrilysin metallopeptidase 1 10p15 
PKHD1L1 polycystic kidney and hepatic disease 1 (autosomal recessive)-like 1 8q23 
PKNOX2 PBX/knotted 1 homeobox 2 11q24 
PKP2 plakophilin 2 12p11 
PLAA phospholipase A2-activating protein 9p21 
PLK1 polo-like kinase 1 16p 
PMPCB peptidase (mitochondrial processing) beta 7q22 
PMS2CL PMS2 C-terminal like pseudogene 7p22 
PMS2P1 postmeiotic segregation increased 2 pseudogene 1 7q22 
PMS2P5 postmeiotic segregation increased 2 pseudogene 5 7q11 
POLE3 polymerase (DNA directed), epsilon 3, accessory subunit 9q33 
POLM polymerase (DNA directed), mu 7p13 
POLR1C polymerase (RNA) I polypeptide C, 30kDa 6p21 
POLR2J polymerase (RNA) II (DNA directed) polypeptide J, 13.3kDa 7q11 
POLR3A polymerase (RNA) III (DNA directed) polypeptide A, 155kDa 10q22 
POM121C POM121 transmembrane nucleoporin C 7q11 
PPAPDC2 phosphatidic acid phosphatase type 2 domain containing 2 9p24 
PPIA peptidylprolyl isomerase A (cyclophilin A) 7p13 
PPP1R12C protein phosphatase 1, regulatory subunit 12C 19q13 
PPP1R35 protein phosphatase 1, regulatory subunit 35 7q22 
PPP2R2D protein phosphatase 2, regulatory subunit B, delta 10q26 
PPP3CB protein phosphatase 3, catalytic subunit, beta isozyme 10q22 
PPP6C protein phosphatase 6, catalytic subunit 9q33 
PPP6R3 protein phosphatase 6, regulatory subunit 3 11q13 
PRAME preferentially expressed antigen in melanoma 22q11 
PRCC papillary renal cell carcinoma (translocation-associated) 1q21 
PRDX3 peroxiredoxin 3 10q25 
PRKAG2 protein kinase, AMP-activated, gamma 2 non-catalytic subunit 7q35 
PRKAR1B protein kinase, cAMP-dependent, regulatory, type I, beta 7p22 
PRKAR2B protein kinase, cAMP-dependent, regulatory, type II, beta 7q22 
PRKRIP1 PRKR interacting protein 1 (IL11 inducible) 7q22 
PRKX protein kinase, X-linked Xp22 
PRPF3 pre-mRNA processing factor 3 1q21 
PRPF4 pre-mRNA processing factor 4 9q31 
PSMA2 proteasome (prosome, macropain) subunit, alpha type, 2 7p13 
PSMB7 proteasome (prosome, macropain) subunit, beta type, 7 9q34 
PSMC2 proteasome (prosome, macropain) 26S subunit, ATPase, 2 7q22 
xxxv 
 
PSMG3 proteasome (prosome, macropain) assembly chaperone 3 7p22 
PSMG4 proteasome (prosome, macropain) assembly chaperone 4 6p25 
PTCD1 pentatricopeptide repeat domain 1 7q22 
PTEN phosphatase and tensin homolog 10q23 
PTGR1 prostaglandin reductase 1 9q32 
PTPRK protein tyrosine phosphatase, receptor type, K 6q22 
PTPRZ1 protein tyrosine phosphatase, receptor-type, Z polypeptide 1 7q31 
PUS7 pseudouridylate synthase 7 (putative) 7q22 
PVRL1 poliovirus receptor-related 1 (herpesvirus entry mediator C) 11q23 
PXDC1 PX domain containing 1 6p25 
PYCR2 pyrroline-5-carboxylate reductase family, member 2 1q42 
PYCRL pyrroline-5-carboxylate reductase-like 8q24 
QKI QKI, KH domain containing, RNA binding 6q26 
QRSL1 glutaminyl-tRNA synthase (glutamine-hydrolyzing)-like 1 6q21 
RAB14 RAB14, member RAS oncogene family 9q32 
RAB18 RAB18, member RAS oncogene family 10p12 
RABGAP1 RAB GTPase activating protein 1 9q34 
RAC1 
ras-related C3 botulinum toxin substrate 1 (rho family, small GTP 
binding protein Rac1) 7p22 
RAC2 
ras-related C3 botulinum toxin substrate 2 (rho family, small GTP 
binding protein Rac2) 22q13 
RACGAP1 Rac GTPase activating protein 1 12q13 
RAE1 ribonucleic acid export 1 20q13 
RANBP6 RAN binding protein 6 9p24 
RASGRP2 RAS guanyl releasing protein 2 (calcium and DAG-regulated) 11q13 
RASSF8 Ras association (RalGDS/AF-6) domain family (N-terminal) member 8 12p12 
RB retinoblastoma 1 13q14 
RBM28 RNA binding motif protein 28 7q32 
RBM34 RNA binding motif protein 34 1q42 
RBM48 RNA binding motif protein 48 7q21 
RECQL RecQ helicase-like 12p12 
REPIN1 replication initiator 1 7q36 
REPS1 RALBP1 associated Eps domain containing 1 6q24 
REXO2 RNA exonuclease 2 11q23 
RGS10 regulator of G-protein signaling 10 10q25 
RHEB Ras homolog enriched in brain 7q36 
RIC3 RIC3 acetylcholine receptor chaperone 11p15 
RINT1 RAD50 interactor 1 7q22 
RNF114 ring finger protein 114 20q13 
RNF146 ring finger protein 146 6q22 
RNF216 ring finger protein 216 7p22 
RNF216P1 ring finger protein 216 pseudogene 1 7p22 
xxxvi 
 
RNF38 ring finger protein 38 9p 
RNGTT RNA guanylyltransferase and 5'-phosphatase 6q16 
RP9 retinitis pigmentosa 9 (autosomal dominant) 7p14 
RP9P retinitis pigmentosa 9 pseudogene 7p14 
RPA3 replication protein A3, 14kDa 7p21 
RPL8 ribosomal protein L8 8q24 
RPRD1B regulation of nuclear pre-mRNA domain containing 1B 20q11 
RPS12 ribosomal protein S12 6q23 
RPS19BP1 ribosomal protein S19 binding protein 1 22q13 
RPS21 ribosomal protein S21 20q13 
RPS6 ribosomal protein S6 9p21 
RPS6KA2 ribosomal protein S6 kinase, 90kDa, polypeptide 2 6q27 
RRAGA Ras-related GTP binding A 9p21 
RRS1 RRS1 ribosome biogenesis regulator homolog (S. cerevisiae) 8q13 
RSU1 Ras suppressor protein 1 10p13 
RTN4IP1 reticulon 4 interacting protein 1 6q21 
RWDD1 RWD domain containing 1 6q13 
RWDD2A RWD domain containing 2A 6q15 
S100A1 S100 calcium binding protein A1 1q21 
S100A16 S100 calcium binding protein A16 1q21 
SAR1A secretion associated, Ras related GTPase 1A 10q22 
SBDS Shwachman-Bodian-Diamond syndrome 7q11 
SDC1 syndecan 1 2p24 
SEC23IP SEC23 interacting protein 10q26 
SEC61G Sec61 gamma subunit 7p11 
SEMA3B 
sema domain, immunoglobulin domain (Ig), short basic domain, 
secreted, (semaphorin) 3B 3p21 
SENP1 SUMO1/sentrin specific peptidase 1 12q13 
SEPHS1 selenophosphate synthetase 1 10p14 
SERAC1 serine active site containing 1 6q25 
SERINC1 serine incorporator 1 6q22 
SERINC3 serine incorporator 3 20q13 
SERPINE1 
serpin peptidase inhibitor, clade E (nexin, plasminogen activator 
inhibitor type 1), member 1 7q22 
SESN1 sestrin 1 6q21 
SET SET nuclear proto-oncogene 9q34 
SF3B4 splicing factor 3b, subunit 4, 49kDa 1q21 
SFXN3 sideroflexin 3 10q24 
SGCE sarcoglycan, epsilon 7q21 
SGPL1 sphingosine-1-phosphate lyase 1 10q21 
SHC4 SHC (Src homology 2 domain containing) family, member 4 15q21 
SHFM1 split hand/foot malformation (ectrodactyly) type 1 7q21 
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SHOC2 soc-2 suppressor of clear homolog (C. elegans) 10q25 
SIGMAR1 sigma non-opioid intracellular receptor 1 9p13 
SIK2 salt-inducible kinase 2 11q23 
SIRT1 sirtuin 1 10q21 
SIRT2 sirtuin 2 19q13 
SKAP2 src kinase associated phosphoprotein 2 7p15 
SLC13A1 solute carrier family 13 (sodium/sulfate symporter), member 1 7q31 
SLC18A1 solute carrier family 18 (vesicular monoamine transporter), member 1 8p21 
SLC28A2 
solute carrier family 28 (concentrative nucleoside transporter), 
member 2 15q15 
SLC2A10 solute carrier family 2 (facilitated glucose transporter), member 10 20q13 
SLC37A3 solute carrier family 37, member 3 7q34 
SLC4A2 solute carrier family 4 (anion exchanger), member 2 7q36 
SLC4A8 solute carrier family 4, sodium bicarbonate cotransporter, member 8 12q13 
SMAGP small cell adhesion glycoprotein 12q13 
SMAP1 small ArfGAP 1 6q12 
SMARCA2 
SWI/SNF related, matrix associated, actin dependent regulator of 
chromatin, subfamily a, member 2 9p24 
SMC3 structural maintenance of chromosomes 3 10q25 
SMOC2 SPARC related modular calcium binding 2 6q27 
SMPD2 
sphingomyelin phosphodiesterase 2, neutral membrane (neutral 
sphingomyelinase) 6q21 
SMPDL3A sphingomyelin phosphodiesterase, acid-like 3A 6q22 
SNAPC3 small nuclear RNA activating complex, polypeptide 3, 50kDa 9p22 
SNX14 sorting nexin 14 6q15 
SNX19 sorting nexin 19 11q25 
SNX3 sorting nexin 3 6q21 
SNX31 sorting nexin 31 8q22 
SNX9 sorting nexin 9 6q25 
SOX10 SRY (sex determining region Y)-box 10 22q13 
SP1 Sp1 transcription factor 12q13 
SPATS2 spermatogenesis associated, serine-rich 2 12q13 
SRF 
serum response factor (c-fos serum response element-binding 
transcription factor) 6p 
SRY Sex Determining Region Y Yp11 
SSBP1 single-stranded DNA binding protein 1, mitochondrial 7q34 
SSX synovial sarcoma, X breakpoint 2 Xp11 
ST13 
suppression of tumorigenicity 13 (colon carcinoma) (Hsp70 interacting 
protein) 22q13 
ST3GAL1 ST3 beta-galactoside alpha-2,3-sialyltransferase 1 8q24 
ST6GALNAC3 
ST6 (alpha-N-acetyl-neuraminyl-2,3-beta-galactosyl-1,3)-N-
acetylgalactosaminide alpha-2,6-sialyltransferase 3 1p31 
STAG3L2 stromal antigen 3-like 2 (pseudogene) 7q11 
STAM signal transducing adaptor molecule (SH3 domain and ITAM motif) 1 10p14 
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STAU1 staufen double-stranded RNA binding protein 1 20q13 
STK19 serine/threonine kinase 19 6p21 
STMN3 stathmin-like 3 20q13 
STOML2 stomatin (EPB72)-like 2 9p13 
STT3A STT3A, subunit of the oligosaccharyltransferase complex (catalytic) 11q23 
STX16 syntaxin 16 20q13 
STX7 syntaxin 7 6q23 
STYXL1 serine/threonine/tyrosine interacting-like 1 7q11 
SUN1 Sad1 and UNC84 domain containing 1 7p22 
SYNE1 spectrin repeat containing, nuclear envelope 1 6q24 
SYNGR2 synaptogyrin 2 17q25 
SYS1 Sys1 golgi trafficking protein 20q13 
SYT13 synaptotagmin XIII 11p11 
TAB1 TGF-beta activated kinase 1/MAP3K7 binding protein 1 22q13 
TACC1 transforming, acidic coiled-coil containing protein 1 8p11 
TAF3 
TAF3 RNA polymerase II, TATA box binding protein (TBP)-associated 
factor, 140kDa 10p15 
TAF6 
TAF6 RNA polymerase II, TATA box binding protein (TBP)-associated 
factor, 80kDa 7q 
TAK1 mitogen-activated protein kinase kinase kinase 7 6q15 
TAX1BP1 Tax1 (human T-cell leukemia virus type I) binding protein 1 7p15 
TBC1D12 TBC1 domain family, member 12 10q23 
TBC1D22B TBC1 domain family, member 22B 6p21 
TBCEL tubulin folding cofactor E-like 11q23 
TBL2 transducin (beta)-like 2 7q11 
TBP TATA box binding protein 6q27 
TBRG1 transforming growth factor beta regulator 1 11q24 
TCF4 transcription factor 4 18q21 
TCP1 t-complex 1 6q25 
TCTN1 tectonic family member 1 12q24 
TDRD3 tudor domain containing 3 13q14 
TEKT4 tektin 4 2q11 
TES testin LIM domain protein 7q31 
TGFB1 Transforming Growth Factor, Beta 1 19q13 
TGM2 transglutaminase 2 20q12 
TGS1 trimethylguanosine synthase 1 8q11 
TIAL1 TIA1 cytotoxic granule-associated RNA binding protein-like 1 10q 
TJAP1 tight junction associated protein 1 (peripheral) 6p21 
TM2D3 TM2 domain containing 3 15q26 
TM9SF3 transmembrane 9 superfamily member 3 10q24 
TMBIM6 transmembrane BAX inhibitor motif containing 6 12q13 
TMED4 transmembrane emp24 protein transport domain containing 4 7p13 
xxxix 
 
TMEM132D transmembrane protein 132D 12q24 
TMEM14B transmembrane protein 14B 6p25 
TMEM158 transmembrane protein 158 (gene/pseudogene) 3p21 
TMEM181 transmembrane protein 181 6q25 
TMEM209 transmembrane protein 209 7q32 
TMEM242 transmembrane protein 242 6q25 
TMUB1 transmembrane and ubiquitin-like domain containing 1 7q36 
TNC tenascin C 9q33 
TNF Tumor Necrosis Factor 6p21 
TNRC18 trinucleotide repeat containing 18 7p22 
TOP1 topoisomerase (DNA) I 20q12 
TOPORS 
topoisomerase I binding, arginine/serine-rich, E3 ubiquitin protein 
ligase 9p21 
TOR1A torsin family 1, member A (torsin A) 9q32 
TP53 tumor protein p53 17p13 
TPMT thiopurine S-methyltransferase 6p22 
TRA2A transformer 2 alpha homolog (Drosophila) 7p15 
TRIB1 tribbles pseudokinase 1 8q24 
TRIM24 tripartite motif containing 24 7q32 
TRIM56 tripartite motif containing 56 7q11 
TRPM2 transient receptor potential cation channel, subfamily M, member 2 21q22 
TSPAN33 tetraspanin 33 7q32 
TSPYL1 TSPY-like 1 6q22 
TSTD2 thiosulfate sulfurtransferase (rhodanese)-like domain containing 2 9q22 
TTC26 tetratricopeptide repeat domain 26 7q34 
TUBA1B tubulin, alpha 1b 12q13 
TUBA1C tubulin, alpha 1c 12q13 
TUBA4A tubulin, alpha 4a 2q36 
TUBGCP2 tubulin, gamma complex associated protein 2 10q26 
TULP4 tubby like protein 4 6q25 
TYR tyrosinase 11q14 
TYRP1 Tyrosinase-Related Protein 1 9p23 
TYW1 tRNA-yW synthesizing protein 1 homolog (S. cerevisiae) 7q11 
UAP1L1 UDP-N-acetylglucosamine pyrophosphorylase 1 like 1 9q34 
UBAP1 ubiquitin associated protein 1 9p13 
UBAP2 ubiquitin associated protein 2 9p11 
UBE2D4 ubiquitin-conjugating enzyme E2D 4 (putative) 7p13 
UBE2H ubiquitin-conjugating enzyme E2H 7q32 
UBE2J1 ubiquitin-conjugating enzyme E2, J1 6q15 
UBE2R2 ubiquitin-conjugating enzyme E2R 2 9p11 
UBE3C ubiquitin protein ligase E3C 7q36 
UBE4A ubiquitination factor E4A 11q23 
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UBQLN1 ubiquilin 1 9q22 
UBQLN3 ubiquilin 3 11p15 
UBQLN4 ubiquilin 4 1q21 
UCK1 uridine-cytidine kinase 1 9q34 
UFL1 UFM1-specific ligase 1 6q16 
UHRF2 
ubiquitin-like with PHD and ring finger domains 2, E3 ubiquitin protein 
ligase 9p24 
UNC13B unc-13 homolog B (C. elegans) 9p13 
UROS uroporphyrinogen III synthase 10q25 
USP28 ubiquitin specific peptidase 28 11q23 
USP45 ubiquitin specific peptidase 45 6q16 
UST uronyl-2-sulfotransferase 6q25 
VAPB 
VAMP (vesicle-associated membrane protein)-associated protein B 
and C 20q13 
VCP valosin containing protein 9p13 
VDAC2 voltage-dependent anion channel 2 10q22 
VEGFA Vascular Endothelial Growth Factor A 6p12 
VPS26A vacuolar protein sorting 26 homolog A (S. pombe) 10q21 
VPS26B vacuolar protein sorting 26 homolog B (S. pombe) 11q25 
VTA1 vesicle (multivesicular body) trafficking 1 6q24 
VTI1A vesicle transport through interaction with t-SNAREs 1A 10q25 
WAPAL wings apart-like homolog (Drosophila) 10q23 
WAS Wiskott-Aldrich syndrome Xp11 
WASL Wiskott-Aldrich syndrome-like 7q31 
WBSCR22 Williams Beuren syndrome chromosome region 22 7q11 
WDR11 WD repeat domain 11 10q26 
WDR37 WD repeat domain 37 10p15 
WDR5 WD repeat domain 5 9q34 
WDR60 WD repeat domain 60 7q36 
WDR91 WD repeat domain 91 7q33 
WFDC1 WAP four-disulfide core domain 1 16q24 
WNT1 wingless-type MMTV integration site family, member 1 12q13 
WNT10B wingless-type MMTV integration site family, member 10B 12q13 
XPNPEP1 X-prolyl aminopeptidase (aminopeptidase P) 1, soluble 10q25 
XRCC2 
X-ray repair complementing defective repair in Chinese hamster cells 
2 7q36 
YAE1D1 Yae1 domain containing 1 7p14 
YTHDF1 YTH N(6)-methyladenosine RNA binding protein 1 20q13 
YY1AP1 YY1 associated protein 1 1q22 
ZBTB24 zinc finger and BTB domain containing 24 6q21 
ZBTB43 zinc finger and BTB domain containing 43 9q33 
ZC3HAV1L zinc finger CCCH-type, antiviral 1-like 7q34 
ZC3HC1 zinc finger, C3HC-type containing 1 7q32 
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ZDHHC16 zinc finger, DHHC-type containing 16 10q24 
ZDHHC6 zinc finger, DHHC-type containing 6 10q26 
ZMAT3 zinc finger, matrin-type 3 3q26 
ZNF12 zinc finger protein 12 7p21 
ZNF133 zinc finger protein 133 20p11 
ZNF212 zinc finger protein 212 7q36 
ZNF282 zinc finger protein 282 7q36 
ZNF3 zinc finger protein 3 7q22 
ZNF343 zinc finger protein 343 20p13 
ZNF394 zinc finger protein 394 7q22 
ZNF398 zinc finger protein 398 7q35 
ZNF511 zinc finger protein 511 10q26 
ZNF655 zinc finger protein 655 7q22 
ZNF7 zinc finger protein 7 8q24 
ZNF74 zinc finger protein 74 22q11 
ZNF746 zinc finger protein 746 7q36 
ZNF76 zinc finger protein 76 6p21 
ZNF786 zinc finger protein 786 7q36 
ZNF79 zinc finger protein 79 9q34 
ZNF853 zinc finger protein 853 7p22 
ZNF862 zinc finger protein 862 7q36 
ZNHIT1 zinc finger, HIT-type containing 1 7q22 
ZP3 zona pellucida glycoprotein 3 (sperm receptor) 7q11 
ZRANB1 zinc finger, RAN-binding domain containing 1 10q26 
ZUFSP zinc finger with UFM1-specific peptidase domain 6q22 
ZW10 zw10 kinetochore protein 11q23 










Melanoma – the malignant tumor of melanocytes – is one of the most aggressive 
human cancers. The worldwide incidence rate of melanoma has increased during 
the last decade, but there are few FDA-approved therapeutic options. Patients 
with lymph node metastasis can show highly variable clinical outcomes, from 
several years’ disease-free survival after excision of the primary lesion to 
extremely aggressive metastatic disease, while patients with distant metastasis 
show poor clinical outcomes. A better understanding of the genomic signatures of 
melanoma maintenance and progression will provide new opportunities for the 
development of novel therapeutic targets for successful management of this fatal 
disease.  
In this chapter, I will introduce known melanoma risk factors, the Clark model of 
melanoma development, the molecular basis of melanoma progression, and the 
known genomic features associated with melanoma. I will also discuss current 
therapeutic options for the clinical management of melanoma patients, and the 




1.1. Risk factors 
Several endogenous and exogenous factors increase the risk of melanoma 
development. A meta-analysis study of skin phototype showed that people with 
blue, green or hazel eyes or people with red hair were at higher risk of developing 
melanoma than people with dark eyes or dark hair [1]. Ultraviolet (UV) light,  the 
most important exogenous factor in melanoma, induces malignant alterations in 
skin by damaging DNA and impairing the immune response. The association of 
UV exposure with increased risk of melanoma development mainly depends on 
skin phototype, with higher risk in people with sun-sensitive skin [2]. 
The presence of multiple benign or clinically atypical nevi is another risk factor for 
melanoma; atypical nevi are > 0.5 cm in diameter with irregularly pigmented 
borders [1, 3]. The presence of multiple primary melanomas in a family member or 
multiple cases with melanoma in a family increases the risk of developing 
metastatic melanoma [1]. CDKN2a and CDK4 mutations are the most prevalent 






1.2. Melanoma progression: the Clark model 
The Clark model describes melanoma development from normal melanocytes. 
Based on this model, there are five steps in melanoma progression [5]: 
 
 
1.2.1. Acquired melanocytic nevus (AMN) 
Because of disrupted control of growth, melanocytes start to proliferate; they 
clump into nests along the basal layer and form a nevus. These benign nevi are 
regular in border and uniform in color, with dot-like pigments. They are commonly 
recognized as moles forming tan or dark-brown areas on skin [5]. 
 
1.2.2. Dysplastic nevus (DN) 
This step, with increased aberrant growth, leads to the presence of asymmetric 
nevus with irregular borders, increased diameter, and multiple colors. These 
lesions are dysplastic cells with random cytologic atypia. These nevi increase the 
risk of melanoma progression up to 20-fold. DN can originate from a preexisting 
AMN or can occur de novo on clear skin; therefore, DN is clinically important as it 




1.2.3. Radial Growth Phase (RGP) 
This is the first malignant stage. The proliferation of these cells is confined to the 
epidermis, and they are dependent on keratinocytes as the exogenous supplier of 
growth factors. These malignant cells are locally invasive, but incapable of rapid 
metastasis. These cells can penetrate the dermis, but are incapable of anchorage 
independent growth and fail to form colonies in soft agar [7, 8]. 
 
1.2.4. Vertical Growth Phase (VGP) 
The lesions with acquired capability of dermal invasion penetrate the dermis and 
the subcutaneous fat as an expanding mass. At this stage, the malignant cells 
have escaped the tight growth control by keratinocytes and gained the capability 
of anchorage independent growth. This step increases the risk of tumor 
metastasis [5].  
 
1.2.5. Metastasis 
 This step is the successful dissemination of malignant cells to a local lymph node 
or distant organs such as the liver, lung, brain, bone, or distant skin. These cells 
can then successfully proliferate and establish a new metastatic lesion. Not all 
patients with lymph node metastasis show distant metastasis; these patients are 
categorized as good, whereas the prognosis of the patients with distant metastasis 
is poor.  
 5 
 
1.3. From melanocyte to melanoma 
The epidermis and the dermis, separated by the basement membrane, constitute 
the human skin. Melanoblasts are undifferentiated precursors that migrate from 
the neural crest to the epidermis and differentiate to become mature melanocytes . 
Melanocytes – derived from neural crest cells (NCCs) – reside in the epidermis 
layer and interact with the skin microenvironment such as keratinocytes, 
fibroblasts, endothelial cells, and the extra cellular matrix .Signaling pathways 
such as Wnt6/ߚ-catenin, and NOTCH and transcription factors such as PAX3, 
SRY, and MITF7 have central roles in the survival and migration of melanocytes 
[9-12].  
The main physiological function of skin melanocytes is to synthesize and transfer 
melanin pigments to neighboring keratinocytes. UV radiation stimulates increased 
pigmentation and melanocyte proliferation [13, 14]. Stimulated by UV radiation, an 
enzymatic cascade (involving tyrosinase, TYRP1, and DCT) in melanocytes 
converts tyrosine into dopa and then to dopaquinone, which is then oxidized into 
melanin, within specialized organelles called melanosomes. Using dendritic 
processes, melanocytes spread out to transfer melanin to the keratinocytes [15]. 
Melanin reduces the DNA damage and genomic instability induced by UV 
radiation through absorbing and scattering UV radiation. Moreover, activation of 
the TP53 in keratinocytes by UV radiation leads in turn to activation of ߙMSH8 [12]. 
αMSH binds to its receptor (MC1-R) and up-regulates the cAMP/PKA/CREB 
signaling pathway, which results in	 weak and transient activation of ERK, up-
regulation of MITF, and, ultimately melanocyte differentiation (tanning response) 
                                                
6 Wingless signaling 
7 Microphthalmia-associated transcription factor 
8 ߙ-melanocyte stimulating hormone 
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[13, 14][16]. MITF is known as a master regulator of melanocytes and is critically 
involved in pigmentation, melanosome biogenesis, and trafficking [10]. More 
importantly, in order to inhibit the UV-radiation-induced DNA damage and 
melanocyte death, MITF triggers an antiapoptotic mechanism by controlling the 
expression of antiapoptotic genes such as BCL2 [17]. Stimulated by UV radiation, 
keratinocyte-released factors such as ߙMSH, LIF9, bFGF10, and HGF11 cause the 
sustained activation of ERK via the ߙMSH/cAMP cascade, leading to melanocyte 
proliferation [18, 19]. The interplay between cAMP, ERK, and proliferation is 
mediated by BRAF and RAS [19]. 
Melanoma is a heterogeneous tumor and several molecular events are associated 
with its development. 15% and 40% of melanomas are associated with mutations 
in NRAS and BRAF, respectively, leading to constitute activation of the MAPK 
(mitogen activated protein kinase) signaling pathway [20]. BRAFV600E (changing 
valine to glutamic acid at position 600) is the most common somatic mutation, 
accounting for 90% of all BRAF mutations observed in cutaneous  melanomas 
[21]; replacement of valine by lysine (V600K) is the second most frequent mutation 
of BRAF in melanoma. The presence of BRAF mutations in 80% of dysplastic nevi 
and its maintenance throughout the melanoma progression implies the major 
contribution of BRAF to melanoma initiation, maintenance, and progression, and 
suggests its function as a founder event, though not all nevi with BRAFV600 
mutations will develop melanoma [20-22]. The predominant presence of BRAF 
mutations in melanoma can be explained mainly by the presence of interplay 
between cAMP, ERK, and proliferation.   
                                                
9 Leukemia inhibitory factor 
10 Basic fibroblast growth factor 
11 Hepatocyte growth factor 
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BRAF plays a major part in melanoma maintenance through inducing tumor 
survival, proliferation, and evasion of apoptosis via several mechanisms; for 
example, cyclin D1 induction by BRAF permits the cell-cycle progression [23]. 
MITF regulation by BRAF leads to inhibition of MITF-induced differentiation and 
apoptosis [24]. BRAF inhibits the pro-apoptotic Bad protein and P53-induced 
apoptosis while activating the NFB, which is an anti-apoptotic and pro-
proliferative transcription factor [25-27]. BRAF’s role in angiogenesis, metastasis, 
and immune evasion has also been reported; BRAF promotes the VEGF secretion 
leading to angiogenesis [25, 28]. Sub-clones with activating BRAF mutations 
appear to be more invasive than the ones without BRAF mutations [20, 22, 25].  
The activating BRAF mutation triggers cell proliferation, which is followed by the 
induction of senescence, which is mediated by p16 (INK4a) [78]. Because of 
PTEN loss and the PI3K/AKT pathway activation, cells can bypass the BRAFV600E-
mediated senescence and favor melanoma proliferation. The PI3K/AKT signaling 
pathway is also involved in EMT (epithelial to mesenchymal transition) and 
invasion through its key targets, such as RAC1 [29].  
The EMT is a process through which normal cells achieve metastatic potential 
through gaining the mesenchymal phenotype, while shedding their epithelial 
phenotype and becoming motile. Although melanomas do not show a classical 
EMT, there are a growing number of studies showing the importance of EMT in 
invasion and metastatic potential of melanoma cells [30]. 
In normal skin, the melanocytes are scattered across every 5 to 10 keratinocytes 
and the melanocyte-to-keratinocytes ratio (1: 35) is tightly controlled; this 
interaction between melanocytes and keratinocytes is mediated by E-cadherin [9].  
During the EMT process, the melanocyte transformation is accompanied by a 
switch in the type of cadherin, which is expressed in the cell, namely the up-
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regulation of N-cadherin and the down-regulation of E-cadherin. This cadherin 
switch disrupts the adherence junctions of melanocytes and increases the cell 
mobility [12]. The loss of E-cadherin results in deregulation of proliferation, 
increased mobility, and scattering of melanocytes; keratinocytes become 
incapable of controlling the melanocytes [14]. At this step, cells have the potential 
to invade the dermis, resulting in VGP [9]. Several signaling molecules have been 
shown to be associated with EMT, including TGFβ, FGF, HGF, WNTs, and Notch 
[31]. 
Autocrine growth factors such as PDGF-A3, bFGF, and IL8 are the major 
contributors to the proliferation and migration of melanoma cells [15]. PDGF-A is 
associated with tumor angiogenesis and stromal formation; bFGF stimulates 
fibroblasts and endothelial cells to favor the malignant cells [17].  
The tumor microenvironment is mainly modulated by paracrine growth factors. 
VEGF5 plays an important role in RGP-to-VGP progression: it orchestrates the 
angiogenesis because of induction by PDGF-A; VEGF is also associated with 
stimulation of endothelial cell growth, migration, and invasion [16].  
Receptor Tyrosine Kinases (RTKs) can stimulate the production of the growth 
factors with ultimate effect on tumor microenvironment [18]. Moreover, RTKs 
stimulate several signaling pathways, such as the PI3/AKT and MAPK pathways. 
Upstream regulators of the MAPK pathway are membrane-bound receptors such 
as G protein-coupled receptors (GPCRs) and RTKs. Growth factor stimulation of 
these receptors will activate the small G-protein RAS. The activated RAS recruits 
RAF kinases to the cytoplasm for phosphorylation, and subsequent activation 
leads to the activation of the MEK1/2, and then the ERK1/2. The ERK1/2 will then 
phosphorylate the target proteins in the cytoplasm or nucleolus with ultimate effect 
on the transcription factors regulating survival, proliferation, or differentiation [19]. 
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1.4. Melanoma therapeutic options 
 
1.4.1. Chemotherapy 
Conventional chemotherapy is based on the use of cytotoxic alkylating agents, 
such as dacarbazine, which act by killing cells that divide rapidly. Dacarbazine 
was the first approved chemotherapeutic  agent administrated intravenously to 
patients with melanoma. Its efficiency is limited to a complete but not durable 
response in only 5% of patients [32]. Dacarbazine is not applicable to patients with 
brain metastasis – which account for two-thirds of melanoma patients – because it 
cannot pass the blood–brain barrier. Its oral analogue, temozolomide, also does 
not provide better efficiency [33]. Before the approval of dabrafenib and 
vemurafenib (BRAF inhibitors), trametinib (MEK inhibitor), and ipilimumab (anti-
CTLA4), the best overall survival rate in phase III clinical trials was that of 
melanoma patients who received dacarbazine [34]. 
 
1.4.2. Targeted therapy 
Targeted therapy is the treatment of cancers through inhibition of driver15 
mutations in tumors. Sorafenib, a multi-kinase inhibitor, is an FDA16-approved 
therapy for cancers such as hepatocellular carcinoma and renal cell carcinoma 
[35]. However, this therapy shows little or no effect on patients with advanced 
melanoma [36], even in combination with chemotherapy [37].  
                                                
15 Somatic mutations conferring oncogenic properties to a tumor cell 
16 U.S. Food and Drug Administration 
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To date, vemurafenib – a selective inhibitor of BRAFV600E – is the most promising 
targeted therapy for melanoma. In order to compare the efficacy of vemurafenib 
and dacarbazine, the BRIM-3 study was performed on 675 patients with surgically 
unresectable stage III or IV melanoma, and harboring BRAFV600E. Overall 
response rates of 48% and 5% were observed for patients receiving vemurafenib 
and dacarbazine, respectively. Patients who received vemurafenib showed a 
median progression-free survival of 5.3 months compared with 1.6 months for the 
patients treated with dacarbazine. According to the study, vemurafenib was 
associated with a significant reduction in disease progression and mortality, 
compared with dacarbazine [38].  
However, patients with initial response to vemurafenib will gain resistance to the 
therapy within nine months. Other patients with BRAFV600 mutations have intrinsic 
resistance to vemurafenib [39, 40]. 
 
1.4.2.1. BRAF 
BRAF is a serine/ threonine-protein kinase, and some mutations of its kinase 
domain can lead to constitutive activation of the MAPK pathway. This pathway is 
involved in several tumorigenic phenotypes, including cell survival, proliferation, 
senescence, apoptosis, and angiogenesis. 
Figure 1 below is a schematic presentation of the BRAF structure. CR1, CR2, and 
CR3 are conserved regions shared among all isoforms of three BRAF paralogs in 
a human: ARAF, BRAF, and CRAF. CR1 and CR2 are regulatory, whereas CR3 
contains the kinase activity. Because of a hydrophobic interaction between the 
glycine-rich loop and the activation segment in the kinase domain, RAF remains 
inactive. Phosphorylation of residues in the activation segment disrupts the 
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hydrophobic interaction and leads to RAF activation. ARAF and CRAF are 
activated when three residues are phosphorylated, whereas BRAF activation 
needs phosphorylation of only two residues (T598 and S601) [41]. This differential 
regulation of RAF isoforms arises from a motif called the N-region. 
Phosphorylation of S299/Y302 and S338/Y341 in the N-region is required for 
maximal activation of ARAF and CRAF, respectively [42]. On the other hand, the 
N-region in BRAF is negatively charged: one of the corresponding residues (S445) 
is constitutively phosphorylated and the other residue (D448) is replaced by an 
aspartic acid, which is a negatively charged amino acid. All RAF paralogs need to 
be recruited to the plasma membrane via RAS for activation. RAS phosphorylation 
activates BRAF by itself, and one amino-acid substitution leads to constitutive 
activation of BRAF (such as V600E), whereas ARAF and CRAF activation is more 
complex and the constitutive activation of ARAF and CRAF requires at least two 
mutations. This difference explains the high frequency of BRAF mutations in 
cancer, compared with the other paralogs.  
The incidence of BRAF mutations is much higher in cancers that harbor RAS 
mutations, although the simultaneous presence of both mutations in one tumor is 
intermittent [43]. Different BRAF mutations show different levels of activity; an in 
vitro examination of kinase activity showed that BRAFV600E had  the highest level of 
kinase activity (500-fold), compared with the activity of BRAFWT [44]. On the other 
hand, strong activation of the MAPK signaling results in cell senescence or 
differentiation via up-regulation of CDK inhibitors [45, 46]. The rare co-occurrence 
of RAS mutation (mostly NRAS mutation in cutaneous melanomas) with 
BRAFV600E , and the frequent co-occurrence of RAS mutation with other BRAF 
mutations (such as G465), suggest that selection of BRAF mutation is compatible 
with successful tumor proliferation [47]. 
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Figure 117: BRAF structure 
a) CR3 structure: Small and large lobes of CR3 are separated by a catalytic cleft. 
The glycine-rich loop (colored green) clamps ATP into the catalytic cleft. 
Moreover, the hydrophobic interaction of the glycine-rich loop with the activation 
segment (magenta) leads to inactive conformation of BRAF. The activation 
segment harbors a phosphorylation site (yellow). The catalytic loop (blue) and the 
DFG and APE motifs (purple) are shown. The red dashed line shows the 
interaction between the N region (brown) and αC-helix. b) Conserved regions in 
BRAF: CR1 and CR2 in the N-terminal and CR3 in the C-terminal 
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Up to 50% of primary melanomas show regression even in the absence of any 
effective therapy; moreover, lymphocytes, mainly CD8+ T cells, infiltrate into 
regressing tumors. These observations reflect the effective contribution of the 
immune system to the partial or complete removal of melanoma [48, 49].  
Melanoma is considered an immunogenic cancer that incites the immune 
response by producing tumor-associated antigens (TAAs) [50].  
In melanoma, TAAs are categorized into several groups: a) somatically mutated 
molecules such as p16 (INK4a) or atypical transcripts, b) differentiation antigens 
(such as tyrosinase and Melan-A) expressed only in either normal or malignant 
cells derived from melanocytes, and c) cancer testis antigens (CTA) (e.g. MAGE-
A1, MAGE-A3, and SSX) expressed in tumors, testis, and placenta, but not in 
other normal tissues [51-55]. 
Since there is an active interaction between melanoma cells and the immune 
system, immunotherapy is applied to control and augment the immune response. 
Immunotherapy aims to overcome the inflammation, tolerance, or 
immunosuppression caused by a tumor and its microenvironment, and can 
stimulate the tumor’s immunogenicity and the function of the immune system 
effectors. 
Interleukin 2 (IL2) is the first immunotherapy for melanoma to have been approved 
by the FDA, although management of the side effects associated with 
administration of IL2, such as high toxicity and cardiac dysrhythmias have 




CTLA418 is a receptor expressed on activated T-cells. It functions as a negative 
regulator of the immune system and limits the immune response against 
tumorigenesis and tumor progression via binding to the B7 molecules present on 
the antigen presenting cells (APCs) [57, 58]. Inhibition of CTLA4 using ipilimumab 
leads to prolonged T-cell activation against the tumor. Ipilimumab is a monoclonal 
antibody against CTLA4, and its success in phase III trials led to the FDA’s 
approval of it for treatment of metastatic melanoma in 2011. In these trials, 676 
patients with unresectable stage III and IV metastatic melanoma were randomly 
assigned to three groups to receive ipilimumab, ipilimumab plus gp10019, or gp100 
only. Patients who received ipilimumab had a median overall survival of 10 months 
compared with 6.4 months for the patients treated with gp100 only. This difference 
was statistically significant (p-value < 0.001) and clinically meaningful (hazard ratio 
[HR] = 0.68). More importantly, an impressive durable response of 23 months was 
observed in patients with complete or partial response to ipilimumab, compared 
with a durable response of 3 months in patients treated with gp100. However, the 
complete response was rare, and severe adverse events occurred [59]. The 
development of these immune-related side effects is because of loss of tolerance 
in the T-cells, which will result in immune inflammation and the targeting of self-
antigens and normal tissues [60]. A combination of ipilimumab and dacarbazine in 
an independent phase III trial increased the  median survival to 11.2 months 
compared with 9.1 months for patients treated with dacarbazine only. Ipilimumab 
showed adverse immune-related events and toxicity similar to that of the first trial, 
but with higher incidence of liver-function abnormalities [61].  
                                                
18 Cytotoxic T-Lymphocyte associated Antigen-4 
19 GP100 is a synthetic peptide cancer vaccine consisting of amino acid residues 
209 through 217 of the glycoprotein 100 (gp100) melanoma antigen, with a 
methionine substitution at position 210. 
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1.5. Resistance to therapy 
Conventional therapies such as combination chemotherapies and targeted 
therapies have provided modest benefits with a slight increase in the overall 
survival rates or progression-free survival rates of patients with leukemia or solid 
tumors. The main reason overall survival rates are not higher is resistance to the 
applied therapy, which can be intrinsic or acquired. The mechanisms underlying 
the drug resistance have common features with both cytotoxic chemotherapies 
and targeted therapies. In the case of intrinsic resistance, the resistance occurs as 
soon as the therapy is applied, and implies the presence of pre-existing factors 
mediating the resistance in the tumor. For example, it has been shown that in 
melanoma cells with innate resistance to BRAF inhibitors, HGF secretion by 
stromal cells stimulates the MET receptors on melanoma cells and leads to 
activation of the MAPK and PI3K–AKT signaling pathways [62]. 
Tumors can acquire resistance to the therapy following the initial response to the 
therapy; these tumors are sensitive to the therapy in the beginning, but then gain 
resistance as a result of several mechanisms, such as alterations of the drug 
targets, activation of other compensatory survival pathways, inactivation of the 
cell-death-signaling pathway, or therapy-induced-selection and expansion of a 
resistant clone present primarily as a minor population in the bulk of the tumor 
(recognized as intratumor heterogeneity) [63, 64]. The following sub-sections will 
focus on the intratumor heterogeneity and the crosstalk between pathways 
involved in cancer as major contributors to therapy resistance.  
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1.5.1. Intratumor heterogeneity 
In 1976, Peter Nowell proposed that the evolutionary process of cancer 
progression was a stepwise accumulation of somatic aberrations accompanied by 
sub-clonal selection [65]. His model, in parallel with Darwinian natural selection, 
provides an outline of intratumor heterogeneity. Comprehensive studies of several 
cancers (such as bile duct carcinoma, breast cancer, ccRCCs22, colorectal cancer, 
head and neck cancer, and lung cancer) have illustrated the spatial and temporal 
dynamics of intratumor heterogeneity and provided evidence of the branched 
evolutionary tumor growth underlying the intratumor heterogeneity [66-71]. Cillo C. 
and colleagues have shown that the B16F10 melanoma cell line has increased 
ability to achieve DNA amplification, and a high metastatic potential that leads to 
the gained resistance to the therapy (methotrexate), at much faster rate than cell 
lines with lower metastatic potential. This observation suggests that the generation 
of heterogeneous amplification  is the mechanism leading to both metastatic 
spread and drug resistance [72]. A comprehensive sequencing analysis of 
spatially separated ccRCC samples (both primary and associated metastasis 
tumors) revealed the presence of mutational heterogeneity and genetic divergence 
between spatially different regions [68]. That study not only showed the presence 
of a distinct mutational burden between spatially different regions, but also 
revealed the ultimate phenotypic convergence during tumor evolution towards 
good versus poor prognosis. In other words, the presence of distinct mutational 
diversity in the tumor (tumor heterogeneity) provides a rich reservoir for Darwinian 
                                                
22 Clear Cell Renal Carcinomas 
23 Human Immunodeficiency Virus 
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selection of the well-adapted clones, with selective survival advantages leading to 
metastatic development or contributing to therapeutic resistance [68]. 
 
1.5.2. Pathways’ crosstalk network in cancer 
The crosstalk among a variety of signaling pathways underlies the redundancy 
and complexity of the cells’ molecular mechanisms [73]. These dynamic crosstalks 
are particularly important for maintaining the cell homeostasis [74]. In response to 
therapy, the functional maintenance of the cancer cells can be achieved by the 
presence of abnormal redundant pathways and their subsequent crosstalks [73]. 
For example, under excessive genomic damage, TP53 protein blocks cell cycle 
progression or triggers apoptosis. Nonetheless, TP53-null mice show proper 
tissue homeostasis and normal development, which are suggestive of the 
presence of functional redundancy [75, 76]. 
The complexity of the MAPK pathway because of feedback mechanisms and 
crosstalk with other signaling pathways results in complication of RAF kinase 
targeted therapy. PI3K inhibitors such as Wortmannin lead to inhibition of the 
MAPK pathway, which suggests the presence of potential crosstalk between the 
PI3K/AKT and MAPK pathways [77]. For instance, in melanoma, the abnormal 
activation of the BRAF protein via the V600E mutation is in itself a signal for the 
cells to undergo senescence. However, a partial reduction of BRAFV600E activity, 
via its phosporylation through the AKT kinase, promotes melanocyte proliferation 
[78]. The inhibition of the MAPK and PI3K pathways increases the sensitivity to 
apoptosis via down-regulation of the JAK-STAT pathway, suggesting the crosstalk 
between these three major pathways in cancer [78].  
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NF-κB has a major role in tumor progression via its involvement in cell survival, 
apoptosis, and migration. To block apoptosis, AKT stimulates the NF-κB in a 
manner dependent on IKK (I-κB kinase) and the MAPK p38 [79, 80]. This crosstalk 
leads to cell survival, EMT induction, and metastasis [81, 82]. Deregulation of the 
Notch signaling as a regulator of the normal development of many tissues can 
contribute to cancer development. In melanoma, up-regulation of the Notch 
ligands and receptors has been reported [83]. The inhibition of AKT or the MAPK 
pathways reverses the effect of Notch on melanoma progression, suggesting that 
Notch involvement in promoting VGP is mediated by AKT and the MAPK 
pathways [84].  
As a superfamily of cytokines, TGFβ is implicated in the regulation of 
developmental processes; therefore, its perturbations can promote tumorigenesis. 
It has been shown that, accompanied by an increased level of AKT/GSK-3β, the 
signaling Nodal (a member of the TGFβ superfamily) induces Snail-mediated EMT 
in B16 murine melanoma [85].  
To achieve desirable treatment outcomes, it is essential to reveal the crosstalks 





1.6. Concurrent combination therapy 
The dependency of cancer on the number of deregulated genes and the presence 
of pathways’ crosstalk makes targeted therapies challenging. Treating a single 
aberration mostly does not give a durable response, as the resistant clones will 
emerge due to tumor heterogeneity. In other words, the genetic diversity in tumors 
assures the presence of the resistant clones as the therapy is started; ultimately, 
survival and clonal expansion of these clones will lead to failure of the applied 
therapy. Successful combination therapy in cancers such as leukemia and some 
infectious diseases such as HIV23 is evidence  of the great potential of combination 
therapy to achieve a durable response [86, 87]. For example, in a melanoma cell 
harboring NRAS mutation, the acquired resistance to BRAF inhibitors can be a 
result of paradoxical activation of the downstream MEK1 in the MAPK pathway. In 
a Phase I/II trial, a combination of trametinib (MEKi) and dabrafenib (BRAFi) 
increased the progression-free survival and delayed the development of 
melanoma resistance [88, 89].  
To design a successful combination therapy, it is important to consider the cross-
resistance mutations, which are genetic aberrations conferring simultaneous 
resistance to both drugs applied in combination [90]. Even in the absence of 
cross-resistance mutations, sequential combination therapy – the application of 
drugs one after the other and not simultaneously – fails to demolish the pre-
existing or emerging resistant clone during the treatment. On the other hand, 
concurrent combination therapy is a promising approach even in the presence of 
cross-resistance mutations [90].  
  
                                                
23 Human Immunodeficiency Virus 
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1.7. Cellular attributes of cancer biology 
During the multistep tumorigenesis, cancer cells acquire functional competencies 
– known  as hallmarks of cancer–, which allow them to survive, proliferate, and 
disseminate. Sustaining proliferative signaling, evading growth suppressors, 
resisting cell death, enabling replicative immortality, inducing angiogenesis, 
activating invasion and metastasis (known as core hallmarks of cancer), 
reprogramming energy metabolism, and evading immune destruction ( introduced 
as emerging hallmarks) are discussed by Hanahan and Weinberg in detail [91]. 
Cancer cells sustain their most fundamental feature, the chronic proliferation, in an 
autocrine manner by producing growth factors; otherwise, because of tumors’ 
stimulant signals, the normal cells within the supporting stroma may act as growth-
factor suppliers [92, 93]. Mostly through inactivation of tumor suppressor genes 
(TSGs) such as CDKN2a, RB and TP53, cancer cells avoid the negative 
regulation of cell proliferation [94].  
Senescence and cell death as crucial barriers to proliferation are considered vital 
anticancer defenses. For instance, normal cells can successfully pass through a 
limited number of cell cycles, whereas cancer cells overcome this limitation by 
expressing telomerase, leading to maintenance of telomeres. Telomerase activity 
leads to circumvention of senescence and cell death, and enables the replicative 
immortality of cancer cells [91, 95].  
Programmed cell death or apoptosis ensures the homeostasis of normal cells 
through elimination of damaged cells (e.g., those containing damaged DNA, 
hypoxia, or nutrient limitation). However evolving tumor cells circumvent apoptosis 
by a variety of mechanisms, such as over-expression of anti-apoptotic regulators 
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(e.g. Bcl-2), down-regulation of pro-apoptotic factors (e.g. Bax), or loss of TP53 as 
a critical damage sensor [96]. 
One of the major prerequisites of tumor cell growth and survival is access to the 
circulatory system; cells obtain their oxygen and nutrients from circulation and 
shed their CO2 and metabolic waste to circulation. Distance from circulation will 
lead to hypoxia and ultimately to necrosis or apoptosis. Tumor angiogenesis refers 
to a process through which tumor cells can provoke the formation of new blood 
vessels to overcome the growth inhibition induced by distance from circulation. 
Angiogenesis not only provides oxygen and nutrients, but also facilitates the tumor 
spreading and metastasis to distant organs through access to the blood stream 
[97]. Dissemination of malignant cells is a multistep process referred to as the 
invasion–metastasis cascade; this cascade includes migration from the primary 
tumor, intravasation (entry into blood and lymphatic vessels), transit through the 
circulatory system, extravasation (escape from vessels) into the parenchyma of 
secondary sites, and formation of metastatic lesions [98, 99].  
Normal cells use oxidative phosphorylation and glycolysis to produce energy 
under normal conditions and oxygen deprivation, respectively. To obtain a fuel 
supply capable of providing for the increased metabolic needs of the highly 
proliferative cancer cells, an altered metabolic program has evolved in cancer 
cells. This metabolic program is described as the Warburg effect: even in the 
presence of oxygen, cancer cells use glycolysis, take up more glucose, and 
produce large amounts of ATP, water, CO2, and lactate [100, 101].  
Immunoediting refers to the dual function of the immune system, which can both 
suppress tumor proliferation and enable tumor growth. Immunoediting is described 
by elimination, equilibrium, and escape. In the elimination phase, the induced 
immune system recruits effector cells from the innate immune system (e.g. NK, 
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dendritic cells) and adaptive immune system (T cells) to eliminate the tumor cells. 
In the equilibrium phase, those tumor cells surviving the initial attack enter the 
dormant state; the immune system cannot eliminate these dormant cells, but has 
control over them. Finally, in the escape phase, cancer cells evade immune 
destruction using several mechanisms, such as expression of tolerogenic 
molecules, induction of immunosuppressor cells, and generation of tumor variants 
not recognizable by the immune system [102]. 
Inflammation is recognized as one of the major factors contributing to tumor 
development by inducing DNA damage and instability, and to tumor progression 
by stimulating angiogenesis and immunosuppression [103]. 
Cancer is characterized by the loss of genomic integrity and the combination of 
genetic and epigenetic modifications leading to the bypassing of cellular regulatory 
control, resulting in tumor establishment [91]. In view of the prominent role of 
genome instability in tumorigenesis, the next subsection is dedicated to a detailed 





1.8. Cancer genome organization 
Somatic mutations including single nucleotide variations (SNVs), structural 
mutations (SMs), and copy number variations (CNVs) play a major role in 
tumorigenesis by affecting the expressional landscape of the cancer genome and 
increasing genome instability [104].  
Theoretically, amplified genes with differentially higher expression in tumors may 
indicate oncogenes, whereas deleted genes with down-regulated expression may 
denote TSGs [105]. Lin and colleagues have identified significant regions of copy 
number gain and loss in 101 melanoma short-term cultures [105]. For instance, 
Chr 7q34 harboring BRAF shows recurrent copy number gain. Chr 13q33 loss is 
mainly seen in primary melanomas with chronic sun damage; the presence of 
ERCC5 in this region suggests the importance of this excision repair gene in 
melanogenesis because of chronic sun damage. TP53 is a well-known TSG 
frequently inactivated in melanoma, mainly because of copy-neutral LOH. Chr 10 
loss mostly covers the entire chromosome, though focal losses of 10q23.31 
harboring PTEN are recurrently reported [105]. Concurrent Chr 7 gain and Chr 10 
loss suggests the cooperative effect of BRAF and PTEN in melanoma [106]. 
Genomic regions with recurrent CNVs have been identified in several studies, but 
the relevant effector genes are mainly anonymous [105, 107, 108]; to address this, 
gene expression data provides a valuable source for the identification of cancer-
promoting genes with possible association with cancer attributes. For instance, 
integrative analysis of aCGH data with gene expression revealed that Chr 10 loss 
not only targets PTEN inactivation, but also other TSGs such as CLU1 – a cell 
cycle regulator [109]. 15q26 gain harbors up-regulated genes including IQGAP1, a 
GTPase-activating protein which is a cell adhesion modulator [110].  
 24 
 
Melanoma has a markedly higher number of somatic SNVs than almost all other 
solid tumors [111]. Moreover, a genome-wide mutational signature analysis of 30 
types of cancer showed the highest prevalence of cytidine to thymidine (C > T) 
transitions in melanoma tumors [112]. 
A high frequency of C > T transitions contributing to the high rate of SNVs is a 
characteristic of UV exposure in melanoma patients. Recurrent driver mutations 
reported in melanoma are NRAS (G12/13, Q61), BRAF (V600), KIT (W557, V559, 
L576, K642, and D816), GNA11 (Q209), and GNAQ (Q209); the rest of the 
patients are referred to as “pan-negative” [113]. In 2012, Hodis and colleagues 
defined the catalogue of driver mutations in 121 melanoma samples using whole 
exome sequencing (here referred to as the HODIS study) [114]. To identify the 
mutations with positive selection during the course of evolution in melanoma, they 
applied a gene-based statistical approach to define exon/intron mutational 
distribution and control the passenger mutational load per gene. PolyPhen-2 was 
used to predict the functional impact of each mutation. ARID2, PPP6C, RAC1, 
SNX31, STK19, and TACC1 with significant mutational burden (FDR q-value < 
0.2) were identified as novel drivers in melanoma. More importantly, this study 
confirmed the definite direct role of UV exposure in melanoma pathogenesis by 
revealing the significant mutation burden in RAC1, STK19, and PPP6C harboring 




1.8.1. Next-Generation Sequencing 
Several cancer studies focus mainly on the mechanisms by which an individual 
pathway or a single gene contributes to tumorigenesis [115, 116]. However, the 
heterogeneous nature of tumor progression makes it extremely inefficient to 
discover the key aberrations through conventional forward genetics. Therefore, a 
systemic and through characterization of cancer genomes and their 
transcriptomes is needed to identify the key aberrations that result in genomic 
instability, altered transcripts, and disease progression [117].  
There are many limitations to the traditional cytogenetic-based (e.g. SKY24, 
FISH25), array-based (e.g. aCGH26), and sequence-based (e.g. SAGE27-based 
digital karyotyping) approaches, such as low sensitivity, low efficiency, poor 
resolution, laborious preparation steps, and high costs, whereas comprehensive 
characterization of the cancer genome needs a large-scale, whole genome and 
low-cost approaches [118].  
Today, owing to the high-throughput, genome-wide technologies, a deeper 
understanding of the genetic determinants of melanoma can be provided by 
systems biology approaches.  
Next-generation DNA sequencing is a promising technology with high-throughputs 
and low costs; however, a short read length is its critical limitation. To overcome 
this pitfall, paired-end tag (PET) sequencing was developed [119, 120]. The basic 
concept of PET sequencing is the concomitant extraction of the 5′ and 3′ paired 
tags from both ends of any long DNA fragment of interest and the linking of them 
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as diTag constructs for sequencing analysis [121].  The sequenced 5′ and 3′ 
paired tags are mapped to the corresponding reference genome (such as hg19) 
for precise delineation of the target DNA boundaries on the genomic landscape. 
Paired-reads are classified into either discordant PETs (dPETs) or concordant 
PETs (cPETs). cPETs represent consistent genome structures between the 
cancer genome and the reference genome and are used to detect CNVs; these 
paired-end tags are mapped to the reference genome sequence as expected (i.e. 
both ends map to the same chromosome, and the same strand in the 5′→3′ 
orientation, within the expected distance). On the other hand, dPETs are indicative 
of structural differences between the cancer and reference genomes. According to 
the dPET classification scheme, long-span dPET clusters show deletions; 
incorrect orientation clusters show tandem replication; different strand clusters 
demonstrate inversions; and different chromosome clusters represent 
translocations [122]. DNA–PET is paired-end tag sequencing of genomic DNA 
fragments for studying genome rearrangements. In DNA–PET analysis, the 
information obtained from linkages between the two ends of DNA fragments using 
diTag constructs allows the comprehensive detection of genome rearrangements 
[123].  
The investigation of SNVs using exome–capture sequencing focuses on the 
protein-coding exons – 1% of the genome – eliminating the need to sequence 
whole genomes. This cost-effective targeted sequencing provides an easy 
approach. It provides a manageable dataset for analysis and functional 
interpretation, which is a definite benefit compared with whole genome sequencing 
[124]. 
Transcriptome analysis provides the functional component of the genome, and is 
the key to revealing the functional consequences of the genomic aberrations 
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associated with disease progression. Conventional methods for examining the 
transcriptome include sequenced-based and hybridization-based approaches. 
Tag-based sequencing methods such as SAGE and MPSS28 are high-throughput 
and quantitative but more expensive than hybridization-based approaches [125, 
126]. Hybridization-based methods such as microarrays are high-throughput and 
relatively low-cost, but rely on current transcriptome knowledge [127], and their 
detection resolution is limited because of signal saturation and high background 
arising from cross-hybridization [128]. To overcome the disadvantages of 
traditional sequencing technologies and achieve successful annotation of the 
entire transcriptome structure, RNAseq has been developed to achieve higher 
accuracy of detection, higher sensitivity, and greater completeness [129]. RNAseq 
quantifies the expression without probe hybridization. Moreover, alignment of the 
sequences provided by RNAseq to the human reference genome reveals the 
novel disease-specific events. The high reproducibility of RNAseq results from the 
biological and experimental replicates is another advantage of this method [130].  
The key targets uncovered through these high-throughput sequencing 
technologies can function as clinical targets for the diagnosis and prognosis of 
melanoma, decisions for therapy, and even development of novel therapies. 
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1.9. A composite of genes are involved in tumorigenesis. 
It has been demonstrated that cancer is a multistep mutation process, during 
which several genetic and epigenetic changes (hits) occur on the way to the 
formation of the malignancy. This was first described with regard to colorectal 
cancer by Vogelstein and colleagues [131]. In addition to the multiple-hits concept, 
there is evidence that genes supporting functional pathways may be co-localized 
in the genome, and that this co-localization has an evolutionary basis. According 
to Lee and Sonnhammer’s study of 975 genes in 98 KEGG29 pathways in Homo 
sapiens, genes from the same metabolic pathway show a significant tendency to 
cluster higher than would be expected if they only clustered by chance [132]. 
These observations imply that evolutionarily conserved clusters of co-expressed 
genes have a functional contribution as architectural components of the genome 
[133].  
In cancer, chromosomal content and structure undergo major alterations, resulting 
in genome instability. Aneuploid chromosomes and segmental gains and losses 
are considered to be among the broad alterations in cancer, affecting segments 
harboring genes with possible functional association [134]. An eminent example of 
this is the CDKN2A locus on Chr 9p21 with co-localization of the genes encoding 
for p16INK4a and p14ARF. A deletion at this locus inactivates both TSGs with an 
ultimate effect on cell-cycle regulation [135]. Another example is the amplifications 
of Chr 1q21.2 reported in different cancers such as melanoma and lung 
carcinoma; in vivo studies confirmed the tumor growth dependency on MCL1 and 
BCL2L1 amplification and up-regulation as anti-apoptotic genes on Chr 1q21.2 
[136-138].  
                                                
29 Kyoto Encyclopedia of Genes and Genomes 
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Regions with copy number changes show significant enrichment of ontology terms 
associated with cancer, such as adhesion and methylation in regions of loss, and 
growth and kinase in regions of gain [138]. On the other hand, despite the 
discovery of a high number of genes mutated in different cancers, only a limited 
number of pathways with aberrations (such as WNT, NOTCH, or RTK) contribute 
to tumorigenesis [139].  
Together, these observations suggest that cancer is not driven by a single gene, 
but by a combination of multiple genes disturbing a few attributes as contributing 
factors in cancer evolution [140].  
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1.10. Hypotheses and Aims of this Study 
The process of oncogenesis could be fundamentally separated into two distinct 
chronological phases: cancer initiation and cancer maintenance. Much has been 
reported about cancer initiation, but the genetic components that maintain cancer 
growth despite cellular stresses such as immune surveillance and the challenges 
of ectopic growth are still largely unknown.   
Though cancers are inherently more vulnerable than normal cells, they are 
characterized by specific genomic configurations, which allow them to survive.  
I hypothesized that melanoma is sustained by genomic modules, which are 
fundaments for sustaining a tumor’s functional maintenance. I defined these 
maintenance functional modules as core sets of somatic mutations persisting 
throughout the tumor evolution of any given melanoma patient. I believe that 
melanoma is not driven by a single gene, but rather by these maintenance 
functional modules, definable as networks of correlated genes mediating a tumor’s 
functional maintenance in an additive or synergistic manner. In other words, the 
mutual effect of the clustered genes within these networks on a tumor phenotype 
is equivalent to (additive) or greater than (synergistic) the sum of the individual 
effects of these genes. These networks can be exclusive to one patient, exist in a 
minor sub-set of patients, or be common to the majority of patients. In any of these 
cases, the genes within these networks perform in a cooperative manner with a 
significant effect on the tumor phenotype, and ultimately a profound impact on 




In this study, I aimed to investigate the systems biology of tumor maintenance in 
melanoma, as defined by somatic mutations that alter the expressional landscape, 
including SMs, CNVs, and SNVs; I refer to this phenomenon as the hardwired 
landscape of the cancer genome.  
As recent evidence has shown that the normal genome is organized in such a way 
that cancer-promoting genes are organized by proximity, my hypothesis suggests 
that cancer-specific SMs are selected to optimize the simultaneous expression 
and silencing of multiple oncogenes and TSGs, respectively [141-143].  
 
 
To test my hypothesis, I proceeded with the following aims: 
 
 
Specific aim 1:  
I performed a comprehensive genomic examination using high-throughput 
sequencing (HTS) platforms, including DNA–PET, exome–capture sequencing, 
and RNAseq, to identify the components of clustered somatic changes leading to 
the maintenance functional modules because of evolutionary selected and 








Specific aim 2:  
I identified the maintenance functional modules as the collection of genomic 
changes found in all tumor specimens from the same patient. These modules 
have the potential to optimize the tumor’s functional  maintenance.  
As a proof of concept, I used a complete set of tumors and matched cell lines from 
one melanoma patient with poor prognosis, whose melanoma metastasized first at 
the axillary lymph node, and then in the lung. I refer to this patient as Patient7PoC. 
Multiple tissues from different stages of the disease provided a valuable model 
system to look for the genomic commonalities across all tumor tissues and cell 
lines obtained from this patient. A detailed examination of the comprehensive 
catalogue of somatic events in Patient7PoC revealed a core set of hardwired 
somatic events common in all samples from this patient.  
As a ‘proof of concept’ and for the purpose of functional validation, I focused on a 
maintenance functional module engaging Chr 7, Chr 9, and Chr 12: I refer to this 
module as FM7/9/12.  
Specific aim 3:   
I hypothesized that within each melanoma patient there is a core maintenance 
functional module, which is shared across many melanomas. Therefore, I 
generalized the discovered maintenance functional module (FM7/9/12) in Patient7PoC 
to a larger cohort of melanoma patients. This cohort consisted of another seven 
patients with comprehensive genomic and transcriptomic data. My goal was to 
identify components of the FM7/9/12 with general contribution to melanoma.  
I tested the functional contribution of the selected components of the FM7/9/12 to the 
tumor phenotype – including proliferation and apoptosis – in two different cell lines 
derived from the metastatic tumors of Patient7PoC.   
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Specific aim 4:  
I hypothesized that elements of the maintenance functional module modulate the 
effect of the BRAF inhibitor as the most impactful targeted therapy in melanoma. 
Therefore, I assessed whether the components of the functional module (FM7/9/12) 
that showed a positive effect on the tumor phenotype could perform synergistically 
when used in combination with the BRAF inhibitor.   
 
Specific aim 5:  
I hypothesized that there are several maintenance functional modules in 
melanoma; therefore, I extended my model to a larger cohort of melanoma 
patients to define a Universal Functional Module (UFM) in general. To achieve 
that, I used the full set of eight patients with either good or poor prognosis, with 
their complete catalogue of somatic events as an exploratory set, and 232 tumors 
in the TCGA database30 as a validation set.  
I classified as UFM those genes affected by hardwired changes that are shared by 
all specimens of any given patient (of the eight patients) with those hardwired 
changes seen in a same direction of copy number and expressional changes  in 
the TCGA melanoma tumors. 
 
In this study, my overall goal was to discover the generic space of melanoma 
modules that are responsible for a tumor’s functional maintenance.  
                                                
30 Downloaded on May 2013 
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1.11. Study Design 
The design of my study is depicted in Figure 2 below.  
Figure 2a shows the list of patients/samples used in this study; good(G) and poor(P) 
refer to the clinical outcome. Abbreviations: peripheral blood lymphocyte (PBL), 
lymph node metastasis tumor (LNM-T3), cell line from lymph node tumor (LNM-
CL3), distant metastatic tumor: (DM-T4), cell line from distant metastasis (DM-
CL4), Human Epidermal Melanocytes (HEMs), adult-lightly pigmented donor (A-
LPD), neonatal-darkly pigmented (N-DPD), neonatal-moderately pigmented donor 
(N-MPD); (please refer to section 2.1).  
Figure 2b shows the next-generation sequencing platforms that were applied to 
catalogue the comprehensive somatic variations (for detailed description, refer to 
section 3.1). 
Figure 2c is a schematic presentation of my model system: samples obtained from 
Patient7PoC are presented; M stands for the maintenance functional module as a 
core set of somatic events common in all samples of this patient. As a proof of 
concept and for the purpose of functional validation, I  focused on FM7/9/12 – the 
maintenance functional module engaging Chr 7, Chr 9, and Chr 12 (for detailed 
description, refer to section 3.4.1.1).  
Figure 2d shows components of the FM7/9/12 that I generalized to a larger cohort of 
melanoma patients to identify a general maintenance functional module in 
melanoma for the purpose of functional validation (for detailed description, refer to 
section 3.4.2).  
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Figure 2e shows the functional validation of the selected components of the 
FM7/9/12 that I performed in both cell lines derived from Patient7PoC’s tumor tissues. 
This validation covered two aspects: first, the functional contribution of the 
maintenance functional module to tumor features including proliferation and 
apoptosis (for detailed description, refer to section 4.5); second, the possible 
presence of synergy between components of the FM7/9/12 and BRAF inhibitor as a 
measurement of clinical impact of the maintenance functional module (for detailed 
description, refer to section 4.6).  
Figure 2f shows that I first used eight patients with multiple samples and their 
comprehensive catalogue of somatic mutations to generalize the maintenance 
concept (for detailed description, refer to section 5.1).  
Figure 2g shows that I categorized genes with hardwired changes across all 
samples of a particular patient as Exploration Functional Module (EFM). G.M. and 
P.M. refer to common events across all samples of good and poor patients, 
respectively. I then used the TCGA melanoma dataset for generalization and 
validation of the EFM and discovery of a Universal Functional Module (UFM) (for 
































2.1. Melanoma patients 
 In collaboration with the John Wayne Cancer Institute (JWCI), we have access to 
a unique set of clinical samples obtained from patients diagnosed with melanoma. 
The IRB protocol was that of WIRB (Western Institutional Review Board) approved 
by the review board of the JWCI, where the clinical samples were obtained. Here, 
I present the comprehensive results from a pilot study comprising a set of eight 
patients, who were characterized by either a good or a poor clinical outcome. In 
this study, I have analyzed the following specimens (Table 1): 
 Four good prognosis patients (patients 1,2,3 and 4):   
 Peripheral blood lymphocytes (PBLG_) as a source of normal genomic DNA 
 Tissues from lymph node metastasis (stage III; LNM-T3G_) 
 Cell lines derived from lymph node metastases (LNM-CL3G_) 
 
 Four poor prognosis patients (patients 5,6,7 and 8): 
 Peripheral blood lymphocytes (PBLP_) 
 Tissues from lymph node metastasis (stage III; LNM-T3P_) 
 Recurrent stage IV tissue (two skin or two lung metastases) (stage IV, DM-
T4P_) 
 Cell lines derived from lymph node and lung metastases (LNM-CL3P7 and 
DM-CL4P7, respectively, derived from Patient7PoC) 
Human Epidermal Melanocytes (HEMs) were used as a source of normal RNA 
and for the purpose of expression analysis.   
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Table 1: Patients, samples and corresponding assays 
 
Patients Specimen DNA–PET Exome RNAseq SNP array31 
Good 
Patient1G 
PBLG1 Yes Yes - - 
LNM-T3G1 Yes Yes Yes - 
LNM-CL3G1 - - - Yes 
Patient2G 
PBLG2 Yes Yes - - 
LNM-T3G2 Yes Yes Yes - 
LNM-CL3G2 - - Yes Yes 
Patient3G 
PBLG3 Yes Yes - - 
LNM-T3G3 Yes Yes Yes - 
LNM-CL3G3 Yes - Yes - 
Patient4G 
PBLG4 Yes Yes - - 
LNM-T3G4 Yes Yes Yes - 
LNM-CL3G4 - - - Yes 
Poor 
Patient5P 
PBLP5 Yes Yes - - 
LNM-T3P5 Yes Yes Yes - 
DM-T4P5 Yes Yes Yes - 
Patient6P 
PBLP6 Yes Yes - - 
LNM-T3P6 Yes Yes Yes - 
DM-T4P6 Yes Yes Yes - 
Patient7PoC 
PBLP7 Yes Yes - - 
LNM-T3P7 Yes Yes Yes - 
LNM-CL3P7 Yes Yes Yes - 
DM-T4P7 Yes Yes Yes - 
DM-CL4P7 Yes Yes Yes - 
Patient8P 
PBLP8 Yes Yes - - 
LNM-T3P8 Yes Yes Yes - 
DM-T4P8 Yes Yes Yes - 
HEMs 
(Donors) 
A-LPD - - Yes - 
N-DPD - - Yes - 
N-MPD - - Yes - 
 
 
A total number of 23, 22 and 19 DNA–PET, exome–capture, and RNAseq 
libraries, respectively, were constructed and sequenced. Abbreviations: peripheral 
blood lymphocyte (PBL), lymph node metastasis tumor (LNM-T3), cell line from 
lymph node tumor (LNM-CL3), distant metastatic tumor: (DM-T4), cell line from 
distant metastasis (DM-CL4), Human Epidermal Melanocytes (HEMs), adult-lightly 
pigmented donor (A-LPD), neonatal-darkly pigmented (N-DPD), neonatal-
moderately pigmented donor (N-MPD). 
                                                
31 Genome-Wide SNP 6.0 array: copy number status for these three cell lines was 
kindly provided by JWCI. 
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2.1.1. Primary melanoma cell lines 
Melanoma cell lines were established32 from the tumor samples of the same 
patients under study, as previously described33 [144].  
 
2.1.1.1. Cell culture 
I cultured the melanoma cells in complete culture medium consisting of RPMI 
supplemented with 10% fetal bovine serum (FBS), L-glutamin, 1% penicillin-
streptomycin and Amphotericin B (Gibco, Invitrogen). All cell cultures were kept at 
standard incubator conditions of 37°C with 5% CO2. I rinsed the cells at 80-90% 
confluence with PBS (Ca2+/Mg2+) and trypsinized with 0.025% trypsin-EDTA 
(Gibco, Invitrogen) for 2 minutes at 37°C. Adding the complete medium to the 
detached cells neutralized the trypsin function; I centrifuged the cells, re-
suspended in complete medium, at 800g for 5 minutes at room temperature. Then, 
I re-plated the resulting cell pellet in a new 15 cm plate at a concentration of 1.5 x 
106, in 25 mL of final volume. A Neubauer haemocytometer was used for cell 
counting. 
 
2.1.1.2. Cells’ freeze and thaw 
Harvesting and counting the cells was performed as described in previous sub-
section. Following centrifugation, I re-suspended cell pellets in freezing medium 
(containing 80% complete medium plus 10% FBS and 10% cell culture grade 
DMSO) at a concentration of 1.5 x 106 cells/ mL and dispensed into cryovials. 
                                                
32 By JWCI 
33 Kindly provided by JWCI 
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Cryovials were kept in a Nalgene freezing container at -80°C for 24 hours before 
transferring to the liquid nitrogen. This period allowed an optimal decrease of 
temperature (-1°C per minute) and inhibited intracellular ice crystals formation.  
To re-establish cell cultures, frozen cellin cryovials were rapidly defrosted in a 
water bath at 37°C. 5 mL complete medium was added slowly to the thawed cells. 
Following centrifugation at 800g for 5 minutes, the resulting pellet was re-




2.2. Next-generation sequencing (NGS)34 
To identify the entire collection of the genomic and transcriptomic aberrations in 
melanoma, I used a combination of HTS approaches. I performed DNA–PET 
sequencing and exome–capture sequencing to catalogue all of the somatic SMs 
and SNVs affecting the tumor genome, as well as for fusion gene discovery. DNA–
PET was a suitable method to detect all types of SMs –insertions, deletions, 
inversions, tandem repeats, and translocations – and it provided the CNV data 
[145]. Exome–capture sequencing allowed the detection of SNVs [146]. At the 
transcriptomic level, using paired-end RNAseq, gene expression levels were 
measured [147]. Following library construction from tumor and normal samples, 
SOLiD35 (version 4), Illumina GAIIx, and Illumina HiSeq 2000 sequencing 
platforms were used for the processing of DNA–PET, exome-capture, and 
                                                
34 I carried out all library constructions and quality assessments for all NGS 
platforms. 
35 Sequencing by Oligonucleotide Ligation and Detection 
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RNAseq libraries, respectively36. The sequenced reads were then mapped back to 
the human reference genome (version hg19). Both the tumor DNA and its normal 
counterpart (DNA isolated from PBLs) were sequenced, so that a pair-wise 
comparison analysis could define the cancer-specific profile. I performed extensive 
validation of the identified somatic rearrangements and point mutations by means 
of PCR and Sanger sequencing. Integrative analysis of data provided by DNA–
PET, RNAseq, and exome–capture sequencing technologies defined the 
comprehensive catalogue of somatic events taking place in melanoma.  
In the following section, I will describe the protocols for library construction, quality 




2.2.1.1. DNA–PET: Library construction and quality assessments 
This section describes a 2x50 bp mate-paired library construction method suitable 
for SOLiD™ System sequencing37. This mate-paired library originates from the two 
ends of the same genomic DNA fragment.  
Figure 3 below is a schematic representation of the library construction workflow. 
To obtain 10 kb fragments, the HydroShear DNA Shearing Device (setting: large 
shearing assembly at speed code= 10) was used to shear at least 30 ug of 
genomic DNA (Table 2). Because large DNA fragments are sensitive to vortexing 
and they may be sheared further, any following step involving DNA mixing or re-
suspending was done by gently inverting tubes or tapping with fingers. Then, LMP 
                                                
36 Performed by the GIS NGS team 
37 Applied Biosystems 
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CAP linkers (ABI SOLiD oligos kit) were ligated to both ends of the end-repaired 
sheared DNA. The sheared DNA was separated by gel electrophoresis, using 
0.5% agarose gel at 80V for 20 min, followed by 20V for 22-24 hours at room 
temperature, to separate 10 kb-sized DNA fragments, as well as other fragments 
of increasing or decreasing size, at 1 kb intervals. Three different ladders were 
loaded as well: Fermentas Generuler High Range ladder (~1 µg), Fermentas 
Generuler 1 kb ladder, and Invitrogen 1 kb Plus ladder (~2 µg). DNA extraction 
from the 10 kb excised fragments was performed using QIAEXII Gel Extraction Kit 
(Qiagen). To choose the most suitable insert DNA with correct size, high purity, 
and enough concentration for circularization, an Agilent DNA 12000 assay was 
performed on size-selected DNA fragments (7 to 11 kb DNA). 8-10 kb fragments 
were selected for all samples, except for three samples, due to low concentration 
of the 8-10 kb fragments, but good quality of the 4-7 kb fragments (Figure 4a 
below). Supported by in silico analyses, larger insert DNA (e.g. 10 kb compared to 
3 kb) results in higher physical coverage, and therefore higher chance of 
breakpoint detection [148, 149]. Then, the 5' and 3' mate-paired sequence tags 
(2×50 bp) were extracted from the selected DNA fragment (insert DNA): a 
minimum amount of 500ng DNA was used for circularization with internal 
adaptors. The LMP CAP Adaptor did not have the 5′ phosphate in one of its 
oligonucleotides; therefore, the resulting DNA circle had one nick in each strand. 
Nick translation of circularized DNA was carried out using E. Coli DNA 
Polymerase I, which pushed the nick into the genomic DNA region in the 5′ to 3′ 
direction. The incubation time and temperature in this step were crucial in 
determining the length of nick-translated DNA, and the size of the final library. T7 
exonuclease and S1 nuclease digestion cut the DNA at the position opposite to 
the nick, and released the DNA paired-end tag constructs (50 bp tags). End-
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repaired DNA was bound to Streptavidin beads. Then, SOLiD Adaptors P1 and P2 
(SOLiD Oligos kit) were ligated to the ends of the mate-paired library for 
subsequent amplification by PCR. A trial PCR was set up with different number of 
PCR cycles to check the intensity of the DNA library – usually at least 13 cycles, 
but not more than 16 cycles). The PCR product was imaged on a Dark Reader to 
visualize the 250-350 bp DNA libraries, which appeared as a smear. Large scale 
PCR was then performed with the appropriate number of PCR cycles. The 
obtained DNA libraries were purified and run on a 6% TBE PAGE gel, with a 25 bp 
DNA Ladder (Invitrogen), at 200V for 35 minutes. After staining with SYBR Green 
for 15 minutes, the gel was imaged on a Dark Reader to excise the 250-350 bp-
sized DNA libraries. The gel-purified library was quantified by Agilent DNA 1000 
assay to access the purity, size, and concentration of the final library (Figure 4b 
below). The final suitable libraries were processed using the SOLiD sequencing 
platform, and 50 bp paired-end-tags were generated. Up to 200x genome-wide 




















Figure 4: DNA–PET library construction - quality checks 
a) With Agilent DNA 12000 assay, an appropriate inset DNA was selected for 
circularization; left: summary of electrophoresis for the DNA ladder and 7-11 kb 
fragments; right: example of an appropriate 8-9 kb fragment with acceptable purity 
and concentration for circularization.   
b) With Agilent DNA 1000 assay, the quality of the final library was assessed for 
sequencing. Left: summary of electrophoresis for ladder and final library for three 
samples (PBL, lymph node and lung tumors).Right: example of a successful 




2.2.1.2. DNA–PET: Sequence assembly and data analysis 
The Computational and Systems Biology Research Group in GIS38 performed the 
raw data processing and identification of SMs and CNVs; sequenced paired-reads 
were mapped back to the hg19, library span range (library insert size) was 
determined and duplicate PETs were removed. Paired-reads were classified into 
either discordant PETs (dPETs) or concordant PETs (cPETs). cPETs represented 
the consistency between the cancer genome and the reference genome and were 
used to detect CNVs; these paired-end tags mapped to the reference genome 
sequence as expected (both ends map to the same chromosome, and the same 
strand in the 5′→3′ orientation, and within expected distance). On the other hand, 
dPETs were indicative of structural differences between the cancer and reference 
genomes. According to the dPET classification scheme, long span dPET clusters 
show deletions; incorrect orientation clusters show tandem replication; different 
strand clusters demonstrate inversions; and different chromosome clusters 
represent translocations (Figure 5 below). To remove the possible technical 
noises, at least three dPETs must span the predicted breakpoints of a respective 
rearrangement. 
 
                                                
38 Charlie LEE, Pramila ARIYARATNE, and Fabianus MULAWADI processed the 




2.2.1.3. DNA–PET: Somatic variants calling 
The cluster size is a measure of confidence and precision in the SM prediction. 
Figure 6 below shows how cluster size is defined for each SM. To cluster39 
different dPETs that span the same fusion point, the following procedure was 
applied: the mapping location of the 5' and 3' tags of a given dPET was extended 
by the maximum insert size of the respective genomic library in both left and right 
directions, creating 5' and 3' windows. If the 5' and 3' tags of a second dPET 
mapped within the 5' and 3' windows of the first dPET, the two PETs were defined 
as a cluster of size equal 2 and the 5' and 3' windows were adjusted so that they 
contained the tag extensions (by the maximum library size) of the second dPET. 
dPETs that subsequently mapped with their 5' and 3' tags within the 5' and 3' 
windows, respectively, were assigned to this cluster and the windows were 
adjusted, if necessary. The number of dPETs clustering together around a fusion 
point was represented by the cluster size. The genomic region covered by the 5’ 
tags of a cluster was defined as the 5' anchor, whereas 3' anchor was the genomic 
region covered by the 3’ tags of a cluster; Figure 6 below represents a SM with 
cluster size equal to 4.  
To define the somatic SMs, a pair-wise comparison was performed between each 
tumor sample and its paired normal sample (Figure 7a below). Furthermore, dPET 
clusters with low confidence (clusters with anchor size < 1kb and cluster size < 4) 
were removed from the analysis. The cancer specific profiles were further 
compared with previously published data [150, 151] and with a GIS in-house 
database of normal SMs, which comprises 19 libraries generated from normal 
                                                
39 Cluster: both PETs overlap with other PETs; (Super-cluster: if at least one of the 
dPETs of one cluster covers the dPETs of another cluster) 
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genomic DNA as part of previous studies. This additional cross-comparison aimed 
at the further filtration of putative normal events that may have been missed in the 
paired normal library and provided a final catalogue of somatic events for each 
tumor library (Figure 7b below). I validated the presence of the identified tumor 
SMs with PCR and Sanger sequencing; for the validated SMs, the breakpoint 





Figure 5: Detection of SMs using dPETs40 
dPETs represent inconsistencies between the cancer genome and the reference 
genome. According to the dPET classification scheme, long span dPET clusters 
show deletions; incorrect orientation clusters show tandem replication; different 






                                                




Figure 6: A schematic presentation of cluster size in DNA–PET analysis41 
The number of dPETs clustering together around a fusion point is represented by 
the cluster size. This Figure represents a SM with cluster size equal to 4. To 
cluster different dPETs that span the same fusion point, the mapping location of 
the 5' and 3' tags of a given dPET was extended by the maximum insert size of 
the respective genomic library in both left and right directions, creating 5' and 3' 
windows. If the 5' and 3' tags of a second dPET mapped within the 5' and 3' 
windows of the first dPET, the two PETs were defined as a cluster of size equal 2 
and the 5' and 3' windows were adjusted so that they contained the tag extensions 
(by the maximum library size) of the second dPET. dPETs that subsequently 
mapped with their 5' and 3' tags within the 5' and 3' windows, respectively, were 
assigned to this cluster and the windows were adjusted, if necessary. The 
genomic region covered by the 5’ tags of a cluster was defined as the 5' anchor, 
whereas 3' anchor was the genomic region covered by the 3’ tags of a cluster. 
  
                                                







Figure 7: Somatic variant calling42 
a) Pair-wise comparison: to define the somatic SMs, a pair-wise comparison was 
carried out between each tumor sample and its paired normal sample. b) cross-
comparison: a final catalogue of somatic events for each tumor library was 
identified using an additional crosscomparison. This crosscomparison aimed at the 
further filtration of putative normal events that may have been missed in the paired 
normal library. For this crosscomparison, we compared the cancer specific profiles 
with previously published datasets and with a GIS in-house database of normal 
SMs. 
                                                
42 GIS DNA-PET pipeline 
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2.2.1.4. DNA–PET: Copy Number Variation 
To define CNVs using NGS data, the density of cPETs along the entire genome 
was computed43. CNVs can be estimated by comparing cPET densities between 
the tumor and the normal genome; but due to the possible normal contamination 
of the tumor samples, the observed CNVs differ from the expected levels of a pure 
tumor making it difficult to detect discrete changes in copy number. In order to 
enhance the power of detection of copy number states, we considered the B-Allele 
Frequency (BAF) information generated by exome–capture sequencing data. A 
ratio between the tumor and normal copy number signals was calculated per 10kb 
windows. Circular Binary Segmentation (CBS) was applied on the copy number 
ratio44: parameters were chosen to agree with validated aberrations (such as 
deletion of CDKN2A) without over-segmenting the data (Figure 8a below). BAFs 
from the exome data were normalized using TumorBoost [152], and integrated 
with the copy number signals. The main steps of TumorBoost included defining 
the normal deviation from the expected genotype (0, ½, 1), using the normal 
deviation to estimate the tumor deviation from expected and finally correcting the 
BAF in the tumor. Normalized BAF data were overlapped with copy number signal 
density plot and the BAF profile was plotted for each peak on the density plot 
(Figure 8b below). The comparison between the density plot and the BAF profiles 
allowed determining the thresholds for the copy number changes. This method did 
not change the copy number values. It only aimed at increasing the power of 
detection of CNVs by normalizing the BAF values.  
  
                                                
43 GIS DNA-PET pipeline 










Figure 8:  Detection of copy number variations 
a) Density plot of the segmented copy number ratio and final copy number calls; 
D, L, N, G and A define deletion, loss, normal, gain and amplification, respectively. 
b)45 Normalized copy number ratio (CNR) per 10kb windows is shown in the 
Manhattan plot. Threshold for gain and loss are shown with red and blue dashed 








                                                
45 Plotted by Dr. Sigrid Laure Rouam 
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2.2.2. Exome–capture sequencing 
2.2.2.1. Exome–capture: Library construction and quality assessments 
This section describes the procedures used for exome library construction using 
NimbleGen’s SeqCap EZ Exome Library46: this solution-based exome–capture 
requires less amount of input DNA compared to chip-based exome–capture; this 
method provide at least 20x physical coverage and it targets 40-60Mb of the 
genome. This method is suitable for sequencing the captured amplified DNA with 
Illumina GAIIx. To capture all coding exons, I hybridized the Exome Library47 to the 
amplified sample library. The captured DNA was then amplified using ligation-
mediated PCR (LM-PCR). Briefly, 3µg genomic DNA was sheared (settings= 
Frequency Sweeping Mode, duty cycle= 10%, cycles per burst= 200, intensity= 2, 
Time= 3 times, each 1minute, water bath temperature limit= 6°C). The sheared 
DNA was purified using Ampure beads. The size and quality of the sheared DNA 
was assessed with Agilent DNA 1000 assay (Figure 9a below); samples with right-
skewed (large fragments) graph were sheared again to get a favorable size of 
DNA. End-repair was done using the NEBNext End Repair kit48 and the sample 
was purified in a QiaQuick column. DuringdA-Tailing Reaction using Klenow 
Fragment, 3' A bases were added to the repaired DNA ends. Following sample 
purification in MinElute columns, a Paired-End adaptor was ligated using Quick T4 
DNA Ligase. The adaptor-ligated library was purified with Ampure beads and was 
amplified with PE-HE1, 2 primers during 6 cycles of LM-PCR. The amplified library 
was then purified. The quality, concentration, and purity of the adaptor ligated 
                                                
46 2010 Roche NimbleGen Inc. 
47 Containing the complete set of biotinylated long oligonucleotide probes  
48 New England BioLabs Inc. 
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DNA was checked before and after LM-PCR (Figure 9b and c, below). I used the 
Roche NimbleGen protocol for hybridization of the amplified sample library and the 
Exome Library. In short, COT DNA and PE-HE1 and PE-HE2 OligosPE= Paired 
End; HE= Hybridization Enhancing) were added to the amplified sample library 
and then the component was dried in a DNA vacuum concentrator on high heat 
(60°C). After adding the Hybridization Cocktail (2X Hybridization Buffer + 
Hybridization Component A), the amplified sample library/ COT DNA/ PE-HE 
Oligos/ Hybridization Cocktail was transferred to the Exome Library (4.5µl) and 
incubated in a thermocycler at 47°C for 64 - 72 hours. Then, Streptavidin 
Dynabeads were used to recover the captured DNA. The captured DNA was then 
amplified using LM-PCR. To minimize the PCR bias, 2 reactions per sample were 
performed independently and their products were subsequently combined. The 
amplified captured DNA was cleaned up using a Qiagen QIAquick PCR 
Purification Kit. The concentration, size distribution, and quality of the amplified 
captured DNA and the negative control was determined using Agilent DNA 1000 
assay (Figure 9d below). The negative control did not show significant 
amplification – indicative of no contamination. The amplified captured DNA met 
the required criteria: the LM-PCR yield was more than 1.0µg; the A260/ A280 ratio 
measured by NanoDrop spectrophotometer was 1.7 - 2.0; and the average 
fragment length was 150 - 400bp. The amplified captured DNA was sent for 
sequencing if the enrichment measured by qPCR LightCycler® 480 Instrument49 
was successful: for this assay two internal control loci were tested; these loci were 
included as capture targets in SeqCap EZ Exome Library. Relative quantification 
comparing the control targets in amplified sample library (pre-hybridization) and 




the corresponding amplified captured DNA (post-hybridization) was done using 
raw Cp values (obtained in qPCR assay) to check the fold enrichment. All samples 
with successful enrichment (fold enrichment > 50) generated higher Cp value for 
pre-hybridization comparing to post-hybridization – amplified and captured– DNA 
sample (Table 3). Moreover, the melting curve (dissociation) analysis verified that 
there was not any non-specific contribution to the Cp values for any samples. If 
the results of the qPCR assays indicated a successful enrichment, I sent the 
amplified captured DNA for sequencing on Illumina GAIIx. 
 
2.2.2.2. Exome–capture: Sequence assembly and data analysis 
Paired-end reads generated using the SOLEXA technology were mapped to the 
UCSC hg19 using ELAND [153]50. After the quality control, the mapping was 
further refined by applying the realignment module of GATK51. Finally, the base 
quality value was re-calibrated using GATK. SNVs were called for each sample 
separately using SAMtools (v0.1.17)52, (Consensus-quality threshold <= -30 or >= 
30, SNP-quality threshold= 20) [154]. Identical variant calls in tumor and matched 
normal samples identified germline variants. Variant calls unique to the tumor 
were called as somatic variants. The possible functional consequence of the SNVs 
was annotated using the PolyPhen-253 [155] and SIFT54 programs [146]. 82.98–
798.1 were the coverage range across sequenced libraries.  
                                                
50 Done by Dr. Denis Bertrand, GIS, Singapore 
51 The Genome Analysis Toolkit 
52 Sequence Alignment/Map 
53 Polymorphism Phenotyping v2 


















Figure 9: Exome–capture library construction – quality checks   




 Figure 9: 
a) An example of successful shearing (left skewed) confirmed by Agilent DNA 
1000 assay. b) Acceptable concentration and purity for the adaptor ligated DNA 
before LM-PCR; c) Acceptable concentration and purity for the adaptor ligated 
DNA after LM-PCR; d) an example of accepted size and concentration for the 






Table 3: Enrichment assessment of amplified captured DNA 
 
The enrichment of amplified captured DNA was assessed with qPCR with two loci.  
Higher Cp value for pre-hybridization compared to post-hybridization shows a 
successful enrichment. 
dcp*= Cp2 (pre-hybridization) - Cp1 (post-hybridization) 
Fold Enrichment**= POWER (PCR Efficiency55, dcp) 
 
 
                                                
55Primer replication efficiency; In theory, = 2; but in reality, = 1.8 or 1.84 
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2.2.3. SOLEXA Paired-end RNAseq56 
2.2.3.1. RNAseq: Library construction and quality assessments 
This section describes the procedure I used to prepare cDNA library for 
subsequent sequencing on the Illumina platform (HiSeq 2000) [156]. I used 
Illumina TruSeq™ RNA Sample Preparation Kit. Figure 10 below is an overview of 
the library construction procedure. To construct the libraries, I checked the 
integrity of all RNA samples using Agilent RNA Pico 6000 (Figure 11a below). 
cDNA libraries were prepared for samples with RNA Integrity Number (RIN) of 
value ≥ 8.0. Poly‐T oligo‐attached magnetic beads were used to purify poly‐A 
containing mRNA molecules from total RNA (5-10 µg). mRNA was selected in two 
steps; first using TruSeq RNA Purification Beads (RBP) and second with TruSeq 
Bead Binding Buffer (BBB).The unbound RNA was washed away in each step. 
Then, mRNA was primed and fragmented using Elute, Prime, and Fragment Mix 
(EPF). This Mix contained random hexamers for reverse transcription priming and 
served as the first strand cDNA synthesis reaction buffer. Under elevated 
temperature, the mRNA was fragmented into small pieces using divalent cations. 
The fragmented-primed RNA was copied into first strand cDNA using Invitrogen 
SuperScript II Reverse Transcriptase. DNA Polymerase I and RNase H were used 
for the second strand cDNA synthesis. Following purification by AMPure XP 
beads, and DNA end-repair, 3' adenylation and adaptors ligation were carried out. 
DNA fragments were enriched by PCR and purified to create the final cDNA 
library. AMPure XP beads can be used to remove samples more than 600bp and 
                                                
56TruSeq RNA Sample Preparation Kit, Protocol is adapted from Illumina TruSeq 
RNA Sample Preparation (revised by Alexis Khng), approved by Dr. Ruan Xiaoan 
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recover samples less than 600bp. The quality of the final library was checked 
using Agilent DNA 1000 (Figure 11b below). The final product was a DNA smear 
of 250-600bp, with a maximum peak around 260-290bp. Moreover, to determine 
the optimal loading concentration in the downstream cluster generation process, I 
performed qPCR to accurately quantify the final library constructs (Table 4): the 
DNA sample was diluted to a 5nM concentration and duplicate reactions at 80pM, 
40pM, 20pM and 10pM dilutions and negative controls were used in the qPCR 
quantification. Satisfactory qPCR results was obtained when maximum efficiency 
≈ 2, 6 < Cp values < 12, Ct / CP < 20pM, Cp values versus log concentration with 
a linear trend-line and R2 value > 0.99. No contamination was observed, as there 
was no amplification for negative controls. Only one melting peak for each sample 
was observed. If the result of the qPCR assay was acceptable, I sent the final 
DNA library for subsequent sequencing on Illumina platform (HiSeq 2000). 
 
2.2.3.2. RNAseq: Sequence assembly, data analysis 
The Computation and System’s Biology Research Group in GIS did the raw data 
processing57; paired-end Illumina reads was mapped to the reference human 
genome (UCSC hg19) using TOPHAT. Expression values were called for each 
sample separately using Cufflinks [157] and measured in Fragments Per Kilobase 
of transcript per Million mapped reads (FPKM)58 [130]. 
  
                                                
57 Done by Dr. Denis Bertrand, GIS, Singapore 





Figure 1059: Schematic presentation of library construction procedure for SOLEXA 
Paired-end RNAseq 
From total RNA, poly‐A containing mRNA molecules were purified using poly‐T 
oligo‐attached magnetic beads. mRNA was primed and fragmented using random 
hexamers for reverse transcription priming, and served as the first strand cDNA 
synthesis reaction buffer (Part A). The fragmented-primed RNA was copied into 
first strand cDNA using Invitrogen SuperScript II Reverse Transcriptase. DNA 
Polymerase I and RNase H were used for the second strand cDNA synthesis (Part 
B-C). Following purification by AMPure XP beads, and DNA end-repair (Part D), 3' 
adenylation (Part E) and adaptors ligation (Part F) were carried out. DNA 
fragments were enriched by PCR and purified to create the final cDNA library (Part 
G).  
                                                








Figure 11: RNAseq library construction – quality check 
a) A typical profile of a good quality total RNA sample (RIN ≥ 8.0) run on Agilent 
RNA Pico 6000, b) profile of a typical processed RNA showing a smear in the 250-


















Example of a successful qPCR results on final RNAseq library: a) linear trend-line 
for Cp values vs. log concentration (R2 value > 0.99), b) 6 < Cp values < 12, and 














2.3. Functional study of putative driver genes - High content screening 
(HCS) platform 
I examined the functional correlation of the putative cancer genes within the 
maintenance functional module, using the primary cell lines of Patient7PoC. To 
assess the oncogenic properties of the candidate genes, I performed siRNA-
based screening using HCS platform and I measured the incorporated EdU (Click-
iT EdU Alexa assay) and Caspase (Caspase-3 antibody) as indicators of active 
cell proliferation and apoptosis, respectively [158-160]. The Click-iT EdU Alexa 
assay is an accurate method of proliferation analysis through direct measurement 
of DNA synthesis. This antibody-based assay is a more robust assay for analyzing 
DNA replication as compared to bromodeoxyuridine (BrdU) methods. EdU (5-
ethynyl-2´-deoxyuridine) is a thymidine analog, which is incorporated into DNA 
during active DNA synthesis. Caspases are synthesized as inactive pro-enzymes 
that are processed to active form in cells undergoing apoptosis.  
2.3.1. Dharmacon siRNA library reconstitution 
siRNA libraries were ordered in 96-well-plate format (Thermo Fisher Scientific). I 
reconstituted each lyophilized siRNA to a final concentration of 25nM using 1 X 
siRNA buffer. The printing procedures (diluting the mother plate to the final 
daughter plates) are shown in Figure 12 below. All plates with different 
concentrations of siRNA were kept at -20°C for short-term and at -80°C for long-
term storage. Gene knockdown experiments were performed using 25nM siRNA 
(2.5µl) for candidate genes and positive and negative controls. 0.2µl lipofectamine 
 68 
 
RNAimax60 diluted in 17.3µl Opti-MEM was added per well with SciClone61. 
Following 20 minutes incubation of siRNA and RNAimax, using WellMate, 80µl of 
the antibiotic free culture medium containing 8000 cells were added to each well 
(in 100µl of a final volume). Plates were kept at room temperature for 20 minutes 
before incubating at 37°C for 72 hours. 12 hours before cell fixation, EdU reagent 
(20µM, 2X) was added to the wells manually. I performed fixation and staining of 
cells per Click-iT EdU Alexa Fluor® 488 HCS Assay62 protocol and Caspase-3 
assay instruction. Automated steps included the use of SciClone, WellMate, and 
Biotek microplate washer. I performed scanning of the stained plates using the 
Cellomics ArrayScan (R) VTI. The protocol was optimized using the target 
activation software. Optimization procedures for siRNA knockdown using a HCS 
platform will be described in section 4.1 in detail.  
2.3.1.1. Real Time – qPCR 
72 hours post-transfection, I carried out RNA extraction and cDNA preparation 
using TaqMan® Fast cells-to-CTTM kit (lifetechnologies) per manufacture 
instruction. TaqMan pre-designed assays were purchased from lifetechnologies. 
Each assay contained sequence-specific, unlabeled primers and FAM™ dye-
labeled TaqMan probe. GAPDH was used as an endogenous Control Genes. I 
performed gene expression quantification on Applied Biosystems 7500 Fast Real 
Time PCR System using the following cycle conditions: 95°C for 20 seconds, 
followed by 40 cycles at 95°C for 1 second and 60°C for 20 seconds. I normalized 
the results against GAPDH expression.  
                                                
60 Life Technology 
61 An automated liquid handler 
62 Life Technologies 
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2.4. The Cancer Genome Atlas database 
The Cancer Genome Atlas (TCGA) complete set of RNAseq-based level 3 gene 
expression values, CNVs, and clinical data for 232 melanoma tumors were 
downloaded from the cBioPortal (http://cbioportal.org) for Cancer Genomics 
website63 [161]. The cBio Portal allows a rapid and intuitive survey of cancer 
genomics data sets, with open-access data from 20 cancer studies including more 
than 5,000 tumor samples. This portal with comprehensive set of somatic 
alterations including mutations, CNVs, mRNA expression changes (both 
microarray-based and RNAseq–based methods), protein and phosphoprotein 
levels and DNA methylation enables an efficient and high-quality translation of 
integrated cancer genomic data sets into biological interpretations and clinical 
applications.  
I classified genes with zero or one copy only as copy number loss, and genes with 
more than two copies as copy number gained.  
For expression, gene-based z-score normalized values (RNAseq platform) were 
used (Equation 1); for example, BRAF z-score in each tumor was calculated 
based on the mean and SD values of BRAF expression in the tumors with BRAF 
normal copy number. To define an acceptable z-score cut-off for highly expressed 
genes vs. genes with low level of expression, I considered two important criteria: 
first the frequency of high vs. low expression for oncogenes and second the 
frequency of low vs. high expression for TSGs in 232 tumors. A collection of 
known oncogenes and TSGs from COSMIC64 and GSEA6566 datasets were used 
                                                
63 Downloaded on May 2013 
64 http://cancer.sanger.ac.uk/cancergenome/projects/cosmic/ 
65 Gene Signature Enrichment Analysis 
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[162]. I tested the frequency values at different z-score cut-offs (±0.5 to ±1) to 
define the most acceptable threshold for the majority of the genes under the test. 
For oncogenes, I calculated the value of frequency of high vs. low expression (on 
z-score normalized values) and for TSGs, the value of frequency of low vs. high 
expression. 
Table 5 shows the frequency of high vs. low and low vs. high expression at 
different z-score cut-offs for the oncogenes and TSGs under the test, respectively.  
Changing the cut-off affected most strikingly the number of differentially expressed 
TSGs. On the contrary, the oncogenes selection appeared to be more stable. 
Considering the effect of cut-offs on frequency of low vs. high for TSG, especially 
CDKN2a and CDKN2b, ±1 appears to be too stringent, as all the samples with 
these genes’ low expression were lost (frequency= 0). Moreover, the scatter plot 
of log2 low/high frequency for different cut-offs shows the presence of higher 
number of outliers with cut off at ±1; this reflects the cut-off stringency at ±1 for 
down-regulated genes (Figure 13 below). For oncogenes on the other hand, there 
was not a big difference for different thresholds and both cut-offs at either ±1 or 
±0.75 seemed to be stable. Finally, I set a cut-off at ±0.75 as an acceptable and 
more liberal threshold for both oncogenes and TSGs. 
 




Equation 1: Z-score normalization 
CNV=0 reflects normal copy number. 
Z െ score஻ோ஺ி	୧୬	୲୳୫୭୰	ଵୀ ܤܴܣܨ value ୧୬ ୲୳୫୭୰ ଵ – mean ܤܴܣܨୟ୪୪ ୲୳୫୭୰ୱ ୵୧୲୦	஻ோ஺ி	େ୒୚ୀ଴SD ܤܴܣܨୟ୪୪ ୲୳୫୭୰ୱ ୵୧୲୦ ஻ோ஺ி େ୒୚ୀ଴  
 
 
Table 5: Frequency of high vs. low for oncogenes and frequency of low vs. high for 
TSG 
 
This table shows some examples of frequency calculation to define an acceptable 
threshold for highly expressed genes, vs. genes with low expression in the TCGA 
database. Different z-score cut-offs (±0.5, ±0.75, ±1) were examined. The yellow 
blocks show the reliable frequencies, whereas the blue blocks define the stringent 
thresholds with high possibility of losing the real changes in expression. Z-score 
cut-off at ±0.75 was selected as a liberal and yet reliable threshold for both 
oncogenes and TSGs. 
a b 
Figure 13: Scatter plot for frequency of expression changes with different cut-offs 
in the TCGA database 
Three different cut-offs were set to calculate the frequency of expression changes: 
green= ±1, red= ±0.75 and orange= ±0.5; a) Oncogenes with frequency of high vs. 
low expression, b) TSGs with frequency of low vs. high expression; higher number 
of outliers (log10 -1 to -4) with cut-off at ±1 reflects the cut-off stringency for TSGs 
with low level of expression. 
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3. RESULTS (A)                                                               
Proof of Concept: Discovery of a Maintenance Functional 
Module in Patient7PoC as a Network of Correlated Genes 
Mediating the Tumor’s Functional Maintenance 
I hypothesized that there is a core set of somatic events common to all of the 
tumor-specimens collected from each patient, which could be defined as a 
functional module, and which is essential in sustaining the tumor’s functional 
maintenance. Somatic events including SMs, CNVs and their expressional 
consequences, and SNVs are selected for tumor survival. I believe that these 
somatic events are hardwired and that they often result in the concomitant gain 
and loss of a number of putative oncogenes and TSGs, respectively. These 
clusters construct a network of significantly correlated genes, whose quantitative 
mutual effect on the tumor biology (such as cell growth or death) is at least 
additive (i.e. comparable to the sum of their individual effects), if not synergistic 
(i.e. greater than the sum of their individual effects). 
Following targeted therapy, tumor heterogeneity is one of the major reasons for 
gain of therapy resistance following several months of initial promising tumor 
shrinkage [63, 64]. In the metastatic lesion, the funder mutations inherited from 
primary tumor can be susceptible to the therapy, but accumulation of further 
aberrations potentiate the tumor to survive the applied therapy [163]. Targeting 
different aberrations simultaneously may decrease the chance of resistance 
development. Considering the highly heterogeneous mutational signature of 
melanoma and its role in therapy resistance, it is vital for the development of 
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successful therapies to identify cooperating oncogenes and to reconstitute the 
genomic architecture that drives their synergistic effects.  
To test my hypothesis, I studied in detail the catalogue of somatic mutations 
occurring in the melanoma of one patient (Patient7PoC) characterized by poor 
prognosis: a 46 year-old man diagnosed with axillary lymph node metastasis 
(LNM-T3P7) was treated with T-cell vaccination (TCV) after the complete lymph 
node dissection. 14.8 months later, a tumor distant metastasis in his lung (DM-
T4P7) was detected. The Patient7PoC’s clinical information is shown in Figure 14 
below. The highlighted time points depict the different stages of tumor 
progression. We were able to obtain stage III and IV tumor samples following 
lymph node dissection and lung metastasectomy. Primary cell lines were 
established from both lymph node (LNM-CL3P7) and lung (DM-CL4P7) metastatic 
tissues. The complete set of samples (tumors and matched cell lines) from the 
same patient provided a unique model system to study melanoma maintenance.  
I performed a deep assessment of genomic aberrations using DNA–PET, RNAseq 
and exome–capture sequencing for all the available specimens of this patient 
(Table 1). I searched for a core set of hardwired somatic events persisting through 
all samples of this patient to define a putative maintenance functional module. I 
specifically focused on hardwired changes on Chr 7, Chr 9, and Chr 12 with 
evidence of SMs involvement;  designated as FM7/9/12. Then, I generalized this 
module to a larger cohort of melanoma patients (eight patients; refer to Table 1 
above), and selected the potential cancer-promoting genes in this putative 
maintenance functional module based on their involvement in melanoma in 
general using correlation analysis. I performed functional analyses that test 
cellular proliferation on the final list of 72 candidate genes within the FM7/9/12 using 
both LNM-CL3P7 and DM-CL4P7 of Patient7PoC. Finally, I tested the presence of 
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synergy to a targeted therapy, for the candidate genes with significant effect on 
tumor proliferation. 
In this section, the genomic examination of Patient7PoC will be discussed in detail. 
Then, I will describe my detailed approach to search for the putative maintenance 
functional module, designated as FM7/9/12, its generalization, and selection of its 
components for functional assays. 
 
3.1. Next-generation sequencing 
Library construction, quality assessments, sequence assembly, and data analysis 
related to the HTS technologies used in this study (DNA–PET, exome–capture 
sequencing, and RNAseq) were described in method section 2.2 in detail. 
I used the DNA–PET technology (SOLiD sequencing platform) to search for SMs 
in tumor samples, and their normal genome counterparts isolated from PBL. For 
Patient7PoC, the genomes of primary cell lines generated from the tumor tissues 
were also analyzed. With this method, kilo base- to mega base-sized SMs were 
revealed including deletions, duplications, insertions, inversions, translocations, 
and complex rearrangements. A final catalogue of somatic events for each tumor 
library was defined using pair-wise-and cross-comparisons, as described in Figure 
7 above. I chose a subset of these SMs for further validation, via standard PCR 
and Sanger sequencing. I achieved a validation rate of 83.3% (25 out of 30 SMs) 
and defined the breakpoint boundaries to the base pair resolution for validated 
SMs. Considering the high specificity of PCR in breakpoint detection in a highly 
heterogeneous tumor sample, this independent validation was a reliable 
estimation of the presence of a rearrangement in the tumor samples [164]. This 
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high validation rate shows the accuracy of the DNA–PET technology to define the 
putative SMs. PCR on the other five SMs gave either no product or multiple PCR 
products; this can be explained by the presence of repetitive sequences and the 
complexity of the breakpoints examined or suboptimal primer binding. The 
validation was performed in all tumors and cell lines of Patient7PoC, and in the 
corresponding normal sample.  
The density of cPETs obtained from DNA–PET platform was computed along the 
entire genome to define the CNVs.  
Exome–capture sequencing on Illumina GAIIx platform was used to search for 
SNVs in each tumor sample, and in its normal counterpart. C/T transitions were 
over-represented among SNVs in both metastatic tissues of Patient7PoC, that is 
suggestive of previously described environmental risk factor of melanoma: UV 
light exposure [165] (Figure 15 below). Using PCR and Sanger sequencing, I 
assessed 172 SNVs, validating 90.69%, indicating 2.32% as germ-line mutations 
and 6.97% as false-positives. This validation was performed in all samples of 
Patient7PoC. 
At the transcriptomic level, 2x75bp pair-end RNAseq was performed (Illumina 
HiSeq platform), on RNA samples isolated from tumors and their matched cell 
lines derived from Patient7PoC; normal donors’ melanocyte RNA samples were 
used as controls (Table 1). There was a range of 43,596,193 to 488,806,548 
mapped read counts across all samples. The overall distribution of gene 
expression values is shown in Figure 16a below as log2 transformed FPMK 
values. Low depth of sequencing coverage is reflected in higher number of non-
expressed transcripts. In other words, the sensitivity of transcription detection 
decreases as the sequencing depth drops off. I used different approaches to 
normalize the RNAseq FPMK values, such as z-score normalization, and the ratio 
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of the FPMK to housekeeping genes. I selected quantile normalization (performed 
in R) as the best method fitting this data (Figure 16b below). 
For each tumor and cell line sample, the comprehensive catalogue of somatic 
mutations, including SMs, CNVs, SNVs, and expressional changes are shown in 




Figure 14: Patient7PoC clinical data 
A poor prognosis patient with a complete set of specimens was selected as a 
proof of concept in this study. This patient was diagnosed with melanoma with 
lymph node metastasis (point= 0 month). PBL (as normal sample), lymph node 
tissue, and its derived cell line were obtained. Following 14.8 months of therapy 
(TCV), a distant metastasis to lung was diagnosed and surgically removed, and its 
corresponding cell lines were established. 
 
a b 
Figure 1567: UV signature in the Patient7PoC 
High percentage of C>T transition was indicative of history of UV exposure. a) 
Metastatic lymph node tumor (LNM-T3P7), b) distant metastasis tumor (DM-T4P7) 
  
                                                







Figure 16: RNAseq normalization 
a) Left: the density plot for log 2 (FPMK+0.001) values do not show an acceptable 
overlap for four samples with different sequencing coverage depth (y-axis: 
density); right: different read counts between samples. Human epidermal 
melanocytes were sequenced as normal samples: adult-lightly pigmented donor 
(A-LPD), neonatal-darkly pigmented (N-DPD), and neonatal-moderately 
pigmented donor (N-MPD). b) Quantile normalization allowed comparisons 
between samples with providing comparable expression values between samples 
































Figure 1768: Circos plots representing the somatic catalogues in Patient7PoC 
The Circos plots display SMs, CNVs, transcriptional changes, and non-
synonymous SNVs. From the outer to the inner track: Chromosome ideogram, 
SNVs, CNVs (red= gain, blue= loss, gray= no change), transcriptional changes 
(red= up-regulation, green= down-regulation), and SMs. a) Metastatic lymph node 
tumor (LNM-T3P7), b) distant metastasis tumor (DM-T4P7), c) cell line from lymph 
node (LNM-CL3P7), d) cell line from distant metastasis (DM-CL4P7).               
                                                
68 Plotted by Dr. Xingyi WOO, the Jackson Lab, CT, USA 
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3.2. Key rearrangements are selected for disease progression. 
I found common SMs between lymph node (LNM-T3P7) and lung (DM-T4P7) 
metastatic samples, as well as some SMs specific to each stage (Figure 26 
below). The common SMs in both stages of the tumor most probably correspond 
to the early variations in the tumor evolution. The observed somatic differences 
between different tumor stages can be explained by divergent evolution of the 
clones that migrated to different sites. Although common, SMs shared between 
LNM-T3P7 and DM-T4P7 are associated with different cluster sizes. As mentioned 
in methods 2.2.1.3, in DNA–PET analysis, the cluster size is a measure of 
confidence and precision in the SM prediction. Moreover, cluster size reflects the 
prevalence of the affected allele within the tumor cell population. A higher cluster 
size suggests the presence of a higher number of copies of the corresponding 
rearrangement. Therefore, I used the cluster size information, to assess whether 
the common SMs between LNM-T3P7 and DM-T4P7 carried a signature of tumor 
evolution. To use cluster size as a measure of SM selection between different 
samples, I investigated the confidence in comparing the cluster size of common 
rearrangements. First, a pair-wise comparison between each tumor and the 
matched normal sample (patient’s PBL) defined all germline variations. Then, the 
cluster size of common germline SMs between tumors was normalized based on 
each library’s X coverage (Table 6a). Figure 18 below shows a scatter plot of all 
common germline SMs between LNM-T3P7 and DM-T4P7. High correlation (R2= 
0.9018) of normalized cluster sizes for germline SMs between tumors and high 
coverage between normalized cluster sizes of germline SMs for different stages of 
the tumor suggest the reliability of cluster size to search for the selected variations 
in the DM-T4P7.    
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Table 6: Normalization of SM cluster size using library X coverage 
a 
b 
Table 6 illustrates the normalization procedure for germline SMs and somatic 
SMs, in order to define the reliability of cluster size in searching for selected SMs 
in the later stages of the tumor. a) Normalization of common germline SMs 
between lymph node (LNM-T3P7) and lung (DM-T4P7) metastasis samples, b) 
normalization of common somatic SMs between lymph node (LNM-T3P7) and 


















Figure 18: High correlation between germline SMs 
a) High correlation (R2= 0.9018) of common germline SMs for normalized cluster 
sizes and b) high coverage between normalized cluster sizes of germline SMs for 
different stages of the tumor confirms the reliability of cluster size in searching for 




Pair-wise comparison between LNM-T3P7 and DM-T4P7 SMs gave a list of common 
and unique SMs in each tumor and they were normalized based on each library’s 
coverage (Table 6b).  
Figure 19a below illustrates the density plot of cluster sizes for common cancer 
SMs. The shift of plot from the LNM-T3P7 cluster sizes to the DM-T4P7 ones for 
common somatic SMs can suggest an evidence for SM selection. Figure 19b 
below shows how many times the cluster sizes of common rearrangements were 
multiplied from LNM-T3P7 to the DM-T4P7. In this Figure, the red rectangular 
defines the SMs with at least a two-fold change in cluster size in the DM-T4P7 
compared to the LNM-T3P7 sample. 
The SMs with the highest cluster size fold change between LNM-T3P7 and DM-
T4P7 was DEL_698 (Table 7). This deletion was present in both LNM-T3P7 and 
DM-T4P7 tumor samples and the corresponding cluster size was 7.5 times lower in 
the LNM-T3P7 (cluster size= 4) compared to the DM-T4P7 (cluster size= 30). Using 
PCR and Sanger sequencing, I validated the presence of this rearrangement and 
the breakpoint boundaries were defined to the base pair resolution. Del_698 
occurred in Chr 9p (left breakpoint was 21,943,295 and right breakpoint was 
22,067,941). Because of this deletion, CDKN2a, CDKN2b and C9orf53 were 








Figure 19: An evidence for selection of specific SMs during tumor progression 
a) The right skewed shift of the cluster sizes of common somatic SMs provides an 
evidence for SM selection. X-axis: cluster size, y-axis: density of SMs, b) Cluster 
fold change from lymph node (LNM-T3P7) to lung (DM-T4P7) tumor: the red 




Table 7: List of SMs with at least 2x fold change of cluster size from LNM-T3P7 to 
DM-T4P7 
 
Based on fold change of cluster sizes, Del-698 harboring important TSGs 
(CDKN2a and CDKN2b) was defined as the selected SM for distant metastasis.  
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Del_698 deletion did not affect the copy number in LNM-T3P7 (Figure 20 below), 
and the neighboring genes remained as normal copy number as well. These 
observations, particularly the intact Chr 9p copy number in LNM-T3P7, suggest the 
presence of Chr 9p (21,943,295–22,067,941) deletion in only small cell 
subpopulation in this tumor. On the other hand, this SM caused a detectable one-
copy number loss in the DM-T4P7. Interestingly, the neighboring genes, such as 
KLHL9, showed increased copy number in the DM-T4P7 (Figure 20).  
Detailed examination of the DM-T4P7 SMs revealed the presence of several 
translocations between Chr 9 and Chr 12 leading to copy number gain (Figure 20). 
More importantly, I observed the presence of translocations at both edges of 
regions with copy number changes on Chr 9: 20,979,979–22,220,637 and Chr 12: 
48,220,840–53,254,170. It seemed that selection of Chr 9 harboring CDKN2a and 
CDKN2b deletion happened by means of several translocations, leading to copy 
number gain of Chr 9: 20,979,979–22,220,637 and copy number gain of Chr 12: 
48,220,840–53,254,170, as the next step in the tumor evolution in this patient. 
Higher cluster size of the Chr 9p (21,943,295–22,067,941) deletion and its 
translocation to Chr 12 accompanied by copy number changes in the DM-T4P7 
suggest that the Chr 9p deletion has occurred in the earlier stages of the tumor 
evolution – present in only a subset of cells – and was then selected and amplified 
during distant metastasis to the lung. To validate this assumption, I performed 
qPCR on the genomic DNAs (obtained from LNM-T3P7 and DM-T4P7 tumors and 
their normal compartment). I examined the amplification of Chr 9p (21,943,295–
22,067,941) deletion (DEL_698) in the DM-T4P7 compared to the LNM-T3P7 
(Figure21 below): the ∆∆Ct fold change from LNM-T3P7 to DM-T4P7 for this 
deletion was comparable with the cluster size fold change from DNA–PET data for 
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DEL_698.  This quantification provided an evidence for the enrichment and 
selection of DEL_698 in the lung metastasis.  
I further examined the biological importance of this region in tumor progression; I 
searched for genes with copy number changes affecting expression in the same 
direction in Patient7PoC tumors. Based on the analysis of differential gene 
expression, 750 genes appeared to be significantly up-regulated in the DM-T4P7 
compared with the LNM-T3P7 (FC > 1.5). On the other hand, pair-wise comparison 
of the CNVs data between LNM-T3P7 and DM-T4P7 identified 1728 genes that were 
amplified in the lung- compared with the lymph node-metastasis. By overlapping 
these two gene lists, the final gene set was identified, that was both amplified and 
over-expressed in the lung- compared with the lymph node-metastasis. This 
integration provided a final list of 71 genes that show significant enrichment in DM-
T4P7 compared with LNM-T3P7 (p-value < 0.005). Interestingly, GSEA for positional 
gene sets showed significant enrichment of these genes on Chr 7, Chr 9, and Chr 
12. The occurrence of several translocations between Chr 9 and Chr 12, and 
enrichment of different SMs in these regions explain these focal amplifications 
affecting the expression.  
Among the candidate genes mapping to the Chr 9 gained region, PD-L1 (Chr 
9p24.1) is a checkpoint molecule on tumor cells resulting in down-regulation of 
immune responses and its blockade is a valuable therapy strategy with promising 






















Figure 20: Chr 9p (21,943,295–22,067,941) deletion as an early event triggers 
subsequent rearrangements in tumor progression 
a) Del_698 corresponds to deletion of critical TSGs on Chr 9p. This deletion did 
not correspond to a detectable copy number change in the LNM-T3P7 (lymph node 
tumor), whereas it associated with a clear one-copy loss in the DM-T4P7 (lung 
tumor). The neighboring genes of this deletion, show copy number gain in DM-
T4P7 (blue arrows). X-axis: chromosome coordinates; y-axis: copy number tumor/ 
normal ratio; b) There are several translocations between Chr 9 (neighboring 
region to Del_698) and Chr 12 resulting in copy number changes (gain in Chr 12 is 
shown by green arrow). It seems that SMs cooperated in the copy number 
changes of the affected regions. c) The blue and green arrows refer to the gain 
regions on Chr 9: 20,979,979- 22,220,637 and Chr 12: 48,220,840-53,254,170 
and correspond to the same colored arrows in (a) and (b). The presence of 
several translocations between Chr 9 and Chr 12 and other intra-chromosomal 







Figure21: Enrichment Quantification of Del_698 in DM-T4P7 
a) For biological validation of selection of Del_698 in DM-T4P7 sample, qPCR was 
performed on genomic DNA from tumor and normal samples of Patient7PoC. Assay 
was done in triplicate using TaqMan Gene Expression Master Mix per 
manufacturer’s instructions (Life Technologies). qPCR reactions were run on 
qPCR LightCycler® 480 Instrument69. (A= GAPDH as the housekeeping gene with 
ct values19, B= DM-T4P7 DNA with Ct values 22-23, C= lymph node tumor DNA 
with Ct values 28, D= PBL with Ct values 37, E= background fluorescence), b) 
Fold change calculated with the standard ∆∆Ct method gave similar results as 
cluster size and confirmed the findings from the DNA–PET. 
 
  




3.3. CNVs convey significant transcriptional consequence. 
The detailed examination of Patient7PoC revealed the presence of translocations at 
the edge of the gained regions, which suggests the involvement of SMs, 
particularly inter-chromosomal translocation, in copy number changes. For 
example, several translocations between Chr 9 and Chr 12 in the DM-T4P7 led to 
copy number gain of Chr 9: 20,979,979–22,220,637 (harboring Del_698) and Chr 
12: 48,220,840–53,254,170.  
In all samples of Patient7PoC, the copy number changes were modest in amplitude 
and mostly with one copy number loss or gain, but these changes affected large 
genomic regions (Table 8). I examined whether the copy number changes in these 
samples were associated with significant expressional consequences. As shown 
in Table 8, the observed overlap between CNVs and expressional changes at the 
same direction is significantly higher than would be expected if they only 
overlapped by chance. Moreover, for each sample obtained from Patient7PoC, I 
ranked and binned the genes with CNVs based on their expression level into 
windows of 2000 genes, while overlapping with 1000 genes from each neighboring 
bin. I used the Fisher’s exact test with significance threshold of p-value < 0.01 to 
test the enrichment of genes with copy number changes in each bin. With this 
analysis, I tested all possibilities, i.e. CNVs with any direction of expressional 
changes. However, only genes with down-loss or up-gain status appear to be 
statistically significant. As shown in Figure 22 below, genes with copy number gain 
or amplification were significantly enriched at the high expression bins, while 
genes with copy number loss or deleted were enriched at the low expression bins 
(p-value < 0.01). In conclusion, CNVs in the Patient7PoC showed significant impact 
on expression of the affected genes.  
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Table 8: The observed and expected overlap between CNVs and expressional 
changes in Patient7PoC 
This Table illustrates that the observed overlap between CNVs and expressional 
changes at the same direction is significantly higher than would be expected if 
they only overlapped by chance. Observed (or expected) overlap illustrates the 
observed (or expected) overlap between CNVs and expression changes at the 
same direction. Values in each cell represent the number of genes (% genes) out 














LNM-T3P7 8397 (41.9%) 7171 (35.8%) 3195 (15.9%) 3010 (15%) 5.9E-07
DM-T4P7 6477 (32.3%) 7365 (36.8%) 2690 (13.4%) 2385 (11.9%) 5.3E-15
LNM-CL3P7 8761 (43.8%) 6711 (33.5%) 3453 (17.2%) 2939 (14.6%) 0 
DM-CL4P7 8459 (42.2%) 6309 (31.5%) 3099 (15.4%) 2668 (13.3%) 0 











Figure 22: CNVs have significant transcriptional consequences 
This Figure shows the density plot of log2 quantile normalized FPKM values (x-
axis) for all genes per sample. After ranking genes based on their expression 
values, they were binned into a window of 2000 genes while overlapping with 
1000 genes from each neighboring bin. Fisher’s exact test with significance 
threshold of p-value < 0.01 was used to test the enrichment of genes with copy 
number changes in each bin. Colors define the directionality of the enrichment: 
blue colored bins show significantly enriched bins with copy number loss; red 
colored bins show significantly enriched bins with copy number gain; NS stands 




3.4. Subsets of maintained variations are roots of tumor maintenance. 
The cell lines derived from the patient’s tumors are suitable model systems to 
study tumor evolution, and which genes may have a possible association with 
tumor characteristics. From a detailed examination of the cell lines’ catalogue of 
somatic events emerged a valuable observation: from LNM-T3P7 and DM-T4P7 
tumors to their respective cell lines, the relationship was very selective; whereas 
the Chr 9:21,943,295–22,067,941 deletion did not produce a measurable copy 
number change in LNM-T3P7, it was associated with a clear two-copy number loss 
in both cell lines. The cluster size analysis showed the selection of Chr 9p deletion 
in the lymph node cell line (LNM-CL3P7) (cluster size= 28) and in the lung cell line 
(DM-CL4P7) (cluster size= 55). In other words, cell lines were not completely 
representative of the corresponding tumors, but rather they were derived from an 
adapted clone present in the tumors (Figure 23 below). This observation suggests 
that the in vitro evolution took benefit of the complete loss of CDKN2a and 
CDKN2b, whereas, selection and amplification of Chr 9p (21,943,295–22,067,941) 
deletion was important for in vivo evolution.   
Figure 24 below is a schematic presentation of the possible subclonal composition 
of all samples of Patient7PoC and its remodeling during the course of tumor 
evolution. Based on a detailed analysis of SMs and CNVs in these samples, Chr 
9p deletion (Del_698: Chr 9:21,943,295–22,067,941) was present in a minor cell 
subpopulation in the LNM-T3P7 (the yellow clone in Figure 24), which clonally 
expanded at the distant metastasis stage (orange arrows). Chr 9 harboring 
CDKN2a and CDKN2b deletion was selected by means of several translocations 
leading to amplification of Chr 9:20,979,979–22,220,637 and amplification of Chr 
12: 48,220,840–53,254,170. These amplicons significantly affected the level of 
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gene expression and led to the gene up-regulation in DM-T4P7 compared to the 
LNM-T3P7.  
The mutations that varied between the different metastases and the cell lines may 
have function, but also may be extraneous to cellular survival. However, either 
those mutations that are present in all the different samples from this patient are in 
the “root” genetics of the tumor, or they represent mutations that have a significant 
role in maintaining cancer viability.  
I have previously defined these putative maintenance genes in Patient7PoC, as the 
core set of aberrations persisting through all of the analyzed samples (including 
the patient derived cell lines) from this patient. I showed that copy number 
changes followed by transcriptional consequences were supported by involvement 
of SMs. For example, the presence of several translocations between Chr 9 and 
Chr 12 led to several amplicons on these chromosomes (Chr 9: 20,979,979– 
22,220,637 and Chr 12: 48,220,840–53,254,170). Moreover, there were common 
somatic changes that persisted through all samples, tumors and cell lines, in this 
patient. Deletion of critical TSGs – CDKN2a and CDKN2b – as an early event and 
its maintenance in all samples suggests an involvement of a core set of somatic 







Figure 23: Cell lines are derived from an adapted clone present in the tumors. 
Del_698 with normal copy number in LNM-T3P7 and one copy loss in DM-T4P7 
showed two-copy number loss in both matched cell lines. High cluster size in both 
cell lines compared to the matched tumors represented the selection of this SM for 







Figure 2470: Tumor evolution: in vivo vs. in vitro 
Del_698 (Chr 9p) did not affect copy number in LNM-T3P7 sample; this suggested 
the presence of this SM in a minority of cells (indicated here in yellow). Selection 
of Del_698 (confirmed by DNA–PET and qPCR) and its amplification via 
translocation to Chr 12 was seen in distant metastasis, which suggested the 
importance of this SM for in vivo evolution (orange arrows). On the other hand, 
two-copy number loss of Chr 9p (21,943,295–22,067,941) was selected for 
deriving the cell lines from both tumors.   
                                                
70 Figure courtesy of Dr. Koichiro Inaki, The Jackson Laboratory, CT, USA 
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3.4.1. The putative maintenance functional module contains gain of mutated 
BRAF and deletion of CDKN2a/b during tumor evolution. 
To further prove my hypothesis of the presence of a functional module, comprising 
a core set of hardwired somatic events with a role in tumor’ functional 
maintenance, I examined in detail the catalogue of somatic mutations of 
Patient7PoC. Tumor samples from different stages of the metastasis (LNM-T3P7 and 
DM-T4P7) and their matched cell lines were a valuable resource to search for the 
core somatic events that sustain tumor maintenance. I observed the presence of 
core sets of somatic mutations that persisted through all samples in this patient. 
To identify the complete set of core events with possible functional importance, I 
assessed the hardwired genetic changes in genome structure common in all 
samples of this patient. Given the chronology of tumor evolution, common somatic 
events should be the earliest events in the tumorigenesis process, originating in 
the lymph node metastasis or even at an earlier stage, and being maintained and 
selected in the later stages, as well as in their corresponding established cell lines. 
Since I confirmed the association of SMs in CNVs and consequent expressional 
changes, I chose a stringent criterion by concentrating on the changes with 
evidence of SMs involvement in this patient. Then, I searched for commonly 
mutated genes with SNVs in this patient. 
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3.4.1.1. The FM7/9/12 is a putative maintenance functional module in 
Patient7PoC, commonly affected by SMs. 
Figure 26 below shows the number of SMs unique or common across all samples 
of Patient7PoC (lymph node tumor, lung tumor, and their corresponding cell lines). 
There were nine common SMs, of which affecting copy number with expressional 
consequences were examined in detail (Figure 25 below): ‘Chr 9: 21,943,295–
22,067,941 deletion’: CDKN2a, CDKN2b and C9orf53 were deleted, and MTAP 
and CDKN2BAS were truncated. ‘Chr 9: 23770688–24143467 unpaired inversion’: 
ELAVL2 was truncated and not expressed. Two unpaired inversion resulting in an 
amplicon on Chr 9:23,221,574–24,451,653. ELAVL2 was the only gene on this 
amplicon. ‘Chr 9–X translocation’ that occurred inside Chr 9 amplicon (Chr 9: 
23,221,574–24,451,653) and connected it to one edge of an amplicon on ‘Chr X: 
13,119,715–13,201,536’. The other edge of Chr X amplicon was translocated to 
Chr 7q. Because of this translocation, ‘Chr 7q:134,953,055–qter’ was gained. It 
seems that Chr X plays as a mediator for Chr 9 connection to Chr 7, and it may 
have epigenetic impact on the expression of translocated genes on Chr 9 and Chr 
7 as well. BRAF known as an important driver in melanoma is located in this 
gained region of Chr 7.  
Moreover, there were three common unpaired inversions on Chr 12, which gave 
rise to four amplicons: ‘Chr 12:16,156,008–27,625,211’, ‘Chr 12:29,122,407–cen’, 
‘Chr 12:40,499,079–42,556,914’ and ‘Chr 12:48,439,018–52,220,000’. These 
amplicons harbored important oncogenes (e.g. KRAS, WNT1, and WNT10B), 
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3.4.1.2. BRAF carried a common double base substitution (GT > AA) with 
significant functional burden. 
Non-synonymous mutations were revealed using exome–capture sequencing. 75 
genes were commonly mutated in all samples of this patient, including ADAM22, 
ADRA1A, ANK2, AOAH, ARHGEF6, ATP13A5, ATRX, BRAF, C11orf16, CADM2, 
CDC27, COL22A1, COL4A6, COL6A5, CTTNBP2, CUL4B, CXorf30, DCAF4, 
DCAF8L1, DGAT2L6, DLG3, DNAH5, DPP6, DYNC1H1, DYNC2H1, EML5, 
EZH2, FAM9A, FOXI1, FPR3, GALNT11, GPR98, GRAMD1B, IDUA, IL31RA, 
ITGB8, ITIH5L, KIAA1199, KIF16B, LGALS9C, LRRC43, MAP7D2, MAPK10, 
MME, MPP3, MUC5B, MUM1L1, MXRA5, NLRP2, OR11G2, OR51F1, OR6C4, 
OR8D1, OXER1, P2RY2, PDE2A, PKHD1L1, PPP1R12C, PPP6R3, PRKX, 
PVRL1, RASGRP2, RIC3, SIRT2, SLC13A1, SLC18A1, SLC28A2, SYT13, 
TCTN1, TEKT4, TRPM2, UBE4A, UBQLN3, WAS, and ZNF74.  
The HODIS study on melanoma exome landscape was described in section 1.8 
[114]. Because of high overlap (94.6%) between the commonly mutated genes in 
Patient7PoC and the HODIS list (Table 9), I applied their results of gene-based 
statistical approach  on my dataset to call for mutations with significant mutational 
burden. A total of 12 genes (BRAF, PVRL1, ITGB8, P2RY2, EZH2, CUL4B, 
SLC13A1, ARHGEF6, DCAF4, SLC28A2, LRRC43, and FOXI1) showed 
significant functional mutation burden with p-value < 0.05, of which only BRAF 
remained significant after FDR correction (FDR q-value < 0.2), which emphasizes 
the importance of BRAFV600K and suggests it to be the core maintenance gene in 
this patient. BRAFV600K on Chr 7q was commonly mutated in all samples of this 
patient; using PCR and Sanger sequencing, I confirmed the presence of 
BRAFV600K somatic mutation (c. 1798_1799GT > AA) in all samples of this case. 
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Table 9: Common SNVs in Patient7PoC and the overlap with the HODIS study 
Only BRAF showed a significant functional mutation burden (FDR q-value < 0.2). 
 













p-value FDR q-value 
BRAF  V600K    <1E-08 5.47E-05 
PVRL1  Q34*    0.0006  
ITGB8  R273Q    0.01  
P2RY2  R148C    0.012  
EZH2  Y590F    0.017  
CUL4B  F516C    0.0201  
SLC13A1  W572*    0.035  
ARHGEF6  S329Y    0.038  
DCAF4  F328Y    0.038  
SLC28A2  K125*    0.04  
LRRC43  F148Y    0.041  
FOXI1  D190N    0.047  
ADAM22  R222K      
ADRA1A  S265F      
ANK2  E2810K      
AOAH  G584E      
ATP13A5  G1065E      
ATRX  S344F      
CADM2  P59S      
CDC27  Y48S      
COL22A1  F452L      
COL4A6  G980R      
CTTNBP2  S1005L      
DCAF8L1  R154C      
DGAT2L6  H107Y      
DLG3  H153Y      
DNAH5  W4443*      
DPP6 
 F667S/ 
Q668*       
DYNC1H1  P2480L      
DYNC2H1  P2014L      
PDE2A  L397F      
EML5  G1541E      
FAM9A  D76N      
FPR3  R315C      
GALNT11  S205*      
GPR98  S1073F      
GRAMD1B  P356S      
 103 
 
IDUA  W648*      
IL31RA  Q216*      
ITIH5L  W1041*      
KIAA1199  N679S      
KIF16B  Q777*      
LGALS9C  V96M      
MAP7D2  K358E      
MAPK10  G254E      
MME  D265Y      
MPP3  P123S      
MUC5B  R1818K      
MUM1L1  G565R      
MXRA5  L688F      
NLRP2  V187M      
TEKT4  A262D      
OR11G2  L145V      
OR51F1  R265C      
OR6C4  M1I      
OR8D1  R122C      
OXER1  P352L      
PKHD1L1  P1749S      
PPP1R12C  P189S      
PRKX  W308*      
RASGRP2  G444S      
RIC3  Q204L      
SIRT2  L278F      
SLC18A1  S369F      
SYT13  P228S      
TCTN1  R428W      
TRPM2  D288N      
UBE4A  R73*      
UBQLN3  E528*      
WAS  E131K      
ZNF74  R491W      
C11orf16  W47*      
COL6A5  G1591E      
CXorf30  P215L      
PPP6R3  Q429*      
 
 Not reported   
 Damaging mutation   
 Nonsense mutation   
 Reported but different amino acid change   
 Reported with same amino acid change   








Figure 26: Number of common and specific somatic mutations in samples of 
Patient7PoC 
a) Nine SMs were common between tumors and matched cell lines in Patient7PoC. 
These SMs led to CNVs of affected genes. Chr 9, Chr 7, and Chr 12 were the 
main chromosomes affected by these common SMs. b) Gene based SNVs 






Despite the copy number status of CDKN2a and CDKN2b, these genes were 
expressed neither in the lymph node sample with normal copy number nor in lung 
tumor with one copy number (log2 quantile FPKM values for CDKN2a= -0.17937, -
0.30712, -9.96578 and -9.96578 for LNM-T3P7, DM-T4P7, LNM-CL3P7 and DM-
CL4P7, respectively). P16 is a cell cycle inhibitor coded by CDKN2a and acts as a 
tumor suppressor. Strong association of EZH2 expression and p16 suppression is 
reported in melanoma [166]. It can be speculated that silence of CDKN2a in tumor 
samples could be attributed to EZH2 function (on Chr 7) that was indeed 
connected to Chr 9 in all samples of this patient. Over expression of EZH2 is 
reported in several cancer types including breast cancer, prostate cancer, lung 
cancer and cutaneous melanoma [144, 195-198]. EZH2 belongs to the polycomb 
repressor complex 2 (PRC2) and catalyzes the methylation of lysine 27 on histone 
3 (H3K27me3) which mediates transcriptional repression of the target genes that 
are involved in fundamental cellular processes, such as cell cycle regulation, cell 
differentiation, senescence, and cancer [145]. EZH2 has a vital role in 
maintenance of DNA methylation and the subsequent stable repression of the 
respective genes; therefore, a deregulated histone modification system leads to 
suppression of TSGs and enhancement of oncogenes [146][167]. 
To further investigate the role of EZH2 in the analyzed melanoma samples, I 
examined the expression pattern of three major chromatin regulators associated 
with EZH2 function: HDAC1, DNMT1, and KDM6B. For methylation, HDAC1 
(histone deacetylase1) first erases the acetyl group from active chromatin 
(H3K27ac). Then, followed by histone methylation and chromatin condensation via 
EZH2, for efficient silencing of EZH2 target genes, promoter CpG islands of the 
target gene will be methylated by DNMT1 [168]. On the other hand, KDM6B 
(lysine demethylase6B) activity removes the methylation group from (H3K27me3) 
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to activate the gene transcription [169]. Figure 27 below shows the density plot of 
log 2 quantile normalized FPKM values for all melanoma samples in this study (16 
tumors and cell lines). As expected, KDM6B as a possible TSG showed low 
expression almost in all samples, whereas DNMT1 and HDAC1 with active effect 
on silencing EZH2 target genes were expressed highly in all samples. These 
observations may imply the presence of genomic–epigenomic interactions 
mediated by SMs in this patient. 
A single gene does not drive melanoma, but combinations of putative oncogenes 
and TSGs with expression aberration defined by genomic events are involved; I 
believe that CDKN2a and CDKN2b loss accompanied by gain and over 
expression of putative cancer-promoting genes on Chr 7q and Chr 12 may offer 
the advantage of functional maintenance to the tumor. In Patient7PoC, common 
somatic aberrations revealed blocks of oncogenes (e.g. BRAF and EZH2) and 
TSGs (e.g. CDKN2a) that were clustered together by means of SMs. Genes on 
amplicons constructed by these intra and/ or inter chromosomal rearrangements 
were significantly up-regulated compared to normal melanocytes, whereas deleted 
regions showed down-regulation and silencing of the truncated and deleted genes, 
respectively. 
I believe that SMs generate expression modules that juxtapose driver genes for 
co-expression, and I aimed at identifying the cancer-promoting module that cuts 
across Ch 7 and Chr 12 in Patient7PoC. I examined the potential of the FM7/9/12 in 
maintenance of the tumor using cell-based assays, by siRNA knockdown 
experiments. Next sub-section illustrates how I selected 72 genes on Patient7PoC’s 




Figure 27: Expressional pattern of chromatin regulators associated with EZH2 
function 
Turquoise, magenta, and red vertical lines exhibit the expression values of 
KDM6B, DNMT1, and HDAC1, respectively in all samples. Expression pattern of 
KDM6B as activator of transcription was skewed toward down-regulation in all 
samples, whereas DNMT1 and HDAC1 with silencing effect showed pattern of up-
regulation in terms of expression. This observation suggests the presence of a 
genetic-epigenetic interplay between EZH2, its associated regulators, and 




3.4.2. Validation and ranking of components of the FM7/9/12 
Common structural aberrations in the Patient7PoC affected 399 genes defined as 
FM7/9/12; six truncated or deleted genes on Chr 9, 176 and 217 gained genes on 
Chr 12 and Chr 7, respectively. Moreover, BRAFV600K with significant functional 
mutation burden was defined as the common core gene with double nucleotide 
variations in this patient. These observations suggest the importance of Chr 9, Chr 
7, and Chr 12 rearrangements as means to cooperate copy number and 
expressional changes in favor of tumor maintenance. I believe that these SMs 
organize the genome in a way to bring important oncogenes in the neighborhoods 
to build an oncogenic module that their hardwired somatic changes sustain the 
tumor’s functional maintenance. To further validate my hypothesis, I assessed the 
functional significance of the FM7/9/12 using cell-based assays. For functional study, 
the components of the FM7/9/12 were prioritized using several filtration steps 
discussed in 3.4.2.1 and 3.4.2.2 below. Since I believe that physical connection 
between these clusters of oncogenes and TSGs is not random, I used all 
melanoma samples obtained from eight patients in this study to assess the 
significance of negative correlation of expression between deleted genes on Chr 9 
and gained genes on Chr 7 and Chr 12. This correlation analysis allowed the 
selection of the final candidate genes for functional validation, based on their 
general contribution in melanoma. The detailed ranking system for selection of the 
putative cancer-promoting genes for functional study will be presented in the 
following sub-sections.   
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3.4.2.1. The putative maintenance functional module on Chr 7 
I defined 217 genes as the putative maintenance functional module on Chr 7 with 
copy number gain and up-regulation in all samples of Patient7PoC compared to 
normal samples. The cut-off for up-regulation was fold change of quantile 
normalized FPKM value (tumor or cell line samples / average of three normal 
melanocytes) >= 1.2. 
I selected 43 genes for further validation based on the following criteria: 
 Genes with expression value higher than the median in each sample. 
 Binary expression correlation was calculated between Chr 9p deleted 
genes (CDKN2a, CDKN2b, and C9orf53), and Chr 7 putative maintenance 
functional module, using Pearson correlation (Figure 28 below). For this 
analysis, quantile normalized FPKM values of total number of 16 samples 
(lymph node and distant metastases and matched cell lines from eight 
patients with either good or poor prognosis) were used. Significant 
negative correlation was defined as p-value < 0.05 and correlation 
coefficient (R) < -0.5.  
Final number of 43 genes on Chr 7 showed significant negative binary expression 
correlation with Chr 9p deleted genes (CDKN2a, CDKN2b, and/or C9orf53). This 
gene list included ABCF2, AGK, BRAF, C7orf13, CASP2, CHPF2, CNOT4, CUL1, 
EN2, ESYT2, EZH2, HIPK2, INSIG1, KRBA1, LMBR1, LOC401431, LUC7L2, 
LUZP6, MLL3, MRPS33, NCAPG2, NOM1, NUB1, PAXIP1, PDIA4, PRKAG2, 
REPIN1, RHEB, SLC37A3, SLC4A2, SSBP1, TRIM24, TTC26, UBE3C, WDR60, 
XRCC2, ZC3HAV1L, ZNF212, ZNF282, ZNF398, ZNF746, ZNF786, and ZYX 




3.4.2.2. The putative maintenance functional module on Chr 12 
The putative maintenance functional module on Chr 12 contained 176 genes 
gained and up-regulated in all samples of Patient7PoC compared to normal 
samples. Same cut-off value as genes on Chr 7 was set for up-regulation (FC >= 
1.2).  
With the following hierarchal criteria, I selected a final number of 29 genes to 
assess their association with tumor phenotype: 
 Genes with expression value higher than median in each sample were 
selected. 
 Binary expression correlation was calculated between Chr 9p deleted 
genes (CDKN2a, CDKN2b, and C9orf53) and Chr 12 putative maintenance 
functional module (176 genes) using Pearson correlation (Figure 28). For 
this analysis, quantile normalized FPKM values of total number of 16 
melanoma samples were used. Significant negative correlation was 
defined as p-value < 0.05 and correlation coefficient (R) < -0.5 
 Final number of 29 genes on Chr 12 showed significant negative binary 
expression correlation with Chr 9p deleted genes (CDKN2a, CDKN2b, 
and/or C9orf53). This gene list included ARNTL2, BICD1, C12orf11, 
CCNT1, CMAS, DENND5B, DNAJC22, DNM1L, ERGIC2, GOLT1B, 
GXYLT1, H3F3C, IPO8, KIAA0528, KRAS, LARP4, LDHB, MED21, PKP2, 
RACGAP1, RASSF8, RECQL, SENP1, SLC4A8, SMAGP, SPATS2, 
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Table 10: Generalization of the FM7/9/12: Pearson correlation between Chr 9 down- 
regulation, and Chr 7 and Chr 12 up-regulation  
Gene Chr. A B C Gene Chr. A B C 
ABCF2 7 ZC3HAV1L 7 
AGK 7 ZNF212 7 
BRAF 7 ZNF282 7 
C7orf13 7 ZNF398 7 
CASP2 7 ZNF746 7 
CHPF2 7 ZNF786 7 
CNOT4 7 ZYX 7 
CUL1 7 ARNTL2 12 
EN2 7 BICD1 12 
ESYT2 7 C12orf11 12 
EZH2 7 CCNT1 12 
HIPK2 7 CMAS 12 
INSIG1 7 DENND5B 12 
KRBA1 7 DNAJC22 12 
LMBR1 7 DNM1L 12 
LOC401431 7 ERGIC2 12 
LUC7L2 7 GOLT1B 12 
LUZP6 7 GXYLT1 12 
MLL3 7 H3F3C 12 
MRPS33 7 IPO8 12 
NCAPG2 7 KIAA0528 12 
NOM1 7 KRAS 12 
NUB1 7 LARP4 12 
PAXIP1 7 LDHB 12 
PDIA4 7 MED21 12 
PRKAG2 7 PKP2 12 
REPIN1 7 RACGAP1 12 
RHEB 7 RASSF8 12 
SLC37A3 7 RECQL 12 
SLC4A2 7 SENP1 12 
SSBP1 7 SLC4A8 12 
TRIM24 7 SMAGP 12 
TTC26 7 SPATS2 12 
UBE3C 7 TMBIM6 12 
WDR60 7 TUBA1B 12 
XRCC2 7 TUBA1C 12 
 
This table summarizes the final number of 43 and 29 genes on Chr 7 and Chr 12 
(respectively) selected for functional study. These genes belonged to the FM7/9/12 
and showed significant negative correlation for expression with deleted genes on 
Chr 9; red blocks represent the significant negative correlation (p-value < 0.05 and 
R < -0.5). A, B and C represent C9orf53, CDKN2A and CDKN2B, respectively. 
 113 
 
4. RESULTS (B)                                                               
Proof of Concept: Functional Validation of the putative 
Maintenance Functional Module (FM7/9/12) Discovered in 
Patient7PoC 
I showed that the putative maintenance functional module in the Patient7PoC 
(designated as FM7/9/12) comprised the copy number gain of BRAFV600 mutation 
and deletion of CDKN2A and CDKN2B. BRAF mutation and CDKN2A and 
CDKN2B deletion are among the most frequent and previously described driver 
aberrations in melanoma. As I confirmed that CDKN2A and CDKN2B deletion 
occurred as an early tumorigenic event in this patient, I believe that gain and over 
expression of genes on Chr 7q and Chr 12, and their structural connection to Chr 
9p imply a subset of cancer-promoting genes in melanoma important for tumor’s 
functional maintenance. I tested the functional significance of these putative 
cancer-promoting genes on the FM7/9/12 using cell-based assays. The  components 
of the FM7/9/12 were prioritized based on the significance of their expression-based 
negative correlation with deleted genes on Chr 9p (CDKN2a, CDKN2b and 
C9orf53) in the larger cohort of melanoma patients (the selection criteria was 
described in 3.4.2.1 and 3.4.2.2 above). As a result, I selected 43 up-gain genes 
on Chr 7 and 29 up-gain genes on Chr 12 with general contribution in melanoma 
for further validation.  
Cell survival is one of the major cellular processes that are abnormally activated in 
cancer; driving mutations give a selective growth advantage to cancer cells by 
impairing the balance between cell division and differentiation, increasing cell 
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growth, and promoting apoptosis evasion. Therefore, to assess the oncogenic 
potential of the putative maintenance functional module, and to confirm its 
contribution to conferring growth advantage to the tumor cell, I selected 
proliferation and apoptosis as critical assay read-outs. Patient7PoC’s LNM-CL3P7 
and DM-CL4P7 subjected to siRNAs for 72 hours were assessed using Click-iT 
EdU HCS and Caspase-3 assays, to quantify changes in active cell proliferation 
and apoptosis, respectively. HCS with its feasibility to study hundreds to 
thousands of genes at the same time was a valuable platform for this screening. 
HCS capability in concurrent quantification of independent read-outs for large-
scale RNAi libraries is a strong and yet complicated tool to screen the candidate 
genes that seem to contribute to cancer features. Library design, technical and 
experimental optimizations, controls selection, and data analysis were crucial 
features to achieve reliable results from large-scale RNAi screening using an HCS 
platform. Moreover, automation of the different steps of the screening procedure 
such as cell seeding, siRNA transfection, and cellular staining was necessary for 
robust and reproducible readings with an HCS platform. The following sub-
sections are dedicated to the detailed description of the optimization protocol for 
siRNA knock down using the HCS platform. In section 4.5, the screening results 




4.1. RNAi Library design 
Prior to the primary screen, it is important to design the experiment carefully, as 
this will have a great impact on data analysis later on. I arrayed the large-scale 
RNAi libraries in the 96-well microplates. The steps involved in the reconstitution 
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of assay plates were described previously in method section 2.3.1. I performed all 
experiments in triplicates, unless otherwise stated.  
 
4.2. Optimizations for efficient transfection 
One of the major challenges in large-scale RNAi was transfection efficiency. This 
section describes several steps of optimization in order to achieve an efficient 
transfection, including: suitable cell seeding density, the identification of the most 
appropriate transfection reagent and of its best working concentration, appropriate 
siRNA concentration, and duration of treatment. 
 
4.2.1. Optimal cell seeding density 
One of the major prerequisites for getting robust and reproducible readings in a 
HCS platform is the homogenous cell seeding in multi-well plates. First, I checked 
whether LNM-CL3P7 and DM-CL4P7 were compatible with the automated pipetting 
system (WellMate by Thermo Scientific). Each cell line was seeded into 96-well 
plates at two different cell densities. At two different time points after cell seeding 
(48 and 72 hours), cells were stained using Hoechst nuclear stain and read by 
CellomicsArrayScan to calculate the variation in cell count between different 
seeding densities. The variation was assessed via calculating the coefficient of 
variation (%CV).Both cell lines reached the 70% to 80% confluency when ~7000 
to 8000 cells were seeded and cultured for 72 hours (Figure 29 below). 8000 cells 
per well seemed to be an optimal density as the CVs were below 10%. Moreover, I 
checked the cells to ensure they were properly attached to the well surface and 









Figure 29: Optimization of cell seeding density 
Two different concentrations of cells were seeded to define the suitable amount of 
cells for 48 and 72hours experiments; a, b) DM-CL4P7, c) based on %CV,  a 
seeding number of 8000 cells per well was suitable for both time points and both 
cell lines as the CVs were below 10%. CL4 and CL3 refer to DM-CL4P7 and LNM-






4.2.2. Optimal transfection condition 
I optimized the transfection conditions for 8000 cells per well (96-well plate) for the 
DM-CL4P7. To identify an optimal transfection, I used the KDalertTM GAPDH 
assay kit (LifeTech). This assay is fluorescence-based and measures the 
enzymatic activity of GAPDH71 at the protein level. GAPDH, as a housekeeping 
gene, is universally expressed at relatively constant levels, and an optimal target 
for optimization of siRNA transfection. Measurement of GAPDH protein level in 
cells treated with a GAPDH siRNA, compared with the cells transfected with a 
non-targeting control siRNA, reflects the efficiency of siRNA delivery. Moreover, 
the effect of non-targeting control siRNA on the endogenous GAPDH protein level 
reveals the transfection cellular toxicity. With this experiment, I aimed to obtain the 
highest level of GAPDH knockdown while minimizing toxicity, to achieve an 
optimal transfection condition. The optimal transfection condition can be calculated 
using Optimal Balance Factor (OBF) (Equation 2). A higher OBF reflects a better 
balance between target knockdown and cell viability. 
In this experiment, I tested four different transfection reagents 
(Lipofectamine200072, Lipofectamine RNAimax73, Dharmafect174, and 
Dharmafect475), at five different concentrations (as LL, L, M, H, HH, ranging from 
0.05 to 0.5μl per well). 8000 cells per well were transfected with either a GAPDH 
siRNA or a non-targeting control siRNA (NTC), at a concentration of 25nM. Knock 
down efficiency and cell viability were measured after 48 hours. Figure 30 below 
summarizes the relative viability, %KD and OBF for each transfection reagent, 
                                                
71 Glyceraldehyde-3-phosphate dehydrogenase 
72 Life Technology 
73 Life Technology 
74 Thermo Scientific 
75 Thermo Scientific 
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comparing different reagents and different doses. RNAimax showed a better 
relative viability at L and M doses. RNAimax and Dharmafect1 had the highest 
%knockdown at M dose compared to the other transfection reagents and other 
doses. All reagents showed high toxicity at HH dose and the lowest %knockdown 
was seen at LL dose. Due to high toxicity at HH dose and low %knockdown at LL 
does, for the next time point (72 hours), only 3 doses were measured (L, M and 
H). Less toxicity and high knockdown were seen for RNAimax and Dharmafect1 at 
M and H doses (Figure 30b below). Since RNAimax and Dharmafect1 showed 
similar results in this experiment, I applied only three doses in the following step 
(M, MM and H), with two different concentrations of siRNAs (25nM and 50nM). 
The best OBF was obtained after 72 hours using RNAimax at the M dose and 
25nM siRNA (Figure 31 below). 
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Equation 2: OBF 




Figure 30: Optimization of transfection; condition 1 
Four different transfection reagents (Lipofectamine2000, RNAimax, Dharmafect1, 
and Dharmafect4) were tested at five different concentrations (as LL, L, M, H and 
HH). 8000 cells per well were transfected with either a GAPDH siRNA or a NTC 
siRNA at a concentration of 25nM. a) Knock down efficiency and cell viability was 
measured after 48 hours. RNAimax showed a better relative viability at L and M 
doses. RNAimax and Dharmafect1 had the highest %knockdown at M dose 
compared to the other transfection reagents and other doses. All reagents showed 
high toxicity at HH dose and the lowest %knockdown was seen at LL dose 
(orange circles). b) Due to high toxicity at HH dose and low %knockdown at LL 
does, at 72 hours, only 3 doses were measured (L, M and H). Less toxicity and 
high knockdown were seen for RNAimax and Dharmafect1 at M and H doses. 








Figure 31: Optimization of transfection; condition 2 
RNAimax and Dharmafect1 were tested at three different concentrations (as M, 
MM, and H). 8000 cells per well were transfected with either a GAPDH siRNA or a 
NTC siRNA at two different concentrations of siRNAs (25nM and 50nM). a) 
RNAimax at 48h, b) Dharma1 at 48h, c) RNAimax at 72h, d) Dharma1 at 72h. e) 
The best OBF was obtained after 72 hours using RNAimax at the M dose and 




4.3. Pilot screening 
Positive and negative controls are essential when planning a large-scale RNAi 
screening. For all positive and negative controls, I set up a high number of 
replicates in order to decrease false positive and false negative results. To 
achieve the optimal knock down condition for the majority of the genes under 
study, I used an even higher number of positive controls (up to 18) during the 
assay optimization. On the other hand, during the main screening, fewer controls 
but with higher number of replicates (minimum 6) were used. For the main 
screening, I used positive controls with a wide range of effect on cancer 
phenotype, from weak to strong, to avoid missing putative genes with weaker 
effect on proliferation and/or apoptosis during data analysis, and hit identification. 
Non-targeting control siRNA (NTC) was included as a negative control in all 
experiments.  
In the pilot screening, a total number of 16 positive controls and one NTC were 
used. My intention was to select the positive controls affecting proliferation and/or 
apoptosis of the cell line under study and to define the weakest to the strongest 
control with positive effect. I used NTC results to define the baseline for toxicity 
and for data normalization. 8000 cells per well were transfected with 15nM siRNA 
and RNAimax (M dose) for 48 and 72 hours. Satisfactory knockdown level was 
obtained at 72 hours, giving optimal OBF. Active DNA replication was measured 
using a Click-IT EdU HCS kit76. The apoptosis rate was measured by 
immunocytochemistry with a purified Rabbit anti- active Caspase-3 antibody77. I 
                                                
76 Life Technologies 
77 BD Pharmingen™ 
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used a metric known as SSMD78 to control the quality of the assay and to measure 
the effect size of the controls in this experiment [170]. SSMD is a statistically 
accurate and robust parameter with different applications in HCS, mainly for 
quality assessment, size effect measurement, and hit identification. Figure 32a 
below summarizes the quality type of an assay based on control strength. For 
example, if an extremely strong control, such as TOX79, showed SSMD (ß) ≤-7, 
the assay would pass the quality check. On the other hand, SSMD was calculated 
for all controls and used to define their size of effect. Figure 32b and c, below, 
show the SSMD results for proliferation and apoptosis assay. TOX and PLK1 with 
ß < -12 in the proliferation assay and ß > 250 in the Caspase assay were defined 
as extremely strong positive controls. BIRC3, CDK1, ICAM1, and CTGF were 
ranked following TOX and PLK1. Based on these data, I selected the PLK1, 
BIRC3, CDK1, and CTGF for the main screening as positive controls, with medium 
to strong effects on proliferation. PLK1 and CDK1 were applied as positive 
controls for Caspase assay. 
 
                                                
78 Strictly Standardized Mean Difference 
79 Transfection efficiency control for optimizing relative siRNA uptake 
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Equation 3: SSMD 
SSMD is a statistically accurate and robust parameter with different applications in 
HCS, mainly for quality assessment, size effect measurement, and hit 
identification. The value calculated using SSMD metric is shown with ß. (б= 
standard deviation, μ= mean) 







Figure 32: Pilot screening- SSMD calculation 
Pilot screening was done using 16 positive controls. a) The quality of assay and 
the size effect of controls were calculated using the SSMD metric [171]. For 
example, if the calculated SSMD for an extremely strong control such as TOX1 is 
β≤ -7, the assay quality will be considered excellent. b) TOX and PLK1 showed 
the strongest effect on proliferation (bottom blue circle), followed by BIRC3, CDK1, 
ICAM1 and CTGF (top blue circle). c) TOX and PLK1 showed the strongest effect 
on apoptosis (top blue circle), followed by CDK1 (bottom red circle).  
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4.4. RNAi screening and analysis workflow 
As part of main screening, I knocked down 43 up-gain genes mapping to Chr 7 
and 29 up-gain genes mapping to Chr 12 using ON-TARGETplus SMARTpool 
siRNAs80 at a concentration of 25nM. CTGF, CDK1, BIRC3, and PLK1 were used 
as the positive controls and NTC as the negative control.  
4.4.1. Data triage 
I calculated the %Relative viability81, %EdU82 and %Caspase83 for each plate. 
Then, I assessed the overall screen performance using heat maps, %CV and 
correlation plots. Figure 33a below shows heat map for %EdU calculated for three 
plates; each plate contains one replicate per each candidate gene mapping to Chr 
7. The heat map shows the presence of edge effect and the necessity of removing 
the edge values from the analysis to get robust and reproducible results. Then, the 
average and standard deviation of valid object count were calculated for all 
replicates of NTC in each plate (Figure 33b below). Only plates with %CV < 10 
were included in further analysis. The next step was to normalize the data to 
compare the reading from different replicates. EdU and Caspase rates where 
normalized to the number of cells (DAPI counts) per replicate (%EdU and 
%Caspase, respectively). Then, the overall reproducibility of the assays was 
assessed by replicates’ correlation plot (Figure 33c below). After normalization, I 
performed the calculation of quality metrics using both Z'-factor and SSMD (Table 
11). 
                                                
80 Dharmacon 
81 (Valid object count/ NTC median(valid object count))*100 
82 (EdU selected object count / DAPI) *100 











Figure 33: Data triage- overall performance and reproducibility of the assay 
The overall performance and reproducibility of the assay were assessed in several 
steps: a) heat map: each plate contains one replicate per each candidate gene. 
Multiple wells per plate contain each of the positive and negative controls; for 
example, the first row of each plate has the same control siRNA. The variable 
reading for a same control siRNA per plate reflects the presence of edge effect. 
These variable values were removed from further analysis. b) %CV per plate: the 
average and standard deviation of valid object counts were calculated for all 
replicates of NTC in each plate; only plates with %CV < 10 were included in further 
analysis. c) Correlation between replicates; high correlation between replicates (R 
> 0.9 for proliferation and R > 0.8 for apoptosis assay) represent the acceptable 
reproducibility of the assay. 
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Equation 4: Z'-factor; a quality metric 
Z'-factor must be > 0, with a value > 0.5 corresponding to a very good assay. 
PLK1 and NTC were chosen as top and bottom controls, respectively. (б= 
standard deviation, ct= top control (PLK1), cb= bottom control (NTC), μ= mean) 
܈ᇱ െ ܎܉܋ܜܗܚ ൌ ૚ െ ૜б܋ܜ ൅ ૜б܋܊|ૄ܋ܜ െ ૄ܋܊|
 






a) The quality of assay calculated by Z'-factor is shown before and after 
normalization. Z'-factor must be > 0. Improvement of Z'-factor for four plates 
(highlighted in yellow) shows the importance of normalization in HCS. At least two 
out of three replicates must pass this quality check to have enough replicates for 
hit identification. b) Using SSMD, the quality of assay was calculated for each 
positive control. All controls showed excellent quality for EdU assay, while PLK1 
showed quality range of good to excellent for Caspase assay. The values are 
highlighted based on the reference table in (c) 
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4.4.2. Positive Hits identification 
Genes with significant effect on tumor cell’s phenotype (e.g. decrease of 
proliferation and/or increase in apoptosis) are referred to as positive hits. This 
effect is statistically different from the effect of NTC on the tumor phenotype. 
Following normalization and quality control assessment of all replicates, I carried 
out the hit identification as follows: First, I calculated a Modified Robust Z-Score 
(MRZS) for all siRNAs, including NTC and positive controls (Equation 5). MRZS 
normalization centered the data on “0” normalizing data from replicates of NTC. 
Based on MRZS values obtained from positive controls with different strength, -1.5 
was set as cut-off point (MRZS < -1.5 for the EdU assay and MRZS > 5 for the 
Caspase assay). Two-tailed t-test was used to assess the statistical difference 
between the average effect of each siRNA (%EdU or %Caspase) and that of the 
NTC [172]. To correct for multiple comparisons, False Discovery Rate (FDR) was 
applied and an FDR q-value < 0.05 was set as cut-off for significant effects. Finally 
an effect threshold was applied so that siRNAs with MRZS < -1.5 and FDR q-value 
< 0.05 should cause a reduction in the proliferation of at least 20% compared to 
NTC in order to be considered positive hits. It is important to bear in mind that 
PLK1, the strongest positive control, showed a maximal growth reduction of 55%. 
Figure 34 below shows density plots of MRZS values for all replicates (3 plates) of 




Equation 5: Modified Robust Z-Score 
Median (M); Median Absolute Deviation (MAD) 









Figure 34: MRZS density plot for candidate genes on Chr 7 
Density plots for EdU and Caspase assay are shown in the first and second row, 
respectively. MRZS was used as one of the criteria for hit identification. MRZS 
normalization centered the data on “0” normalizing data from replicates of NTC 
(blue vertical line). Positive controls such as PLK1, CDK1, and CTGF are shown 
on each plot based on their MRZS values. MRZS value for BRAF as a prominent 
driver in melanoma is shown as well. Based on the MRZS values obtained for 
positive hits, a cut-off at -1.5 was set to define the positive hits in EdU assay (red 
lines). MDRZ > 5 was set as cut-off for positive hits in Caspase assay. X-axis: 




4.5. The FM7/9/12 has a high content of functional cancer-promoting genes. 
siRNA knockdown for the FM7/9/12 (29 and 43 up-gain genes mapping to Chr 12 
and Chr 7, respectively) was done with RNAimax (M dose) and 25nM siRNA for 
72 hours in 96-well assay format. I performed the experiment with siRNA 
triplicates for candidate genes. CTGF, CDK1, BIRC3, and PLK1 were used as 
positive controls, and NTC as a negative control. For all controls, four or more 
replicates were seeded in each plate. Following data triage, assessing the overall 
reproducibility of the assay, and normalization, I calculatied the quality metrics 
using two methods: Z'-factor and SSMD (Table 11). Normalized values gave an 
acceptable Z'-factor for all replicates (Z'-factor > 0). SSMD was calculated based 
on three positive controls (PLK1, CDK1, and CTFG) and the negative control 
generating good or excellent effect subtypes for the EdU assay, to confirm the 
high reducibility and low variability between replicates.  
For the Caspase assay, only PLK1 showed an excellent effect across three plates, 
good effect in two plates, and inferior effect for one plate. Since only one of the 
candidate genes showed significant effect on apoptosis, I will focus on the effect of 
the FM7/9/12 on tumor proliferation.  
To identify the positive hits with significant effect on cell proliferation, these criteria 
should have met:  MRZS < -1.5 and FDR q-value < 0.05. As shown in Figure 34 
above, for EdU assay, the density of MRZS for each plate is left skewed; this 
implies the positive effect of the majority of the siRNAs on proliferation. On the 
other hand, modified robust z-score normalization for Caspase assay showed 
normal distribution, which reflects the presence of few siRNA affecting apoptosis 
(Figure 34 above). Other than experimental replicates, biological repeats were 
performed as well: the knock down experiment was done twice in the DM-CL4P7 
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and once in the LNM-CL3P7. Only siRNAs that could pass the selection criteria in 
all three biological replicates were categorized as positive hits.  
To assess the knock down efficiency, I performed RT-qPCR on randomly selected 
13 and 14 positive and negative hits, respectively. I used GAPDH as an 
endogenous control gene and normalized the results against GAPDH expression 
(Figure 35 below).  
To increase my confidence in the results obtained from siRNA screening with 
pooled siRNAs, I randomly chose 10 positive hits, and repeated the siRNA 
screening with four individual siRNA per gene. Figure 36 below shows the 
individual knock down results. At least two individual siRNAs resulted in significant 
decrease of proliferation (compared to the negative control) in all genes under the 
test. In conclusion, targeting one gene with different siRNAs produced comparable 
results and this comparable efficacy of individual siRNAs in targeting one gene 






Figure 35: Detection of siRNA induced expression silencing by RT-qPCR 
RT-qPCR showed successful knockdown for all genes under the test. Orange and 
blue bars represent the remaining %expression for positive and negative hits, 






Figure 36: Individual siRNA knock down 
To confirm the phenotypic results obtained from pooled siRNA knockdown, 10 
positive hits were selected randomly and were knocked down with four individual 
siRNA. At least two individual siRNA per each positive hit showed significant 
decrease in proliferation (compared to the negative control); this comparable 
efficacy of individual siRNAs in targeting one gene discarded the possibility of off-




4.5.1. The FM7/9/12’s positive hits on Chr 7 
19 of the 43 up-gain genes on Chr 7 (44.18%) showed significant effect on 
proliferation (MRZS < -1.5, FDR q-value < 0.05)(Figure 37 below): AGK, BRAF, 
C7orf13, EN2, EZH2, INSIG1, KRBA1, LOC401431, LUC7L2, LUZP6, MLL3, 
NUB1, PAXIP1, PDIA4, SLC37A3, TRIM24, TTC26, ZNF398, and ZNF746. More 
importantly, all of these positive hits reduced the proliferation by at least 20% 
compared to the negative control. 
For apoptosis assay, TRIM24, SLC37A3, and LMBR1 showed acceptable MRZS > 
3 and significant p-value < 0.05; however, they appeared to be non-significant 
following multiple testing corrections using FDR. This assay only showed 
significant apoptotic effect for the positive control PLK1.  
 
4.5.2. The FM7/9/12’s positive hits on Chr 12 
Eleven of the 29 up-gain genes on Chr 12 (37.93%) were categorized as positive 
hits with significant effect on proliferation (Figure 38 below): DNM1L, KIAA0528, 
LDHB, MED21, PKP2, RASSF8, SMAGP, SPATS2, TMBIM6, TUBA1B, and 
TUBA1C. All of these positive hits reduced the growth by at least 20% compared 
to the negative control. 
TUBA1C showed significant effect on apoptosis (modified robust z-score > 4, FDR 











Figure 37: The FM7/9/12’s Positive hits on Chr 7- proliferation assay 
19 genes on Chr 7 showed significant effect on proliferation. a) MRZS 
normalization centered the data on “0” normalizing data from replicates of NTC 
(blue vertical line). MRZS < -1.5 was set as a cutoff to define positive hits. b) 19 
genes with MRZS < -1.5 reduced the growth by at least 20% and their effect on 
proliferation was statistically significant compared to the effect of negative control 
on cell proliferation (FDR q-value < 0.03). Genes highlighted in green, blue and 










Figure 38: The FM7/9/12’s Positive hits on Chr 12- proliferation 
Eleven genes on Chr 12 showed significant effect on proliferation. a) MRZS 
normalization centered the data on “0” normalizing data from replicates of NTC 
(blue vertical line). MRZS < -1.5 was set as a cutoff to define positive hits. b) 19 
genes with MRZS < -1.5 reduced the growth by at least 20% and their effect on 
proliferation was statistically significant compared to the effect of negative control 
on cell proliferation (FDR q-value < 0.02). Genes highlighted in green, blue and 




4.6. High number of the FM7/9/12’s positive hits shows a synergistic effect, 
when combined with BRAF inhibition. 
Detailed examination of the somatic genomic and transcriptomic catalogue in 
Patient7PoC suggested that the common aberrations of a sub-set of genes on Chr 7 
and Chr 12 might characterize a beneficial expression pattern for melanoma 
maintenance. Functional studies with significant validation rates for these 
maintenance genes confirmed the importance of this gene module in tumor 
proliferation. I believe that tumor specific rearrangements such as translocations 
carry a weight of the biological importance by bringing different genes of different 
chromosomes in the vicinity of each other in order to facilitate the tumor’s 
functional maintenance, by mediating additive or synergistic functional 
consequences. In other words, I hypothesize that orchestrated genomic and 
transcriptomic aberrations are the fundaments for hardwiring the core set of 
events, juxtaposing the genes with at least additive contribution to tumor features. 
Therefore, following the functional validation of the functional module on Chr 7 and 
Chr 12, I assessed whether positive hits carried any synergistic effect to BRAF 
inhibition. I chose BRAF inhibition for this study, mainly because of BRAF 
participation as a core maintenance gene in Patient7PoC, and its therapy value in 
melanoma. I showed its physical genomic connection to the amplified up-regulated 
functional module and more importantly, the BRAFV600K damaging mutation was 
defined as the mutation with significant functional mutation burden common in all 
samples of this patient (3.4.1.2 above). 
To test the possible synergism, I first incubated the target cells for 24 hours with 
each siRNA (targeting individual positive hits), and then treated with the pre-
identified IC50 concentration of PLX4032 (BRAF inhibitor) for an additional 48 
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hours. I used both LNM-CL3P7 and DM-CL4P7 for this experiment. Dr. Wagner86 
calculated the presence of synergy using the Bliss independence metric for each 
cell line separately [174]. First, the relative growth inhibition with test siRNA 
(GIsiRNA), the relative growth inhibition with drug (GIdrug), and the relative growth 
inhibition with test siRNA plus drug (GIsiRNA+drug) were calculated. GIBliss defined the 
expected relative growth inhibition with test siRNA plus drug (Equation 6). Then, 
the expected (GIBliss) and observed (GIsiRNA+drug) values across three replicates 
were compared using a two-sample, two-tailed t-test assuming the two sample 
populations had equal variances, implemented using the ttest2 function in 
MATLAB. Resultant p-values were converted to FDR values using the Benjamini 
and Hochberg correction method, implemented using the mafdr function in 
MATLAB.  
Figure 39 below shows the genes with synergistic, antagonistic, or additive effect 
in both cell lines (FDR q-value < 0.1). Genes that are synergistic in both cell lines 
are shown with two red outlines, whereas genes that are synergistic in only one 
cell line have only one red outline. The rest of the genes showed additive effect to 
BRAF inhibition.  
A total number of 11/30 positive hits showed potential for synergy with BRAF in 
both cell lines (FDR q-value < 0.1): AGK, C7orf13, EZH2, LUC7L2, MLL3, and 
TRIM24on Chr 7, and KIAA0528, LDHB, MED21, SPATS2, andTMBIM6 on Chr 
12. These genes showed greater impact on tumor proliferation when combined 
with BRAF inhibitor compared to the sum of their individual effects. Moreover, 9/30 
genes showed additive effect to BRAF inhibition in both cell lines including: 
KRBA1, LOC401431, LUZP6, SMAGP, TTC26, TUBA1B, TUBA1C, ZNF398, and 
                                                
86 Dr. Joel Wagner, The Jackson Laboratory, CT, USA 
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ZNF746. The combined effect of these genes with BRAF inhibitor was similar to 
the sum of their effect when applied individually. EN2 and RASSF8 were classified 
as antagonistic genes in LNM-CL3P7 and DM-CL4P7, respectively.   
Form the list of positive hits synergistic to BRAF in both cell lines, I chose AGK 
and MLL3 for further validation. I tested the synergism at different concentrations 
of the drug (range of 16 times lower and higher than IC50) in the presence of one 
constant concentration of siRNA (25nM), and Dr. Wagner calculated the 
synergistic effect using the Bliss independence metric, as discussed earlier in this 
section. Figure 40 below plots the proliferation values for drug effect, expected 
combined effect, and observed combined effect in different drug concentrations. 
Inhibition of the AGK gene resulted in a significant synergistic effect in the 
presence of four increasing concentrations of drug (0 < log10 drug dose < 1), and 
MLL3 gene showed significant synergistic effect in the presence of six increasing 
concentrations of drug (-0.5 < log10 drug dose < 1). Figure 41 below shows the 
images scanned by Cellomics ArrayScan(R) VTI600 for each siRNA (AGK and 
MLL3), alone and combined with drug with increasing concentration from left to 
right. 
11/30 and 9/30 positive hits had synergistic and additive effect, respectively, when 
combined with BRAF inhibitor. In conclusion, I showed not only the importance of 
maintenance functional module for tumor proliferation, but I also confirmed the 





Equation 6: Bliss Independence approach 
	ܩܫ௦௜ோே஺	ୀଵ ି %	౦౨౥ౢ౟౜౛౨౗౪౟౥౤	౭౟౪౞	౪౛౩౪	౩౟౎ొఽ%౦౨౥ౢ౟౜౛౨౗౪౟౥౤౭౟౪౞ ౙ౥౤౪౨౥ౢ ౩౟౎ొఽ 
 ܩܫௗ௥௨௚	ୀ	ଵ	ି ౦౨౥ౢ౟౜౛౨౗౪౟౥౤౭౟౪౞ ౙ౥౤౪౨౥ౢ ౩౟౎ొఽ ౦ౢ౫౩ ౚ౨౫ౝ% ౦౨౥ౢ౟౜౛౨౗౪౟౥౤౭౟౪౞ ౙ౥౤౪౨౥ౢ ౩౟౎ొఽ  
 ܩܫ஻௟௜௦௦ୀܩܫୱ୧ୖ୒୅ ൅ ܩୢܫ ୰୳୥ െ ܩܫୱ୧ୖ୒୅ ൈ ܩୢܫ ୰୳୥ 







Figure 39: Positive hits with synergistic function to BRAF inhibition 
The synergism effect between positive hits and BRAF inhibitor was calculated by 
Bliss Independence approach. This plot shows synergism (red circles), 
antagonism (blue circles), or additive effect (gray circles), when positive hits’ 
knockdown is combined with BRAF inhibition. Genes that are synergistic in both 
cell lines are shown with two red outlines, whereas genes that are synergistic in 
only one cell line have only one red outline. It also applies to antagonistic effect 
with blue outlines. Rest of the genes are additive. CL3 and CL4 represent LNM-
CL3P7 and DM-CL4P7, respectively. Threshold cut-off was set at FDR q-value <0.1. 
9 and 11 positive hits (out of 30) showed additive and synergistic effect to BRAF 
inhibition, respectively. EN2 and RASSF8 were antagonistic effect to BRAF 
inhibition in LNM-CL3P7 and DM-CL4P7, respectively. PLK was a positive control 













Figure 40: Significant synergy of AGK and MLL3 with BRAF inhibitor at increasing 
concentrations 
a) AGK and b) MLL3, AGK and MLL3 were chosen from positive hits with 
synergistic effect to BRAF for further validation. The blue lines show the base line 
drug effect at different concentrations. Black lines are the expected values for 
proliferation effect, when siRNA is combined with drug, and the red lines are the 
observed combined effects. n.s. and ** (and ***) represent the not significant and 
significant effects for synergy between siRNA and drug at different concentrations 
of drug with FDR q-value < 0.1, respectively. The x-axis is log10 (drug 







Figure 41: MLL3 and AGK synergy with BRAF- image 
Both a) MLL3 and b) AGK: Top left cell shows drug’s effect. Bottom left cell shows 
siRNA effect. Second to eighth cells of the first row show the effect of drug on cell 
proliferation at different concentrations. Second to eighth cells of the second row 
show the combined effect (siRNA+ drug). The concentration of drug increases 
from the second to the eighth column, in each row, with the same concentration 








4.6.1. The positive hits synergistic to BRAF are part of the same co-
expression cluster in samples with BRAFV600 mutation. 
It has been shown that similar expression patterns shared by a group of genes 
across high number of samples are more likely representative of the functional 
association between those genes. Gene co-expression networks with systematic 
clustering of genes with similar expression pattern can reveal the clusters with 
probable functional relatedness [173]. Here, I asked whether the maintenance 
functional module discovered in Patient7PoC followed a specific expression pattern, 
when BRAF was mutated. Therefore, I examined the presence of a core module 
within the FM7/9/12’s positive hits that was significantly associated with BRAF 
mutation status, in a large cohort of melanoma patients (162 tumors from the 
TCGA database with BRAFV600 mutation information). For this analysis, Dr. LIN87 
used an unsupervised hierarchical clustering, as implemented in the Pvclust R 
package, to cluster the FM7/9/12’s positive hits in 68 samples with BRAFV600 
mutation, or 94 samples with BRAFWT as a control (Figure 42 below). Stable 
clusters were defined as those with AU ≥ 0.95 [175]. Using this clustering, we 
identified the highly expressed (z-score > 0.75) positive hits whose expression 
profiles were similar to the ones observed for the BRAF gene across the set of 
samples with BRAFV600 mutation, and which clustered (AU > 95%) with BRAF (we 
refer to this cluster as ClusterBRAF). Similar analysis on the samples with BRAFWT 
did not generate any significant cluster with BRAF, whereas in samples with 
BRAFV600 mutation, 13 genes passed the criteria for significant clustering with 
BRAF and generated a significant ClusterBRAF. In ClusterBRAF, MLL3, AGK, 
LUC7L2, and TRIM24 showed significant synergy with BRAF, and KRBA1, 
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LUZP6, TTC26, ZNF398, and ZNF746 were additive to BRAF in both LNM-CL3P7 
and DM-CL4P7.  
We found a sub-cluster within the FM7/9/12’s positive hits correlated with BRAFV600 
mutation. This observation suggests the presence of biological implications for the 
clustered genes in affecting the tumor phenotype in samples with BRAFV600 
mutation.  
Some of the synergistic genes to BRAF including LDHB, EZH2, MED21, TMBIM6, 
and SPATS2 were not part of ClusterBRAF in samples with BRAFV600 mutation. This 
can be explained as follows: first, clustering implies the presence of genes with 
correlated expression status and suggests the involvement of those genes in the 
same or overlapping pathways; whereas the synergistic non-clustered genes with 
ClusterBRAF may act in BRAF-independent pathways, but result in the same 
functional consequences. Second, the synergistic function of the non-clustered 
genes in ClusterBRAF can be related to BRAF expression and copy number status, 
and not to the BRAFV600 mutation. To examine the latter option for LDHB, EZH2, 
MED21, TMBIM6, and SPATS2, the clustering was repeated in samples with gain 
and high expression of BRAF (disregarding the BRAFV600 mutation status). EZH2, 
MED21, and SPATS2 were clustered significantly with BRAF (ClusterBRAF) based 
on their expression profiles, and not BRAFV600 mutation status. The results are 
shown for EZH2 in Figure 43 below. On the other hand, LDHB and TMBIM6 did 
not cluster with BRAF under any circumstances, this suggest that these genes 
may interact with components of ClusterBRAF using alternative pathways, which 








Figure 4288: Some synergistic effects to BRAF are universally dependent on 
BRAFV600 mutation. 
This Figure illustrates an unsupervised hierarchical clustering with AU/BP values 
(%). This Figure shows the clustering of positive hits, if they were up-regulated in 
the TCGA database, a) samples with BRAFWT, b) samples with BRAFV600 
mutation. 
There is no ClusterBRAF in Samples with BRAFWT (a). On the other hand, significant 
ClusterBRAF is generated in samples with BRAFV600 mutation (AU > 95%) (b). 
ClusterBRAF is shown with a red rectangle; red, blue, and orange arrows refer to 
BRAF, synergistic genes inside ClusterBRAF, and synergistic genes outside 
ClusterBRAF, respectively. Clustering implies the presence of genes with correlated 
expression status; clustering of synergistic genes with BRAF may suggest the 
involvement of these genes in the same or overlapping pathways.   
                                                






Figure 4389: EZH2 synergistic effect to BRAF is independent from BRAFV600 
mutation 
This Figure illustrates the unsupervised hierarchical clustering with AU/BP values 
(%).a) BRAFWT samples with up-gain EZH2 (n= 21), b) samples with BRAFV600 
mutation and up-gain EZH2 (n= 22), c) samples with up-gain BRAF and up-gain 
EZH2 (n= 48); blue and orange arrows show EZH2 and BRAF in ClusterBRAF, 
respectively. EZH2 is clustered with BRAF only based on expression and copy 
number profile of BRAF and independent from BRAFV600 mutation (AU > 95%). 
 
                                                
89 Done by Dr. LIN Suling Joyce, GIS, Singapore 
 146 
 
4.6.2. Amplified TRIM24 as a driver gene in melanoma, predicted by 
OncoIMPACT 
Distinguishing the unique complement of genes that drive tumorigenesis in each 
patient, from a sea of passenger mutations, is necessary for translating the full 
benefit of cancer genome sequencing into the clinic.  
Working with Dr. Niranjan Nagarajan and his group at the GIS, I helped develop a 
data integration framework (OncoIMPACT) that acts to nominate patient-specific 
driver genes from a panel of mutations based on their phenotypic impact [176]. 
OncoIMPACT nominates patient specific driver genes by evaluating the impact of 
a mutation, (SNVs, SMs, and CNVs, and the resulting perturbations in 
transcriptional programs), by associating them to modules of patient-specific 
deregulated genes through the gene interaction network. A key step in this 
process is the identification of sentinel phenotype genes frequently deregulated in 
a cancer subtype and to distinguish relevant driver mutations from passengers. 
The nominated patient-specific drivers are ranked based on their impact on 
associated modules.  
We applied the OncoIMPACT analysis on DM-T4P7 in combination with a data set 
of the TCGA melanoma samples. BRAF and TRIM24 were identified as amplified 
predicted driver genes in this sample. TRIM24 on its own has not been 
characterized as a driver before and is ranked 671 in the list of frequently mutated 
genes in the TCGA melanoma data set. While TRIM24 was initially identified as a 
transcriptional co-regulator, it has been recently shown to ubiquitinate TP53 for 
degradation in breast cancer [177] and may play a similar role in melanoma. 
Appropriately, negative hits such as CASP2, CNOT4, CUL1, HIPK2, SSBP1, and 
ZYX were not predicted as driver, using OncoIMPACT.  
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Together, these results provide evidence that a computational approach, 
combined with clinical genome sequencing could serve as a means to reliably 




















5. RESULTS (C)                                                               
Discovery of a Universal Functional Module in Melanoma 
As a proof of concept, I studied the comprehensive genomic and transcriptomic 
landscape of somatic events in Patient7PoC with a complete set of tumors and 
matched cell lines, and identified a core set of hardwired somatic events of 
synergistic function for tumor proliferation. I then described the FM7/9/12 as the 
maintenance functional module, shared across all eight melanoma patients in this 
study. I confirmed the functional contribution of the components of the FM7/9/12 to 
tumor proliferation in both cell lines derived from Patient7PoC. Then I showed that 
elements of the maintenance functional module modulate the effect of BRAF 
inhibitor.  
These observations and successful functional validation from the proof of concept 
led me to aim at discovery of a universal functional module (UFM) in melanoma. 
To achieve that, I extended my model to a larger cohort of melanoma patients: I 
used eight patients with comprehensive catalogue of somatic mutations as an 
exploratory set, and 232 tumors in the TCGA database as a validation set. 
In this chapter, I will present a descriptive analysis of sequencing results for all 
samples of eight patients. Then, I will discuss the workflow of the discovery of the 
hardwired UFM.  
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5.1. Sequencing descriptive analysis 
5.1.1. DNA–PET 
For 23 DNA samples isolated from PBL, tumor tissues, and their established cell 
lines from eight melanoma patients, I prepared DNA-PET mate-pair libraries and 
2x50bp sequencing was performed by the GIS NGS team (Table 1). Samples from 
four patients characterized by a good clinical outcome included PBL as normal 
genomic control DNA (PBLGx), tissues from lymph node metastasis (LNM-T3Gx), 
and cell lines derived from lymph node metastases (LNM-CL3Gx). Samples from 
four patients characterized by a poor clinical outcome comprised PBL (PBLPx), 
lymph node metastasis tumors (LNM-T3Px), the corresponding cell line for one 
patient (Patient7Poc) referred to as LNM-CL3P7, distant metastasis tumors (DM-
T4Px), and the corresponding cell line for one patient (Patient7Poc) referred to as 
DM-CL4P7. Per sample, 9 to 46 million mate-pair sequence reads (without 
redundancy) were generated with an average insert size of 9 to 10 kb, resulting up 
to 176-fold physical genome coverage per sample (90-fold in average). I found 
527 somatically acquired rearrangements in my cancer data set; including 
deletions, tandem duplications, inversions, and translocations (Figure 44 below). 
Translocations were more prevalent compared to other rearrangements in most of 
the tumor samples, whereas deletions were over-represented among normal 
samples, after final cross comparison. Almost all SMs were specific to each 
patient. Distinct sets of rearrangements were found for the patients under study; 
only 3/527 SMs (two tandem duplications and one inverted orientation) – no gene 




Figure 45 below shows a Circos plot of all of the somatic SMs found in the 
examined cancer samples. The number of SMs per sample was not associated 
with the prognosis status of the patients, as only 5 SMs were detected in the poor 
prognosis Patient8P (lymph node tumor), whereas 80 SMs were found in the good 
prognosis Patient1G. Most of the inter-chromosomal SMs in Patient1G were 
restricted to Chr 1 and Chr 3. Restriction of the majority of the SMs to two or three 
chromosomes was observed in Patient6P (lung metastasis) as well; this pattern 
was suggestive of the presence of chromothripsis in Patient1G and Patient6P [178]. 
Except for Patient1G and Patient6P, most of the samples contained a low number 
of SMs. This observation was expected, as the low frequency of SMs was 
reported in cutaneous melanoma compared to other types of melanoma such as 
acral melanoma [179].  
Figure 46 below shows a distribution of copy number states for each one of the 
examined cancer genomes. In the samples under study, the copy number 
changes were modest in amplitude, and mostly with one copy number loss or 
gain, but these changes affected large genomic regions; up to 16.71%, 61.71%, 
41.79%, and 40.79% of the examined cancer genomes showed deletion (2 copy 
number loss), loss (single-copy loss), gain (low-level gain), and amplification (high-







Figure 44: Statistics for somatic structural mutations 
 
Diverse contribution of rearrangements can be seen in each sample. Complex 
rearrangements are rearrangements with > 3 breakpoint junctions. 
a) Somatic SMs: In general, translocations were more prevalent, followed by 
deletions. b) Germline SMs: deletions were the dominant SMs (note that these 





















Figure 45              
 
        (Continued …) 
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Figure 4590: DNA–PET, Circos plots of seven melanoma patients  
 
Circos plots displaying SMs and CNVs; from outer to the inner ring: chromosome 
ideogram, CNVs (red= gain, blue= loss, gray= no change), SMs (every SM is 
shown by different color; the SMs color-code is shown in Figure 45-l). For 


















Figure 46: Statistics for copy number variations 
 
All samples showed broad range of CNVs. Genome-Wide SNP 6.0 array was 
used to define the copy number status for LNM-CL3G1, LNM-CL3G2, and LNM-
CL3G4. CNV status of all other samples was identified using cPETs information 
from DNA–PET technology.  
                                                





I prepared RNAseq libraries for 16 samples, isolated from tumor and their 
matched cell lines, derived from eight melanoma patients; normal donors’ 
melanocyte RNA samples were used as controls (Table 1). Library construction 
procedure was described in details in methods section 2.2.3. Libraries were 
sequenced 2x75bp paired-end by the GIS NGS team. 
5.1.2.1. Normal RNA contamination removal 
One of the major advantages of sequencing primary cell lines together with their 
tumor tissues of origin was to be able to differentiate between the transcriptional 
output of the cancer cells, and that of the surrounding normal cells such as stroma 
and immune cell infiltration. To show the importance of cell lines in removing 
normal cell contamination, I performed a transcriptional analysis (Mode analysis) 
using Patient7PoC, for whom a complete set of tumors and cell lines from both 
lymph node and lung metastases was available. 
First, I performed the analysis on tumors vs. normal melanocytes. Then, I 
repeated the analysis using all tumors and cell lines vs. normal melanocytes. 
Figure 47a below illustrates the concept of Mode analysis. In this analysis, 
differentially expressed genes with expression values > mode+0.5 in tumors (and 
cell lines), but < mode-0.5 in normal samples were defined as putative oncogenes 
(up-regulated in tumors and cell lines); whereas genes with expression value > 
mode+0.5 in normal samples, but < mode-0.5 in tumors (and cell lines) were 
defined as putative TSGs (down-regulated in tumors and cell lines). GSEA 
analysis for the KEGG gene set on 381 putative oncogenes and 152 putative 
TSGs defined by the first analysis (only tumors vs. normal samples) revealed 
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significant enrichment for immune pathways (e.g. biological functions associated 
with leukocytes and lymphocytes), and stroma associated pathways (e.g. Type I 
diabetes mellitus) (Figure 47b and Figure 48, below). Conversely, GSEA analysis 
on 36 putative oncogenes and 48 putative TSGs from the second analysis (both 
tumors and their matched cell lines vs. normal samples) showed significant 
enrichment for p53 signaling pathway, focal adhesion, ECM-receptor interaction, 
cell adhesion molecules (CAMs), and leukocyte transendothelial migration, while 






Figure 47: Mode analysis  
The Mode analysis was performed to show the importance of cell lines’ 
sequencing data in removal of normal cell contamination; a) this plot represents 
the concept of mode analysis; genes with expression values > mode+0.5 in 
tumors but < mode-0.5 in normal samples were categorized as putative 






























































 Figure 47: 
b) heat map; log2 quantile FPMK values for 381 putative oncogenes and 152 
putative TSGs identified by mode analysis on only Patient7PoC tumors vs. normal 
melanocytes; c) heat map; log2 quantile FPMK values for 36 putative oncogenes 
and 48putative TSGs identified by mode analysis on Patient7PoC all samples – 
tumors and cell lines. Blue and red blocks represent low and high expression, 
respectively. Genes highlighted in blue and red represent putative TSG and 
putative oncogenes, respectively.   
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Figure 48: Enrichment of immune pathways due to normal contamination 
KEGG pathways analysis was performed on the final list of putative oncogenes 
and TSGs obtained from first (Patient7PoC tumors vs. normal melanocytes), and 





 Figure 48 
KEGG analysis showed enrichment of immune related and stroma pathways for 
the first Mode analysis, whereas second analysis removed the possible normal 
contamination. Only red bars were enriched pathways in the second analysis 
overlapping with the significant pathways from the first analysis (FDR q-value < 
0.05). Significant enrichment of cancer-related pathways such as ECM-receptor 
interaction, focal adhesion, cell adhesion molecules (CAMs), p53 signaling 
pathway and leukocyte transendothelial migration, while removing all immune 
related pathways (obtained from the first mode analysis) confirms the importance 




5.1.3. Exome–capture sequencing 
I constructed a total number of 22 libraries using NimbleGen’s SeqCap EZ Exome 
Library preparation kit. Libraries were sequenced by GIS NGS team using Illumina 
GAIIx (Table 1). Library construction procedure was described in details in 
methods section 2.2.2. Total number of 726 genes carried non-synonymous 
mutations predicted as damaging or nonsense. Integrating with Cosmic database, 
268/726 genes were known mutated genes, but only AKT1-E17K, BRAF-V600E, 
BRAF-V600K, CDKN2A-R80*, and ZNF804A-R97Q showed the same reported 
base substitutions. One of the patients with good prognosis and three patients with 
poor prognosis carried BRAFV600 mutation; the rest of the patients were "pan-
negative" as they did not carry any of the recurrent mutations reported in 
melanoma as drivers: (NRAS (G12/13, Q61), BRAF (V600), KIT (W557, V559, 
L576, K642 and D816), GNA11 (Q209), and GNAQ (Q209)). Since there is a 
chance of presence of BRAF fusion rearrangements as driver in "pan-negative" 
samples, I checked the DNA–PET fusion genes, but none of the samples carried 
any form of fusion with BRAF.   
The HODIS study on melanoma exome landscape was described in section 1.8 
[114]. Of the 726 genes with non-synonymous mutations in the eight patients in 
this study, 663 genes overlapped with the HODIS study as the most updated 
somatic catalogue of driver mutations with significant functional burden in 
melanoma. Of the 663 common genes with the HODIS study, 288 genes carried 
the same amino acid changes (shown in Table 12). I only used TP53, BRAF, 
CDKN2A, and SNX31, with significant functional mutation burden (FDR q-value < 




Table 12: Amino acid changes with significant functional mutation burden 
This table is the list of non-synonymous mutations with significant functional 
mutation burden (FDR q-value < 0.2), as reported in the HODIS study. Only TP53, 
BRAF, CDKN2A, and SNX31 with significant functional mutation burden were 
categorized as maintenance genes in this study. 
 
Non-synonymous SNVs (p-value < 0.05) Public dataset 
HODIS paper 






























































BRAF  V600E/V600K 4    <1E-08 5.47E-05 
TP53  C44Y/R116W 2    <1E-08 5.47E-05 
CDKN2A  R80* 1    9.00E-08 0.000253 






Reported but different amino acid change 






5.2. The universal functional module (UFM) was identified based on 
hardwired genomic aberrations and functional mutation burden. 
To discover the UFM, first, in the full set of eight patients with either good or poor 
prognosis (including Patient7PoC), I classified as exploration functional module 
(EFM) those genes affected by hardwired changes that were shared by all 
specimens of any given patient (i.e. lymph node tumor and its matched cell line in 
each patient with good prognosis, lymph node and distant metastasis samples and 
– if available – their matched cell lines in each patient with poor prognosis).  
The EFM comprised of 4086 genes including 2212 up-regulated and gained 
genes, 1871 down-regulated and loss genes and BRAF, TP53, CDKN2A, and 
SNX31 (harboring non-synonymous damaging or nonsense mutation with 
significant mutation burden), across multiple samples per patient in the set of eight 
patients. I then examined the components of the EFM in a larger cohort of 
melanoma patients, using 232 tumors from the TCGA melanoma dataset, to see if 
any could be generalized to a larger dataset of melanoma samples.  
Hardwired events were defined in the TCGA melanoma dataset based on z-score 
normalized expression values and copy number status per gene (described in 
methods section 2.4): genes with z-score ≤ 0.75 and copy number loss were 
categorized as low-expressed with loss, whereas genes with z-score ≥ 0.75 and 
copy number gain were categorized as highly-expressed with gain. In the TCGA 
database, I performed a frequency-based analysis using EFM dose assessment to 
discover the universal functional module (UFM), as a subset of the EFM, with 
the most frequent events across all melanoma tumors. Figure 49 below is a 
schematic presentation of the steps used to define the EFM and UFM: to obtain 
the most common and probably the most critical components in maintenance of 
 164 
 
melanoma, I performed a dose assessment of how frequent any component of the 
EFM is hardwired in the TCGA database. I performed separate analyses for up-
gain and down-loss genes (the EFM components).  
Figure 50 below illustrates the pattern of the EFM components’ frequency in the 
TCGA database; for example in Figure 50a, red bars represent components of the 
EFM that are down-loss only in one (of the eight) patient: 10% of these genes are 
down-loss in >30% of the TCGA melanoma tumors as well. Same way of 
interpretation can be applied to the other bars. Based on this analysis, the EFM 
components showed a consistent pattern of increase in frequency in 20-30% and 
>30% of the TCGA samples (marked with an asterisk in Figure 50a). The EFM 
components with up-gain direction showed a consistent pattern of increase in 
frequency in 10-20%, 20-30% and >30% of the TCGA samples (marked with an 
asterisk in Figure 50b).  
The EFM components seen in >30% and >20% (marked with arrows in Figure 50) 
of the TCGA melanoma tumors were kept as the final UFM for down-loss and up-
gain genes, respectively.   
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Figure 49: Discovery of the universal functional module (UFM) – workflow 
To identify the UFM, I used eight patients with multiple samples (four patients with 
good and four patients with poor prognosis; refer to Table 1). Genes with 
hardwired changes shared across all samples per patient were categorized as 
EFM. The EFM includes a combination of good maintenance genes (hardwired 
events common in both tumor and cell line per each patient with good prognosis) 
and poor maintenance genes (common events in all tumors (and if available cell 
lines) obtained from each patient with poor prognosis). G.M. and P.M. refer to 
good and poor maintenance genes, respectively. The TCGA melanoma dataset 
was then used for generalization and, validation of the EFM, and discovery of the 
UFM: the EFM components hardwired in >30% and >20% of the TCGA melanoma 







Figure 50: Dose assessment of the frequency of the EFM components in the 
TCGA database 
a) Genes with down-loss, b) genes with up-gain; EFM refers to hardwired changes 
that are shared by all specimens of any given patient (of the eight patients in this 
study). To obtain the most common and probably the most critical components in 
maintenance of melanoma, I performed a dose assessment of how frequent any 
component of the EFM is hardwired in the TCGA database. Components of the 
EFM were analyzed separately based on their pattern of expression and CNV (up-
regulated and gained genes vs. down-regulated and loss genes). For example, the 
green bars represent components of the EFM seen in two of the eight patients: 
13% of genes with up- gain in two patients (y-axis) are hardwired in a same 
direction as in 20-30% of the TCGA melanoma tumors (x-axis). Same way of 
interpretation can be applied to the other bars. Bars marked asterisk refer to the 
EFM components with consistent pattern of increase in frequency in the TCGA 
samples. A stringent threshold was applied to filter out the less common and non-
consistent components of the EFM. Therefore, the EFM components hardwired in 
>30% and >20% (marked with arrow) of the TCGA melanoma tumors were kept 
as the final UFM for down-loss and up-gain genes, respectively.  
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The UFM consists of 542 genes: 248 genes are up-regulated with gain in at least 
one patient (of the eight patients in this study), and highly-expressed with gain in > 
20% of the TCGA melanoma tumors. 291 genes are down-regulated with loss in at 
least one patient (of the eight patients in this study), and lowly-expressed with loss 
in > 30% of the TCGA melanoma tumors. TP53, BRAF, CDKN2A, and SNX31 with 
significant functional mutation burden (FDR q-value < 0.2) are part of the UFM 
components as well. To discover the association of the UFM with biological 
pathways, I performed the GSEA analysis; the top significant Canonical pathways, 
BioCarta and KEGG gene sets (FDR q-value < 0.05) are shown in Figure 51 
below. For instance, pathways including ‘cell cycle’, ‘DNA replication’, ‘cell cycle 
checkpoints’, ‘mTOR signalling pathway’, ‘p53 signalling pathway’, ‘JNK MAPK 
pathway’, ‘Wnt signalling pathway’, ‘p38 MAPK pathway’, ‘Sonic Hedgehog (SHH) 
pathway’, and ‘EGFR signalling in cancer’ imply the major contribution of the UFM 
components in cell survival and proliferation. Enrichment of ‘nucleotide excision 
repair’ pathway confirms the importance of intact DNA replication for tumor 
progression as reported in other studies [180]. Enrichment of ‘mCalpain and 
friends in Cell motility’ and ‘HIF-1α pathway’ represents the tumor potential for 
migration, invasion, and angiogenesis, respectively.   
I used the Drug-Gene Interaction database (DGIdb)91 [181] to find the potentially 
druggable genes within the UFM; 22 genes turned out to be druggable (highlighted 
in yellow in Table 14): EPHB4, GSTK1, GUSB, NDUFA4, NDUFB2, PPIA, 
PSMC2, PYCR2, PYCRL, TPMT, BRAF, PRKAR2B, PSMA2, TOP1, AARS2, 
ACSS1, CRTC2, DTNBP1, NDUFB9, NEU1, RPL8, and S100A1.  






Figure 51: GSEA analysis- the UFM   
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5.2.1. The universal functional module (UFM) is composed of seven gene-
regulation pathways.  
As discussed previously in section 4.6.1, similar expression patterns shared by a 
group of genes across high number of samples are more likely representative of 
the functional association between those genes. To reveal the clusters with 
probable functional relatedness within components of the UFM, Dr. Wagner92 
applied the Spearman correlation and principal component analysis (PCA). With 
these analyses, we identified genes with correlated expression patterns, and then 
identified gene nodes that tend to be connected to other genes in a similar 
manner. First, the z-score normalized expression value of 542 genes as 
components of the UFM was extracted from the TCGA melanoma tumors (232 
tumor samples). I considered only the expression data, since based on my 
selection criteria for discovery of the UFM, the copy number data should 
correspond well to the expression data in these genes set. Spearman correlation 
was calculated as a distance metric, between each gene pair among the 542 
genes of the UFM, using the ‘corr’ function in MATLAB (R2013b), creating a 
symmetric 542 x 542 correlation matrix, C. Figure 52a below represent the 
resultant correlation matrix; the clusters are indicated by the different colors of the 
dendrogram leaves. These clusters can be thought of as "pathways" in the 
expression data, which were identified de novo directly from the TCGA expression 
data. The top bar in this figure shows which genes in the dendrogram columns 
correspond to the up-gain genes (shown in red), versus down-loss genes (shown 
in blue). We can see that the up-gain genes and the down-loss genes tend to form 
independent sub-networks (i.e., tend not to be correlated with one another). 
                                                
92 Dr. Joel Wagner, The Jackson Laboratory, CT, USA 
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To identify strongly correlated gene pairs, only correlation values exceeding the 
60th percentile of the absolute correlation values, |R| > 0.1641) were kept (p-value 
< 1.229e-2; FDR q-value < 3.081e-2 (Benjamini-Hochberg method)). The applied 
threshold would filter out genes not/weakly correlated with any other given gene in 
the matrix; but interestingly, none of the gene pairs showed disconnection from the 
matrix as all had strong and significant correlation with other genes in the matrix. 
At the applied 60th percentile threshold, the most sparsely connected gene was 
connected to (i.e., correlated with) 33 other genes, whereas the most densely 
connected gene was connected to 354 other genes. This strong connection 
between all components of the UFM in the correlation matrix, even under stringent 
filtration criteria, supports my applied criteria for discovery of components of the 
UFM as a central module implicated in melanoma biology.  
Dr. Wagner applied the PCA to the matrix C using the ‘pca’ function in MATLAB. 
The diagonals of the matrix C (i.e., the self-correlation values) were set to zero, 
and then the resultant matrix was clustered using k-means clustering (using the 
‘kmeans’ function in MATLAB). The k-means procedure was repeated 20 times, 
and the best fit cluster identities were used (Figure 52b): the "best" number of 
clusters to describe a data set in this analysis was estimated at k-mean = 7, 
indicating seven clusters as the data-driven gene regulation pathways – referred 
to as GRP94– within the UFM. The GRPs tend to contain primarily TSGs (down-
loss genes) or primarily oncogenes (up-gain genes). The enrichment of mutated 
genes in the de novo pathways was calculated using the hypergeometric 
distribution from the ‘hygepdf’ function in MATLAB. Given Nobs mutated genes in a 
                                                
94 Gene regulation pathways 
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pathway, this calculated the likelihood of observing Nobs or more mutated genes in 
that pathway, and Nobs or fewer mutated genes in that pathway.  
Figure 53 and Figure 54, below, represent the PCA plots; the first and second 
principal components are shown on the x- and y-axes of the created PCA plot, 
respectively. Triangles and circles represent up-gain and down-loss genes, 
respectively. In Figure 53, each one of the seven GRPs is shown with a different 
color. Figure 54 represent the same data as Figure 53, but the GRPs are color-
coded based on their chromosomal position (i.e. each color represent different 
chromosome). In the PCA of the correlation matrix, principal component #1 (x-
axis) approximately separates up-gain genes (shown in triangles, and largely with 
negative x-axis values) from down-loss genes (shown in circles and largely with 
positive x-axis values). 
Only chromosomes 1, 6, 7, 8, 9, 10, 11, 14, 15, 17, 20, and 22 are present in the 
selected gene list (the UFM). The genes in the adjacency matrix cluster are largely 
according to which chromosome those genes came from. In other words, genes 
from the same chromosome tend to exhibit correlated expression; this observation 
is not surprising as hardwired connections were my main criteria for selection of 
maintenance genes. With this analysis, we generalized the UFM on a 
chromosomal level; these chromosomal segments may harbor blocks of hardwired 
and functionally related oncogenes (up-gain genes) and/or TSGs (down-loss 
genes). 
Some other interesting observations in PCA results are as follows: down-loss 
genes on Chr 9 and Chr 10 tend to exhibit similar correlation values. Similarly, 
down-loss genes on Chr 11 and Chr 6 also tend to exhibit similar correlation 
values. Further, the up-gain genes on Chr 7 and Chr 20 tend to exhibit similar 
correlation values. PCA indicates not just clustering, but also the sign (positive vs. 
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negative) of the relationships. The PCA results show that Chr 10 loss (and to a 
lesser extent Chr 9 loss) is strongly correlated with Chr 7 gain (and to a lesser 
extent Chr 20 gain). Similarly, gain of one arm of Chr 6 is strongly correlated with 
loss of the other arm of Chr 6. Principal component #2 (y-axis) approximately 
separates down-loss genes on Chr 6 (positive y-axis values) from down-loss 
genes on Chr 10 (negative y-axis values). 
Table 13 is the list of components in each of the seven GRPs. For instance, GRP1 
is consist of 91 genes with up-gain status, these genes reside on chromosomes 
1q, 20q, 22q, 7p, 7q, and 8q; whereas GRP2 contains both down-loss (56 genes 
residing on 11q, 9p, and 9q) and up-gain (10 genes on chromosomes 1q, 20q, 6p, 
8p, and 8q); this pathway includes one gene (SNX31) with non-synonymous 
mutation as well. A complete list of the UFM genes and the corresponding 































Figure 5295: Spearman correlation network with k-mean clustering- the UFM 
components 
a) Spearman correlation matrix at 60th percentile threshold; top bar indicates 
which genes in the dendrogram columns (matrix) correspond to up-gain genes 
(shown in red) versus down-loss genes (shown in blue). The matrix represents the 
dendrogram + correlation matrix (the dendrogram was clustered using the 
Euclidean distance). In the matrix, the red represents positively correlated gene 
pairs, whereas the blue represents negatively correlated gene pairs. The bottom 
bar shows the data-driven cluster identities. b) k-mean clustering using silhouette 
plot: the silhouette width was used to estimate the best number of clusters to 
describe the data-driven GRPs within the UFM; an approximate local maximum, at 
k=7 was used for further analysis.   
                                                




Figure 5396: The seven GRPs within the UFM - PCA plot 
PCA was applied to the thresholded Spearman correlation matrix; the first and 
second principal components are shown on the x- and y-axes of the created PCA 
plot, respectively. Up-gain genes are shown as triangles. Down-loss genes are 
shown as circles. Each color represents one GRP. A few selected genes’ labels 
are shown in red boxes. Interestingly, principal component #1 (x-axis) 
approximately separates up-gain genes (shown in triangles, and largely with 
negative x-axis values) from down-loss genes (shown in circles and largely with 
positive x-axis values). 
 
  
                                                




Figure 5497: The seven GRPs within the UFM – chromosome-based PCA plot 
This Figure represents the same data as Figure 53; only the seven GRPs are 
color-coded based on their chromosomal position (i.e. each color represent 
different chromosome). Only chromosomes 1, 6, 7, 8, 9, 10, 11, 14, 15, 17, 20, 
and 22 were present in the selected gene list (the UFM). The genes in the 
adjacency matrix cluster are largely according to which chromosome those genes 
came from. In other words, genes from the same chromosome tend to exhibit 
correlated expression. With this analysis, we generalized the UFM on a 
chromosomal level; these chromosomal segments may harbor blocks of hardwired 
and functionally related oncogenes and/or TSGs. 
  
                                                
97 Done by Dr. Joel Wagner, The Jackson Laboratory, CT, USA 
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Table 13: Components of the seven GRPs within the UFM 
 
GRP 
the UFM status  
(number of genes) 
Chromosome 
(number of genes) 
1 up-gain (91) 1q (2), 20q (14),22q (4), 7p (19), 7q (51), 8q (1) 
2 
down-loss (56) 11q (16), 9p (22), 9q (18) 
up-gain (10) 1q (2), 20q (1), 6p (4), 8p (1), 8q (2) 
SNV (1) 8q (SNX31) 
3 
down-loss (3) 11q (3) 
up-gain (92) 
15q (1), 1q (3), 20p (4), 20q (7), 
22q (2), 7p (22), 7q (50), 8q (3) 
SNV (1) 7q (BRAF) 
4 down-loss (79) 10p (14), 10q (65) 
5 
down-loss (37) 11q (7), 6p (1), 9p (11), 9q (18) 
up-gain (54) 
1q (12), 20p (1), 20q (11), 22q (3), 
6p (20), 7p (1), 8q (6) 
SNV (1) 17p (TP53) 
6 
down-loss (75) 6q (75) 
up-gain (1) 7p (1) 







 Table 14: The seven GRPs within the UFM – gene symbols and chromosomal 
location 
This table lists the genes and the corresponding chromosomal locations in each 
pathway. Genes highlighted in red and blue represent the up-gain and down-loss, 
respectively. Green blocks contain genes with non-synonymous mutation. Genes 
highlighted in yellow are druggable based on DGIdb.  
GRP1 
ABCF2 7q36.1 GUSB 7q11.21 REPIN1 7q36.1 
ACTR3B 7q36.1 JTB 1q21 RNF216 7p22.1 
ADCK2 7q34 LOC202781 7q36.2 RNF216P1 7p22.1 
AGAP3 7q36.1 LOC441204 7p15.2 RP9 7p14.3 
ANKRD54 22q13.1 MAP1LC3A 20q11.22 RP9P 7p14.3 
ARF5 7q31.3 MGC72080 7q21.3 RPA3 7p21.3 
ARFRP1 20q13.3 MOSPD3 7q22 RPS19BP1 22q13.1 
ATP5J2 7q22.1 MRPS17 7p11-q11.21 SEC61G 7p11.2 
ATP6V0E2 7q36.1 MRPS33 7q34 SHFM1 7q21.3 
BCL7B 7q11.23 NDUFA4 7p21.3 SLC2A10 20q13.12 
BLCAP 20q11.23 NDUFB2 7q34 SSBP1 7q34 
BUD31 7q22.1 NUDCD3 7p13-p12 STMN3 20q13.3 
CASP2 7q34-q35 PDIA4 7q35 STYXL1 7q11.23 
CHMP4B 20q11.22 PDRG1 20q11.21 SYS1 20q13.12 
CHPF2 7q36.1 PIGT 20q12-q13.12 TAF6 7q 
CHST12 7p22 PIM3 22q13 TBL2 7q11.23 
CNPY4 7q22.1 PMS2P1 7q22.1 TMED4 7p13 
COMMD7 20q11 PMS2P5 7q11.23 TMUB1 7q36.1 
COPG2 7q32 POLM 7p13 TNRC18 7p22.1 
COPS6 7q22.1 POLR2J 7q11.2 TSPAN33 7q32.3 
CPSF4 7q22 POM121C 7q11.23 UBE2D4 7p13 
CTNNBL1 20q11.23-q12 PPIA 7p13 WBSCR22 7q11.23 
DNAJC30 7q11.23 PPP1R35 7q22.1 WDR91 7q33 
DNAL4 22q13.1 PRKAR1B 7p22.3 ZC3HC1 7q32.2 
EPB41L1 20q11.2-q12 PRKRIP1 7q22.1 ZNF212 7q36.1 
EPHB4 7q22 PSMC2 7q22.1-q22.3 ZNF282 7q36.1 
ERGIC3 20q11.22 PSMG3 7p22.3 ZNF394 7q22.1 
FASTK 7q35 PTCD1 7q22.1 ZNHIT1 7q22.1 
GET4 7p22.3 PYCR2 1q42.13 ZP3 7q11.23 
GGT7 20q11.22 PYCRL 8q24.3 







 Table 14 
 GRP2 
 ARHGEF12 11q23.3 POLE3 9q33 
 BICD2 9q22.32 PPAPDC2 9p24 
 BRD3 9q34 PPP6C 9q33.3 
 CBL 11q23.3 RAB14 9q32-q34.11 
 CBWD1 9p24.3 RABGAP1 9q34.11 
 CCDC15 11q24.2 RANBP6 9p24.1 
 CDC37L1 9p24.1 RNF38 9p 
 DDX6 11q23.3 RPS6 9p21 
 DENND4C 9p22.1 SET 9q34 
 DLAT 11q23.1 SIK2 11q23.1 
 ERMP1 9p24 SMARCA2 9p24.3 
 FAM118B 11q24.2 SNAPC3 9p22.3 
 FAM120A 9q22.31 SNX19 11q25 
 FBXW2 9q34 TBCEL 11q23.3 
 FDXACB1 11q23.1 TOPORS 9p21 
 GAPVD1 9q34.11 TSTD2 9q22.33 
 HAUS6 9p22.1 UBAP1 9p13.3 
 HIATL1 9q22.32 UBQLN1 9q22 
 INVS 9q31 UHRF2 9p24.1 
 KIAA0368 9q32 USP28 11q23 
 KIAA1432 9p24.1 ZBTB43 9q33.3 
 KIAA2026 9p24.1 ZW10 11q23 
 KLHL9 9p22 BTN2A1 6p22.1 
 MAPKAP1 9q34.11 BTN2A2 6p22.1 
 MED17 11q21 GON4L 1q22 
 MLLT3 9p22 KIAA0907 1q22 
 MTAP 9p21 MTSS1 8p22 
 NCAPD3 11q25 NUDCD1 8q23 
 NCBP1 9q34.1 PAK1IP1 6p24.1 
 NDUFB6 9p13.2 RPRD1B 20q11.21-q12 
 NFIB 9p24.1 TGS1 8q11 
 NPAT 11q22-q23 TPMT 6p22.3 
 PAFAH1B2 11q23 SNX31 8q22.3 








 Table 14 
 
GRP3 
AGK 7q34 ING3 7q31 SERINC3 20q13.12 
ARFGAP3 22q13.2 JHDM1D 7q34 SGCE 7q21.3 
BCAP29 7q22.3 KBTBD2 7p14.3 SKAP2 7p15.2 
BET1 7q21.1-q22 KHDRBS3 8q24.23 ST13 22q13.2 
CCT6P1 7q11.21 KIAA0895 7p14.2 STAG3L2 7q11.23 
CDK13 7p14.1 KRIT1 7q21.2 STX16 20q13.32 
COG5 7q31 LINC00174 7q11.21 SUN1 7p22.3 
CRCP 7q11.1 LOC100128822 7q36.1 TAX1BP1 7p15 
CREB5 7p15 LOC100134229 7q34 TES 7q31.2 
CRLS1 20p13-p12.3 LOC100216545 7q22.3 TM2D3 15q26.3 
CUL1 7q36.1 LOC154761 7q35 TMEM209 7q32.2 
DBF4 7q21.3 LOC493754 7q11.21 TOP1 20q12-q13.1 
DNAH14 1q42.13 LSM5 7p14.3 TRA2A 7p15.3 
DNAJC2 7q22-q32 MKLN1 7q32 TRIM24 7q32-q34 
DPM1 20q13.1 MTERFD1 8q22.1 TRIM56 7q11.2 
DUS4L 7q22-q31 NAA20 20p11.23 TYW1 7q11.21 
ESYT2 7q36.3 NUB1 7q36 UBE2H 7q32 
ETV1 7p22 NUPL2 7p15 VAPB 20q13 
EZH2 7q35-q36 ORC5 7q22.1 WASL 7q31.3 
FAM115C 7q35 PCMTD2 20q13.33 WDR60 7q36.3 
FAM3C 7q22.1-q31.1 PFDN4 20q13.2 YAE1D1 7p14.1 
GATAD1 7q21-q22 PHF14 7p21.3 ZNF12 7p21.1 
GLI3 7p13 PMPCB 7q22.1 ZNF133 20p11.23 
GORAB 1q24.2 PMS2CL 7p22.1 ZNF3 7q22.1 
GRB10 7p12.2 PRKAR2B 7q22.3 ZNF343 20p13 
H2AFV 7p13 PSMA2 7p13 ZNF655 7q22.1 
HBP1 7q22-q31 PTPRZ1 7q31.3 ZNF7 8q24 
HERPUD2 7p14.2 PUS7 7q22.3 ZNF862 7q36.1 
HIP1 7q11.23 RBM34 1q42.3 FDX1 11q22.3 
HOXA3 7p15.2 RBM48 7q21.2 REXO2 11q23.2 
HOXA4 7p15.2 RINT1 7q22.2 TBRG1 11q24.2 
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 Table 14 GRP4 



















ADO 10q21.3 INPP5A 10q26.3 
AP3M1 10q22.1-q22.3 KIAA1279 10q22.1 
ARHGAP12 10p11.22 LARP4B 10p15.3 
ARL3 10q23.3 MAPK8 10q11 
ASCC1 10q22.1 MCMBP 10q26.13 
ATAD1 10q23.31 MTPAP 10p12.1 
ATE1 10q26 NCOA4 10q11.2 
ATP5C1 10p14 NRBF2 10q22.1 
BLOC1S2 10q24.31 OAT 10q26 
BTRC 10q24.32 OBFC1 10q25.1 
BUB3 10q24 OPTN 10p14 
CCDC6 10q21.2 PARG 10q11.23 
CDC123 10p13 PCGF6 10q24.33 
CHUK 10q24-q25 PDZD8 10q26.12 
COX15 10q24 PGBD3 10q11 
CSTF2T 10q11 PPP3CB 10q22.2 
CTBP2 10q26.13 PRDX3 10q25-q26 
CUL2 10p11.2 PTEN 10q23 
CUTC 10q24.31 RAB18 10p12 
CWF19L1 10q24.31 RSU1 10p13 
DHX32 10q26 SAR1A 10q22.1 
DNAJC9 10q22.3 SEC23IP 10q26.11-q26.12 
DOCK1 10q26 SGPL1 10q21 
EIF3A 10q26.11 SHOC2 10q25 
EIF4EBP2 10q21-q22 SIRT1 10q21 
ERCC6 10q11 SMC3 10q25 
ERLIN1 10q24.31 STAM 10p14-p13 
FAM149B1 10q22.2 TAF3 10p15.1 
FAM175B 10q26.2 TBC1D12 10q23.33 
FAM204A 10q26.12 TIAL1 10q 
FAM21A 10q11.23 TM9SF3 10q24.2 
FAM21C 10q11.22 VPS26A 10q21.1 
FAM45A 10q25 VTI1A 10q25.2 
FUT11 10q22.3 WAPAL 10q23.31 
GDI2 10p15 WDR11 10q26 
GHITM 10q23.1 WDR37 10p15.3 
GLRX3 10q26 ZDHHC6 10q26.11 





 Table 14 
GRP5 
CDKN2A 9p21 UBE2R2 9p11.2 OSBPL2 20q13.3 
ABL1 9q34.1 UCK1 9q34.1 PEX6 6p22 
ACAT1 11q22.3 VCP 9p13.3 PFDN2 1q23.3 
ALG9 11q23 VPS26B 11q25 PHF5A 22q13.2 
APTX 9p13.3 WDR5 9q34 POLR1C 6p21.1 
CDK20 9q22.1 ZNF79 9q34 PRCC 1q21.1 
DOLPP1 9q34.1 AARS2 6p21.1 PRPF3 1q21.1 
EI24 11q24.2 ABT1 6p21.31 PSMG4 6p25.2 
FANCC 9q22.3 ACSS1 20p11 PXDC1 6p25.1 
FXN 9q21.11 CAP2 6p22.3 RAE1 20q13.31
GLE1 9q34.13 CDK5RAP1 20q11.21 RNF114 20q13 
GRHPR 9q12 CHTOP 1q21.3 RPL8 8q24.3 
HYLS1 11q24 CLK2 1q21 RPS21 20q13.3 
KIF24 9p13.3 CPNE1 20q11.22 RRS1 8q13.1 
LRRC8A 9q34.2 CRTC2 1q21.3 S100A1 1q21 
MOB3B 9p21.1 CUL7 6p21.1 SF3B4 1q21.2 
NEK6 9q33.3-q34 DDX27 20q13.13 SRF 6p 
NFRKB 11q24-q25 DHX35 20q11.22-q12 ST3GAL1 8q24.22 
NUDT2 9p13 DIDO1 20q13.33 STAU1 20q13.1 
NUP188 9q34.13 DTNBP1 6p22.3 TAB1 22q13.1 
PRPF4 9q31-q33 ENSA 1q21.3 TBC1D22B 6p21.2 
PSMB7 9q34 FOXP4 6p21.1 TJAP1 6p21.1 
PTGR1 9q32 FTSJD2 6p21.2 TMEM14B 6p25 
RRAGA 9p21.3 GPATCH4 1q22 TRIB1 8q24.13 
SIGMAR1 9p13.3 JARID2 6p24-p23 UBQLN4 1q21 
SMPD2 6q21 L3MBTL2 22q13 YTHDF1 20q13.33
STOML2 9p13.1 LEMD2 6p21.31 YY1AP1 1q22 
STT3A 11q23.3 LOC100270746 6p22.2 ZNF76 6p21.31 
TOR1A 9q32-q34 MRPL15 8q11.2-q13 ZNF853 7p22.1 
UAP1L1 9q34.3 NDUFB9 8q24.13 TP53 17p13.1 












 Table 14 
GRP6 
ADAT2 6q24.2 PCMT1 6q25.1 
AHI1 6q23.2 PDCD2 6q27 
AKAP7 6q23.2 PEX3 6q24.2 
ARID1B 6q25.3 PGM3 6q14.1-q15 
CDC40 6q22.1 PTPRK 6q22.2-q22.3 
CENPW 6q22.32 QKI 6q26 
CEP57L1 6q21 QRSL1 6q21 
COQ3 6q21 REPS1 6q24.1 
CYB5R4 6q14.2 RNF146 6q22.1-q22.33 
DOPEY1 6q15 RNGTT 6q16 
ECHDC1 6q22.33 RPS12 6q23 
EPM2A 6q24 RTN4IP1 6q21 
FAM120B 6q27 RWDD1 6q13-q22.33 
FBXL4 6q16.1-q16.3 RWDD2A 6q15 
FBXO30 6q24 SERAC1 6q25.3 
FBXO5 6q25-q26 SERINC1 6q22.32 
FIG4 6q21 SESN1 6q21 
GOPC 6q21 SMAP1 6q12-q13 
GTF2H5 6q25.3 SMPDL3A 6q22.32 
GTF3C6 6q21 SNX14 6q15 
HACE1 6q21 SNX3 6q21 
HBS1L 6q23.3 SNX9 6q25.1-q26 
HDDC2 6q13-q24.3 STX7 6q23.1 
HSF2 6q22 SYNE1 6q24.2-q25.3 
IBTK 6q14.3 TBP 6q27 
LACE1 6q22.1 TCP1 6q25-q27 
LYRM2 6q15 TMEM181 6q25.3 
MAP3K4 6q26 TMEM242 6q25.3 
MARCKS 6q21 TSPYL1 6q22.1 
MDN1 6q15 TULP4 6q25-q26 
MMS22L 6q16.3 UBE2J1 6q15 
MRPL18 6q25.3 UFL1 6q16.3 
MTO1 6q14.1 USP45 6q16.2 
MTRF1L 6q25-q26 UST 6q25.1 
NDUFAF4 6q16.3 VTA1 6q24.1 
NT5DC1 6q22.31 ZBTB24 6q21 
NUP43 6q25.1 ZUFSP 6q22.31 





 Table 14 GRP7 
 ACTR1A 10q24 
 ANXA11 10q22.3 
 B4GALT1 9p13 
 CHCHD1 10q22.3 
 CISD1 10q21.3 
 CNNM2 10q24.32 
 CUEDC2 10q24.32 
 ECHS1 10q26.2-q26.3 
 EZR 6q25.3 
 FAM53B 10q26.13 






























































5.2.1.1. Pro-proliferation, anti-apoptosis and pro-invasion are main 
features in the UFM in a subset of melanoma samples. 
I asked whether some of these seven gene-regulation pathways (GRPs) were 
more frequently mutated than others in melanoma. To answer this question, the 
activity levels of the de novo pathways in each tumor sample (the TCGA 
melanoma dataset) were scored by calculating the mean gene expression level of 
all genes in each pathway. Given seven de novo pathways, this provided seven 
pathway activity features associated with each tumor sample (i.e. a matrix of 
seven pathways x 232 tumor samples). This matrix was clustered by Dr. Wagner 
using the ‘linkage’ function in MATLAB (using the unweighted average distance 
and the Euclidean distance metric), and then plotted using the ‘clustergram’ 
function (Figure 55 below). As shown in Figure 55, the TCGA tumors mainly 
cluster into three groups for the seven GRPs, which are represented in a 
clustergram by purple (TT1), orange (TT2), and green (TT3) colors, (TT 
represents tumor type). Only TT1 and TT3 show dominant signatures of gene 
expression among the samples: TT1 is dominated by particularly low expression 
of components of GRP4, and TT3 is dominated by particularly high expression of 
components of GRP3. . An interesting observation is high expression of GRP1 in 
both groups. BRAF, with an established role in melanoma development, 
maintenance, and progression, is one of the components in GRP3. Since this 
clustering was based on expression signature of the seven GRPs, Dr. Wagner 
assessed the enrichment and/or depletion of BRAFV600 mutations across these 
three tumor types. The heat map in Figure 55 shows BRAFV600 mutation status of 
each sample in the same order as in the clustergram. Based on this analysis, we 
observed a significant enrichment for BRAFV600 mutants in TT3 (p-value < 
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0.00001), whereas TT2 is significantly depleted for BRAFV600 mutations (p-value < 
0.00001). There is no significant enrichment/depletion for BRAFV600 in TT1. 
Significant enrichment of BRAFV600 mutations and its up-regulation (as a 
component of GRP3) suggests a core contribution of BRAF in maintenance of the 
TCGA tumors clustered as TT3. 
Figure 56 below illustrates a model system for interplay between the GRPs’ 
components in TT1 and TT3. GPR1, 3, and 4 are referred to as ‘pro-invasion’, 
‘pro-proliferation’ and ‘pro-survival’ networks, respectively, based on the 
characteristics of their components: 
DNA replication, DNA repair, homologous recombination, mitochondrial genes, 
and oxidative phosphorylation are the top canonical pathways, BioCarta, and 
KEGG gene sets enriched by GRP1 components (FDR q-value <0.05). For 
instance, ADCK2 is involved in TNFα-mediated HIF-1α stability resulting in cancer 
cell survival, proliferation, and metastasis [182, 183]. PPIA and RPA3 are DNA 
repair genes, which potentiate the high paced and intact replication vital for distant 
metastasis [180]. ATP6V0E2 is a Vacuolar H+-ATPases that helps tumor cells to 
survive in an acidic extracellular pH, and its inhibition decreases the invasiveness 
of metastatic cells [184]. Wbscr22 is a methyltransferase promoting metastasis 
through suppressing Zac1/p53-dependent apoptosis [185]. 
Components of GRP3 show significant enrichment for cell cycle, G1/S transition, 
mitotic G1-G1/S phases, and SHH pathway (FDR q-value <0.05). SHH-GLI 
signaling has been shown to regulate the proliferation and survival of melanoma 
tumors; moreover, there is a crosstalk between the RAS/AKT and SHH-GLI 
pathways [186]. PRKAR2B is involved in HIF-1α stabilization resulting in cancer 
cell survival, proliferation, and metastasis [182, 183].  
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Pathways in cancer, BCR signalling pathway, FoxO98 family signalling, Wnt 
signalling pathway, Integrin signalling pathway, ERBB4 signalling, mTOR 
signalling pathway, mitochondrial genes, and EGFR signalling in cancer are 
significantly enriched in GRP4 (FDR q-value <0.05). CCDC699 (present in GRP4) 
is a pro-apoptotic protein, involved in DNA damage response (DDR) and 
maintenance of genome integrity [187, 188]. SIRT1100 is involved in several 
cellular functions including stress resistance and apoptosis by deacetylating 
proteins such as PTEN, p53, and FOXO [189, 190]. CTBP1 and BTRC are 
negative regulators of Wnt signaling pathway. BTRC leads to the ubiquitin-
mediated degradation of β-catenin [191], whereas CTBP is a transcriptional 
repressor of LEF1. Canonical Wnt signalling drives proliferative cell phenotype 
because of LEF1 activation [192-194].  
This pattern would suggest that a given tumor needs the pro-invasion network, but 
then only needs either the high expression of the pro-proliferation network or low 
expression of the survival network to survive. This analysis also suggests that 
targeting a member of the pro-invasion network could be useful in BRAF-driven 
tumors because the BRAF pro-proliferation network is always ‘high/on’ when the 
pro-invasion network is ‘high/on’, but the pro-invasion network can be ‘high/on’ by 
itself without BRAF. This suggests some but not complete dependency between 
BRAF and the invasion network.  
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Figure 55101: The TCGA melanoma tumors cluster to three groups based on the 
expression status of the seven GRPs within the UFM 
The heat map represents the tumor clustering based on mean expression of 
genes in each GRP; this reduced the 542 UFM genes into just seven values; 232 
tumor samples were then clustered according to those seven values (i.e., 
according to the "activity" of the seven GRPs in each sample); in the heat map, the 
blue and red represent the low and high expression, respectively. Clustergram 
shows the TCGA tumors that are mainly clustered into three groups (purple, 
orange, and green). TT stands for tumor type: TT1 (shown in purple in the 
clustergram) and TT3 (shown in green) represent the most distinct tumor types 
clustered based on specific expression patterns given by GRP1, 3, and 4.  
BRAFV600 mutation status of each sample is shown in the same order as in the 
clustergram. Based on this analysis, TT3 is significantly enriched for BRAFV600 
mutations (p-value < 0.00001), whereas TT2 is significantly depleted for BRAFV600 
mutations (p-value < 0.00001). There is no significant enrichment/depletion for 
BRAFV600 in TT1. WBSCR22, BRAF, and PTEN are shown as examples present in 
each pathway. Heat map: x-axis: 232 tumors, y-axis: mean expression of genes in 
each pathway  
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Figure 56: Pro-proliferation, anti-apoptosis, and pro-invasion as the main features 
of the UFM in a subset of melanoma samples 
The TCGA tumors were clustered based on the expressional pattern of GRP1, 3 
and 4. These GRPs are referred to as ‘pro-invasion’, ‘pro-proliferation’, and ‘pro-
survival’ networks, based on the biological features of their components. GRP1 is 
mostly enriched with genes potentiating metastasis; GRP3 components are 
involved in proliferative/survival pathway; components of GRP4 are pro-apoptotic 
and all down-regulated in the UFM. The red and blue arrows represent the 
direction of expression as up and down, respectively. Genes highlighted in red are 
up-gain, whereas genes highlighted in blue are down-loss. BRAF harbors non-








6. Discussion and Concluding Remarks 
Cutaneous melanoma is a tumor of melanocytes. The increasing worldwide 
prevalence of melanoma skin cancer makes it a vital public health problem. 
Despite the striking success of new therapies such as vemurafenib and 
ipilimumab, melanoma remains incurable. Underlying molecular complexity, 
functional redundancy among survival pathways and tumor heterogeneity can lead 
to intrinsic or de novo resistance to applied therapies in melanoma. Extensive 
research has been performed to define the catalogue of genetic mutations in 
melanoma [114, 195].  
In this study, using deep genomic analysis of eight patients with melanoma, the 
detailed genomic and transcriptomic landscape of each tumor and its matched cell 
line was revealed. To examine the relatedness of somatic events – including SMs, 
CNVs and their expressional consequences, and SNVs – in sustaining tumor 
maintenance, I first analyzed one patient – Patient7PoC – with a complete set of 
tumors from different stages of tumor progression (LNM-T3P7 and DM-T4P7), and 
their matched cell lines (LNM-CL3P7 and DM-CL4P7).  
Domcke S. and colleagues used systematic genomic comparison to reveal evident 
differences between the molecular profiles of ovarian tumors and commonly used 
ovarian cancer cell lines [196]. Their study indicates that in vitro experiments using 
the ‘good’ cell lines – which have a genomic background highly similar to that of 
the tumor – can be conclusive and are worth translating into the clinic [196]. Cell 
lines derived from the same tumors have a genomic profile most similar to that of 
the tumor, with similar growth characteristics; this is important for the purpose of 
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functional validation, especially when molecular similarity to the tumors is 
desirable. Therefore, in my study, matched cell lines represent the most 
appropriate and highly suited in vitro model system. These cell lines, having been 
comprehensively characterized for the genomic make up, represent a valuable 
resource for functional studies, especially in personalized medicine.  
Both LNM-CL3P7 and DM-CL4P7 were derived from an adapted clone present in the 
tumors, which is suggestive of the presence of a core set of mutations persisting 
through all clones; this core set of mutations is important for tumor maintenance.  
In all samples examined in Patient7PoC, CNVs were associated with significant 
transcriptional consequence, as I found the higher expression of gained genes 
and lower expression of loss genes in tumors and their matched cell lines; a 
reverse pattern was observed in normal melanocytes. On the other hand, the 
presence of translocations at the edge of the regions affected by copy number 
changes provided evidence of the involvement of SMs, particularly translocations, 
in copy number changes; in other words, SMs coinciding with copy number 
alterations generated expressional modules that juxtapose driver genes for co-
expression. These observations suggest that somatic events are hardwired and 
that this often results in the concomitant gain and loss of a number of putative 
oncogenes and TSGs, respectively. To reveal the contribution of SMs to the 
hardwiring of the cancer genomic and transcriptomic landscape in favor of tumor 
maintenance, I searched for all common SMs that caused copy number 
aberrations in all samples of Patient7PoC.  
Given the chronology of tumor evolution, it is expected that the common somatic 
events are the earliest events in the tumorigenesis process, originating in the 
lymph node metastasis, or even at an earlier stage, and being maintained and 
selected in the later stages, as well as in their corresponding established cell lines. 
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These common events represent a combination of up-regulated oncogenes and 
inactivated TSGs disrupted via genomic aberrations leading to melanoma. 
I examined the structural aberrations in detail and identified the FM7/9/12 as the 
hardwired maintenance functional module affecting recurrent regions of genomic 
gain or loss common in all samples of this patient. BRAFV600 mutation, Chr 9p 
deletion, Chr 7 and Chr 12 gain and over-expression, and the inter-chromosomal 
connection between Chr X, Chr 9, Chr 7, and Chr 12 were the major 
characteristics of this module. This module revealed blocks of oncogenes (e.g. 
BRAF) and TSGs (e.g. CDKN2a) clustered together by means of SMs. The 
involvement of SMs in copy number changes was supported by the presence of 
several translocations between and at the edges of Chr 9 and Chr 12 amplicons. 
Chr X mediated the inter-chromosomal connection between Chr 9 and Chr 7; 
though there was no gene on this Chr X amplicon, a high number of DNase 
clusters and histone 3 acetylations (H3K27ac) in this region suggested the active 
form of chromatin. Moreover, the presence of several transcription factors such as 
NANOG, PoLR2A, Fos, CTCF, NR3C1, and CEBPB suggested that they may act 
as enhancers on this region [197]. These data suggest that Chr X functions as a 
mediator for the Chr 9 connection to Chr 7, and that it may have an epigenetic 
impact on the expression of translocated genes on Chr 9 and Chr 7. Epigenetic 
studies are beyond the scope of this thesis, but whether or not Chr X had an 
epigenetic impact in this patient would be an interesting subject of study in future. 
The deletion of CDKN2a and CDKN2b as critical TSGs on Chr 9p was defined as 
one of the early events in this patient. This observation was in agreement with 
Bastian, who proposed the occurrence of Chr 9p deletion as an early event in the 
evolution of sporadic melanoma, based on its prevalent presence in dysplastic 
nevi and primary melanomas [198, 199]. 
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EZH2 has been shown to be highly associated with the proliferation in breast 
cancer, prostate cancer, and melanoma [166]. More importantly, a strong 
association between EZH2 expression and p16 suppression in melanoma has 
been reported [166]. The expression pattern of major chromatin regulators 
associated with the EZH2 function revealed low expression of KDM6B as a 
possible TSG, vs. high expression of DNMT1 and HDAC1 as putative oncogenes 
in all tumors and cell lines sequenced in this study. The previously reported loss of 
function of KDM6B on the one hand, and the success of HDAC and DNMT 
inhibition therapies on the other, prove the importance of these regulators to tumor 
survival [200, 201]. The possible silencing effect of EZH2 on CDKN2a, with 
involvement of KDM6B, DNMT1, and HDAC1, and the expressional pattern of 
these epigenetic regulators in all samples of my study, may indicate the presence 
of genomic–epigenomic interactions in this patient, which were probably facilitated 
by the physical connection between Chr 7 and Chr 9.  
The higher-order organization of the cancer genome has been shown in several 
studies; amplification can confer a selective advantage to the tumor by 
augmenting the expression of adjacent oncogenic components [119]. In breast 
cancer, putative oncogenes and TSGs are organized in proximity clusters with 
significant correlation with regions of gain and loss, respectively [202].  
I hypothesized that in Patient7PoC, the presence of several common SMs 
juxtaposing chromosomal segments with a deletion of the TSGs on Chr 9 
(CDKN2a and CDKN2b), and the presence of known oncogenes on Chr 7 (e.g. 
BRAF, EZH2) and Chr 12 (e.g. KRAS, WNT1, WNT10B) for co-expression shapes 
the dynamic architecture of the cancer genome, providing an evolutionary 
advantage for tumorigenesis. The universal presence of the FM7/9/12 in the other 
seven patients examined in this study strongly suggested that the maintenance 
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functional module is a universal hardwired system of melanoma tumorigenesis. 
Universal components of the FM7/9/12 included 72 genes, whose function as 
putative cancer-promoting genes with general contribution to melanoma was 
tested.  
The expression signature of the final 72 genes chosen for functional validation 
showed significant enrichment for several chemical and genetic perturbations 
based on previous studies of different cancers, suggesting the functional 
importance of these genes to cancer. For instance, 23 of the 72 genes on the 
FM7/9/12 (FDR q-value= 2.23 e-12) were down-regulated in ME-A breast cancer cells 
undergoing apoptosis in response to doxorubicin therapy [203]: AGK, BICD1, 
BRAF, CASP2, CNOT4, DNM1L, HIPK2, IPO8, KRAS, KRBA1, LMBR1, LUC7L2, 
MLL3, NCAPG2, PAXIP1, RACGAP1, RASSF8, SENP1, SPATS2, SSBP1, 
ZNF212, ZNF282, and ZNF398. Koyama’s study of large cell neuroendocrine 
carcinoma NCI-H1299 cells identified the genes that were down-regulated as a 
result of the stable expression of SEMA3B; SEMA3B is a TSG and induces 
apoptosis [204]. Koyama’s gene list overlapped with 12 of the 72 genes on the 
FM7/9/12 (FDR q-value= 2.01 e-9), including AGK, BRAF, CUL1, INSIG1, KRBA1, 
PAXIP1, PDIA4, SENP1, SLC37A3, TRIM24, TTC26, and XRCC2. Moreover, 12 
of the 72 genes on the FM7/9/12 were down-regulated upon over-expression of 
PARVB in MDA-MB-231 cells (breast cancer) (FDR q-value= 6.18 e-6): CASP2, 
ERGIC2, EZH2, GOLT1B, LUC7L2, NCAPG2, NUB1, RACGAP1, RECQL, RHEB, 
TTC26, and ZC3HAV1L. PARVB is a TSG involved in cytoskeleton organization 
and cell adhesion [205]. 
The distorted rate of cell proliferation contributes to tumor development and 
growth [115]. I tested 72 genes on the FM7/9/12 for changes in cell proliferation and 
apoptosis after siRNA knockdown in both LNM-CL3P7 and DM-CL4P7 cell lines. Of 
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these, 30 genes showed a significant effect on cell proliferation in both cell lines of 
Patient7PoC. My experimental validation focused on only proliferation and 
apoptosis; therefore, the negative hits may have had a significant impact on other 
biological attributes such as migration, invasion, or angiogenesis.  
Based on an IPA102 analysis of positive hits, BRAF, DNM1L, EZH2, LDHB, 
LUC7L2, MLL3, TUBA1C, TRIM24, TMBIM6, PKP2, INSIG1, PAXIP1, and 
ZNF746 have been shown to be implicated in cancer. For instance, EZH2 is a 
polycomb protein that regulates the cell cycle, and is involved in breast cancer, 
prostate cancer, hepatocellular carcinoma, cutaneous melanoma, and urothelial 
carcinoma; however, how EZH2 is implicated in tumor initiation or progression is 
not clear yet [166, 206-209]. The over expression of TMBIM6 in several cancers, 
such as lung adenocarcinoma, breast cancer, prostate cancer, and acute myeloid 
leukemia, contributes to cell proliferation and tumor growth [210-213]; in mouse 
melanoma cell lines, TMBIM6 up-regulation led to in vivo metastasis, whereas its 
knockdown reduced the metastatic potential [214]. Ca2+ can trigger apoptosis 
through the mitochondria or endoplasmic reticulum (ER) [215]. TMBIM6 
expression reduces ER stress-induced apoptosis by reduction of ER Ca2+ 
depletion. Evidence of a similar activity at ER by the anti-apoptotic family of BCL-2 
(such as BCL-XL and BCL-2), and the presence of a physical interaction between 
BCL-XL, BCL-2, and TMBIM6 suggest the presence of crosstalk between the 
BCL-2 canonical apoptosis pathway and TMBIM6 [216-218]. LDHB is a 
component of glycolytic metabolism; although no study has shown its implication 
in melanoma yet, it has been reported to be an essential mediator for tumor 
                                                
102 Ingenuity Pathway Analysis 
 195 
 
growth in triple-negative breast cancer, as this tumor subtype is mostly dependent 
on glycolysis for growth [219]. 
Of the positive hits, EN2, EZH2, MED21, PAXIP1, TRIM24, and ZNF746 are 
known transcription factors. For example, TRIM24 is a protein kinase and its 
fusion with BRAF (TRIM24-BRAF) induces the MAPK signaling in melanoma 
[113]. PXIP1 regulates transcription by recruiting histone methyltransferases 
(HMTase) such as MLL5 [220]. Moreover, following ionizing radiation, PAXIP1 is 
involved in cell survival and chromosomal stability in response to DNA damage103. 
Chromosomal instability is a hallmark of most human cancers, and aberrations in 
genes associated with chromosomal stability augment the chromosomal 
rearrangements during cell proliferation in the course of tumor evolution. Some 
studies support the hypothesis that genome instability is an early event in 
tumorigenesis [221, 222]. In breast cancer, for instance, deregulation of BAP1, 
TP53, and PAXIP1, prominent examples of genes implicated in chromosome 
instability, was classified as an early oncogenic event  [221]. Chromosomal 
instability has a direct impact on the early loss of TSGs [223]. In this study, Chr 9p 
deletion, harboring CDKN2a and CDKN2b, was identified as an early event during 
the course of tumor evolution in Patient7PoC.  
Other melanoma studies have shown the presence of positive hits in the earlier 
stages of melanoma initiation. In the HAQQ study, PDIA4, DNM1L, AGK, BRAF, 
and TRIM24 (defined as maintenance genes with significant effect on tumor 
proliferation) showed differential expression in benign nevus samples compared 
with normal tissues, suggesting their early role in initiating a tumorigenic process 
[224]. The involvement of maintenance genes in the early stages of oncogenic 
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changes, such as the stage of benign nevus, was again confirmed by the 
TALANTOV study, in which positive hits such as TMBIM6, MED21, TUBA1C, 
LDHB, CDKN2A, SPATS2, and TUBA1B were differentially expressed in benign 
melanocytic skin nevus compared with normal skin samples [225]. These 
observations provide a validation of my main hypothesis regarding the presence of 
disrupted maintenance genes not only in metastatic melanoma samples, but also 
in earlier stages of the tumor, and their maintenance during tumor evolution. A 
prominent example of this concept is BRAF. The presence of BRAF mutation in 
80% of nevi and melanocytic skin lesions, and its maintenance throughout the 
melanoma progression, implies its major contribution in melanoma initiation, 
maintenance, and progression, and suggests its function as a founder event, 
although BRAF mutation by itself is not enough to induce tumorigenesis, as not all 
the nevi become malignant [46]. Nevi are mainly composed of senescent cells that 
are associated with presence of BRAF mutation mediating up-regulation of 
p16CDKN2A or IL6 [226]. Deregulated cell proliferation happens as a result of down-
regulation or loss of p16CDKN2A and stimulation of cell cycle progression genes 
(such as CDK2) mediated by mutated BRAF, which in turn will lead to the RGP 
[227]. VGP is the hallmark of melanocyte metastatic potential. The higher rate of 
BRAF mutation in VGP than the RGP suggests the importance of BRAF in 
melanoma progression [228]. 
The GSEA for transcription factor targets, using the list of 30 positive hits affecting 
tumor proliferation, showed two interesting trends: first, LEF1 was defined as a 
significant potential master regulator for AGK, BRAF, EN2, EZH2, MLL3, and 
TRIM24 on Chr 7, and SPATS2 on Chr 12 (FDR q-value < 0.05). The importance 
of LEF1 expression has been shown in melanoma cells’ phenotype switching 
[229]. Observation of two distinctive expression signatures corresponding to 
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proliferative and invasive cellular phenotypes in melanoma cell lines suggested a 
possible phenotype switch in melanoma cells in vivo. The hallmark of proliferative 
signature is up-regulation of MITF, melanocytic genes (e.g. TYR, MLANA), and 
some neural crest-related factors (e.g. SOX10, EDNRB); more importantly, the 
canonical Wnt/-catenin signaling plays a major role in the cells with high 
proliferative rate but low motility. On the other hand, genes involved in the 
modification of the extracellular environment are up-regulated in cells with an 
invasive signature (e.g. INHBA, SERPINE1); this expression signature seen in 
cells with low proliferation and high motility is shown to be TGFβ-driven [193]. 
These observations suggest that a balance of an opposing crosstalk between the 
Wnt signaling and TGFβ signaling derives these two distinct expressional 
signatures under the influence of microenvironmental conditions such as 
inflammation and hypoxia [230]. The expression patterns of LEF1 and TCF4 as 
co-factors of -catenin inversely correlate with the phenotypic status of melanoma 
cells; LEF1 is up-regulated in proliferative cells, whereas invasive cells contain 
down-regulated LEF1 and up-regulated TCF4 [229, 231]. It has been shown that 
the -catenin tumorigenic effect is mediated by the MITF function [232]. MITF is an 
essential regulator for phenotype switching in melanoma; knockdown experiments 
of MITF, as the lineage-addiction oncogene in melanoma, lead to reduction of 
proliferation and augmentation of invasion in melanoma [193, 233, 234]. Overall, 
the canonical Wnt signalling drives the proliferative cell phenotype via regulating 
MITF as a result of -catenin interaction with its co-factor – LEF1 – at the MITF 
promoter [192, 193]. Considering the important role of LEF1 as a co-factor in Wnt 
signalling that affects the proliferative state of melanoma cells via expressional 
regulation of critical genes such as MITF, and its involvement in phenotype 
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switching, one can speculate that significant enrichment of LEF1 targets in positive 
hits on the FM7/9/12 may have biological importance. In other words, SMs in 
melanoma not only juxtapose chromosomal segments with a high burden of 
putative cancer-promoting genes, but also engage cancer genes with common 
transcriptinal regulators such as LEF1. Interestingly, it has been shown that 
p16INK4a expression is suppressed when LEF1⁄ -catenin is expressed [235]; this 
offers further proof of the biological importance of the hardwired mutations on the 
FM7/9/12, with involvement of a structural connection between Chr 9p harboring 
CDKN2a with Chr 7 and Chr 12.  
The second interesting trend regarding the transcription factor targets was that 
SP1 was identified as another significant potential master regulator for BRAF, 
EZH2, TRIM24, LUC7L2, and NUB1 on Chr 7, and DNM1L, TUBA1C, and 
KIAA0528 on Chr 12 (FDR q-value < 0.05). The importance of SP1 is 
demonstrated by the SK-Mel2104 cells leading to expression of the MCAM 
(Melanoma Cell Adhesion Molecule). MCAM is implicated in melanoma 
progression [236]. This molecule is not expressed in normal melanocytes, 
whereas its constitutive expression in melanoma cells is SP1-dependent [237-
239].  
A better understanding of the biological implications between LEF1 and SP1, as 
statistically significant master regulators, and their targets – components of the 
maintenance functional module – may reveal the importance of these co-
regulators and their networks in providing a sustainable growth advantage for 
tumor cells. 
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In this study, I showed that SMs organize the genome in a way that brings 
together important oncogenes to build an oncogenic module whose hardwired 
somatic changes sustain tumor growth. Moreover, BRAFV600 mutation was defined 
as the maintenance gene common in all samples of Patient7PoC with significant 
functional mutation burden [114].  
BRAF is part of the MAPK pathway. The importance of this pathway in several 
biological functions including proliferation, senescence, apoptosis, and 
angiogenesis through activation of a wide range of proteins such as cytoskeletal 
proteins, protein kinases, and transcription factors is described in several studies 
[22, 240]. However, this pathway is not considered a uni-directional pathway, but 
rather a multi-directional one with multiple modes of regulation at all levels of the 
cascade [240]. One striking example is the activation of CRAFWT and RASWT in 
melanoma samples with BRAFV600 mutation, although none of them is downstream 
of BRAF in this cascade, which is suggestive of the presence of alternative 
mechanisms activating this pathway [241]. Molecular complexities, redundancy, 
and pathway crosstalk not only interfere with the comprehensive discovery of the 
downstream targets of the components of the MAPK pathway, but also complicate 
the therapeutic effects of the BRAF inhibitors developed to block this pathway. 
The success of single chemical inhibitors such as Gleevec inhibition of BCR-ABL 
in CML105 is due to the dependency of tumor cells on specific oncogenes for 
growth and survival [242]. On the other hand, despite the promising results 
obtained by therapies, such as targeted inhibition of protein kinases, tumor cells 
can evade inhibition because of the presence of alternative pathways or 
compensatory mechanisms such as secondary mutations interfering with the 
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ultimate therapeutic effect. To address this problem, strategies such as 
combination therapies have potentially promising outcomes [243].  
One of the mechanisms underlying the resistance to BRAF therapy is reactivation 
of the MAPK pathway. A combination of dabrafenib (selective inhibitor of BRAF) 
and trametinib (selective MEK inhibitor) in phase 1 and 2 trials led to a complete or 
partial response in 76% of patients receiving combination therapy, compared with 
54% for patients receiving dabrafenib monotherapy. Moreover, a significantly 
better median progression-free survival was observed in the combinatory group 
(9.4 months), versus the monotherapy group (5.8 months) (HR for progression or 
death, 0.39; p-value < 0.001) [88]. The presence of molecular crosstalk between 
the MAPK and LKB1-AMPK energy sensor pathway showed a therapeutic benefit. 
Under metabolic stress, tumor suppressor LKB1 activates AMPK, resulting in 
inhibition of cell proliferation [244]. However, in BRAFV600 mutated melanoma cells, 
ERK can phosphorylate and inactivate LKB1, leading to inactivation of AMPK, 
resistance to energy stress, and evasion of apoptosis [245, 246]. In these 
melanoma cells, the combination of vemurafenib and metformin results in 
synergistic inhibition of proliferation and induction of apoptosis. Vemurafenib 
inhibits oncogenic BRAFV600, whereas metformin targets metabolic modulation of 
AMPK through its activation by LKB1 [244].  
Considering the promising outcomes obtained from combinatory therapies on one 
hand and the validated effect of hardwired somatic changes on tumor proliferation 
in Patient7PoC on the other, I tested the 30 positive hits on the FM7/9/12 for their 
combinatory effect for changes in tumor proliferation with BRAF in both LNM-
CL3P7 and DM-CL4P7 cell lines, and found that 20 of the 30 genes showed at least 
additive effect, with 11 showing synergistic effects with BRAF in both cell lines. 
Synergistic genes included: AGK, C7orf13, EZH2, LUC7L2, MLL3, TRIM24, 
 201 
 
KIAA0528, LDHB, MED21, SPATS2, and TMBIM6, while additive genes were 
KRBA1, LOC401431, LUZP6, SMAGP, TTC26, TUBA1B, TUBA1C, ZNF398, and 
ZNF746, 
From the list of genes with synergistic effect to BRAF inhibition, the association 
between AGK, EZH2, and TMBIM6 with components of the MAPK pathway has 
been previously studied. siRNA knockdown of AGK inhibited the ERK1/2 
stimulation and decreased DNA synthesis in prostate cancer [247]. The MAPK 
pathway is considered one of the most critical factors affecting EZH2 function in 
melanoma. This synergistic effect can be explained by an epigenetic study 
performed by Hou and colleagues: considering the fundamental contribution of 
aberrant gene methylation in tumorigenesis, they found an epigenetic interplay 
between BRAFV600 mutation and aberrant gene methylation using the MCA106/CpG 
island microarray approach in melanoma. In their study, BRAFV600 mutation 
knockdown resulted in hypermethylation and down-regulation of 59 genes, and 
decreased the expression level of both EZH2 and DNMT1. These observations 
revealed the BRAFV600 mutation–driven epigenetic impact on melanoma 
tumorigenesis on one hand, and on the other identified the EZH2 and DNMT1 as 
major epigenetic regulators of this epigenetic effect [248]. Another interesting 
synergistic effect was found between BRAF and TMBIM6. In a study done by Kim 
and colleagues, the over-expression of TMBIM6 (known as Bax Inhibitor-1 (BI-1)) 
suppressed the stress-induced apoptosis via activation of ERK1/2 [249]. 
Moreover, the activated TMBIM6-mediated ERK activation reduced the 
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intracellular ROS107 level. ROS production mainly occurs in mitochondria and 
leads to oxidative stress and apoptosis [249].  
The presence of a high number of genes with at least additive effect to BRAF 
inhibition on the FM7/9/12 in Patient7PoC was strong evidence of the biological 
importance of rearrangements in hardwiring the maintenance functional module in 
this patient via constructing a network of significantly correlated genes, whose 
quantitative mutual effect on tumor proliferation was at least additive if not 
synergistic. Previous studies providing evidence of crosstalk between these 
synergistic genes and the MAPK pathway are another confirmation of the 
biological importance of the hardwired maintenance functional module. However, 
further studies are required to discover the biological mechanism underlying the 
interplay between other validated synergistic genes in the maintenance functional 
module with the MAPK pathway.   
I questioned whether the validated synergistic effect between maintenance 
components had any potential biological implication when generalized to a bigger 
cohort of melanoma tumors. To answer this question, we constructed a gene co-
expression network from positive hits using the TCGA data set. Gene co-
expression networks with systematic clustering of genes with similar expression 
patterns across a set of samples can reveal the clusters – referred to as data-
driven gene regulation pathways – with probable functional relatedness. With RNA 
co-expression networks on 60 large human microarray data sets and GO 
integration, Lee and colleagues established the presence of a clear association 
between co-expression and related gene function [173]. The correlation network 
between breast cancer reference genes (ATM, BRCA1, BRCA2, and CHEK2) and 
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the global transcription profile revealed the gene sets with probable functional 
association with reference genes. This perturbed macromolecular network 
centered by BRCA in breast cancer consisted of 118 genes linked by 866 
functional associations performed by GO annotations. The discovery of significant 
connectivity higher than would be expected by chance suggested that the 
components of this network played a role in related pathways. For instance, 
HMMR and AURKA were among the novel components in the BRCA-centered 
network; the biological association between HMMR, AURKA, and BRCA1 in 
proper chromosomal segregation and breast tumorigenesis was experimentally 
confirmed with immunofluorescence and coimmunoprecipitation assays [250]. 
Therefore, we examined the expression pattern of synergistic genes as a measure 
of their functional relatedness with BRAF using the TCGA database.  
We first assessed the impact of the presence of BRAFV600 mutation: with 
stratification of tumors based on their BRAFV600 mutation status, we found a sub-
cluster within the FM7/9/12’s positive hits (referred to as ClusterBRAF) whose 
expression pattern was significantly correlated with BRAF in samples carrying 
BRAFV600 mutation. ClusterBRAF mainly consisted of synergistic genes to BRAF 
including MLL3, AGK, LUC7L2, and TRIM24, and additive genes to BRAF 
including KRBA1, LUZP6, TTC26, ZNF398, and ZNF746. The correlation of 
expression patterns between these synergistic maintenance genes in samples 
with BRAFV600 mutation suggests the involvement of these genes in the same or 
overlapping pathways resulting in similar functional consequences. EZH2, MED21, 
and SPATS2 experimentally defined as synergistic genes to BRAF in this study 
were not part of ClusterBRAF in samples with BRAFV600 mutation; the synergism 
between these genes and BRAF was independent of BRAFV600’s mutation status. 
However, we discovered  significant clustering of these synergistic genes in 
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ClusterBRAF when BRAF was up-regulated and gained. In other words, in 
Patient7PoC, BRAF was one of the components of the maintenance functional 
module not only because of its mutation status, but also because of its common 
gain and up-regulation on Chr 7. LDHB and TMBIM6 with synergistic effect to 
BRAF, however, were not part of ClusterBRAF under any condition; this observation 
can be explained by the presence of alternative pathways taken by these genes 
leading to similar phenotypic consequences and ultimate impact on the tumor’s 
functional maintenance; alternatively, they may represent unique events occurring 
in Patient7PoC not generalizable across a larger melanoma cohort.  
Taking everything together, we developed a predictive model system for 
modulating melanoma therapy using the BRAF inhibitor. We defined a 
maintenance functional module with synergistic effect to BRAF: a) dependent on 
BRAFV600 mutation with significant clustering in a large set of samples (MLL3, 
AGK, LUC7L2, and TRIM24), and b) independent of BRAFV600 mutation but 
dependent on BRAF expression status in a subset of samples (EZH2, MED21, 
and SPATS2). 
I showed that CNVs could significantly change the transcriptional landscape of the 
tumor genome. The functional consequences of CNVs in Patient7PoC confirmed the 
crucial role of CNVs as the key providers in sustaining tumor features in 
melanoma. More importantly, the validated synergism between components of the 
FM7/9/12 provided strong evidence of the biological significance of hardwired 
aberration contributing to melanoma survival. These observations and successful 
functional validation from the proof of concept led me to aim for the discovery of a 
universal functional module in melanoma. To achieve this, I extended my model to 
a larger cohort of melanoma patients: I used eight patients with a comprehensive 
catalogue of somatic mutations as an exploratory set, and 232 tumors in the 
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TCGA database as a validation set. The universal functional module (UFM) – 
consisting of 542 genes – was identified as a core set of somatic events common 
to all the tumor specimens collected from each patient, with hardwired changes in 
the same direction in >30% and >20% of the TCGA melanoma tumors for down-
loss and up-gain genes, respectively. TP53, BRAF, CDKN2A, and SNX31 with 
significant functional mutation burden were also part of UMC.  
For several reasons, I performed the discovery of UMC starting with the samples 
obtained from only eight patients, rather than a bigger cohort such as TCGA 
database. First, I believe that to sustain tumor growth, UMC needs to be present 
across multiple samples per patient; therefore, eight patients with complete sets of 
samples were used as a probe set for the discovery of UMC; this type of 
information is not provided for a larger cohort of tumors, such as those in TCGA 
database. Second, I have a comprehensive transcriptomic landscape of three 
normal melanocytes, which enabled me to search for the differential expression 
pattern between normal samples and tumors (and cell lines); again, this normal 
catalogue is not provided in the TCGA. Third, the presence of matched cell lines 
helps to remove the normal contamination as much as possible while searching 
for the somatic catalogue. Finally, extensive genomic information in each of the 
eight melanoma patients can help to exploit the architecture and underlying 
mechanisms of genomic and transcriptomic aberrations. 
During the course of tumorigenesis and tumor progression, multiple cell-
autonomous changes are caused by cancer-promoting genes, such as 
uncontrolled proliferation, aberrant metabolism, and angiogenesis [251]. BRAF, 
ETV1, HIP1, PRCC, TOP1, and TRIM24 as eminent oncogenes showed up-gain 
status in UMC, whereas CDKN2A, FANCC, and PTEN as well-known TSGs were 
down-loss in the UFM. Components of the UFM showed significant enrichment for 
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‘pathways in cancer’; for instance, ABL1, CBL, CCDC6, CDKN2A, CHUK, CTBP2, 
CUL2, MAPK8, NCOA4, and PTEN (down-loss in the UFM), GLI3 (up-gain), TP53, 
and BRAF (mutated) have prominent contributions to cancer. Significant 
enrichments of proliferation and survival pathways such as ‘cell cycle’, ‘DNA 
replication’, ‘cell cycle checkpoints’, ‘mTOR signalling pathway’, ‘p53 signalling 
pathway’, ‘JNK MAPK pathway’, ‘Wnt signalling pathway’, ‘p38 MAPK pathway’, 
‘SHH pathway’, and ‘EGFR signalling in cancer’ reflected the biological importance 
of hardwired genomic changes in melanoma. The RAS-dependent MAPK 
pathway, Ras-TGFβ cooperation, SHH pathway, and Wnt signalling pathway have 
been shown to contribute to EMT as a central process during cancer progression 
[252, 253]. For instance, FAM3C108 with up-gain in the UFM is a cytokine-like 
protein, considered one of the key players in metastasis, shown to be sufficient for 
tumorigenesis of normal epithelial cells, and correlated with EMT and metastatic 
potential in colon cancers [254]. The enrichment of the BCR pathway and 
adaptive/ immune system showed the presence of maintenance genes affecting 
the interplay between melanoma and the immune system. For instance, the critical 
contribution of TAK1 and its binding protein TAB1 (up-gain in the UFM) to immune 
response, inflammation, and cancer is shown in MDA-MB-231 breast cancer cells. 
Pro-inflammatory cytokines such as IL1 and TNF-α can activate TAK1, leading to 
inflammation [255]. Moreover, siRNA knockdown of TAB1 led to suppression of 
several pathways including p38, IKK, and JNK, resulting in the reduction of 
lymphatic invasion and metastasis. Interestingly, TAB1 inhibition resulted in the 
suppression of E-cadherin, which is a master regulator of EMT [256]; this 
observation may suggest interplay between inflammation and EMT mediated by 
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TAB1 expression. HIF1AN, also known as Factor Inhibiting HIF (FIH-1), showed 
down-loss status in the UFM. Hypoxia-inducible factor-1α (HIF-1α) – significantly 
enriched pathway by the UFM components – is known to be involved in cancer 
cell survival, proliferation, angiogenesis, and metastasis [257]. HIF-1α mediates 
the transcription of GLUT1 and VEGFA involved in glycolysis and angiogenesis. 
Wang and colleagues have shown that in glioblastoma multiforme (GBM), HIF1AN 
knockdown inhibited HIF-1α function even under normoxia; therefore, HIF1AN is 
more effective in inhibiting HIF function than  PTEN is [257]. 
I believe that melanoma is not driven by a single gene, but rather by the 
maintenance functional module, definable as a network of correlated genes 
mediating the tumor’s maintenance in an additive or synergistic manner. 
Therefore, we used the expression pattern of components of the UFM as a 
measure of functional relatedness to define gene clusters with probable functional 
association. We defined seven gene-regulation pathways (GRPs) enriched with 
chromosomes 1, 6, 7, 8, 9, 10, 11, 14, 15, 17, 20, and 22.  
It has been shown that in melanoma, focal deletions and amplifications can target 
specific cancer genes such as BRAF, CDKN2A, MITF, and PTEN [105, 258-262]. 
PTEN is considered the main target of Chr 10 loss in cancer; however, complete 
loss of Chr 10 has been observed in >50% of melanomas, compared with focal 
loss of Chr 10, observed only in 10% of melanoma samples. On the other hand, 
CDKN2a deletion by focal deletion of Chr 9p has been reported in 60% of 
melanomas. These observations suggest the presence of other TSGs on Chr 10 
[105]. For example, HIF1AN located at 10q24 is recurrently lost in GBM, leading to 
tumor progression [257]. Lawrence and colleagues, using in vitro invasion assay 
and in vivo shRNA screening, provided functional evidence that in melanoma, 
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broad regional and recurrent loss of Chr 10 targets the expression of multiple 
TSGs, with ultimate effect on both tumor growth and invasion [263].  
In my findings, it is noticeable that chromosomes 1, 6, 7, 8, 9, 10, 11, 14, 15, 17, 
20, and 22 harbor the most recurrent copy number changes in the UFM. This 
finding is in accordance with several cytogenetic and aCGH studies of primary and 
metastatic melanomas, which have reported that chromosomes 1, 6, 7, 9, and 10 
have the most recurrent structural and numerical aberrations [198, 264-266].  
I observed recurrent gain and loss in Chr 6p and Chr 6q, respectively, in 
agreement with other studies [264-266]. Chr 6 involvement in melanoma 
pathogenesis has been discovered by different studies; for instance, Trent and 
colleagues showed that Chr 6+ microcell hybrids cannot form tumors in nude mice, 
whereas a reverse phenotype was observed in mice receiving Chr 6– microcell 
hybrids [267].  Chr 6q harbors TSGs associated with melanoma pathogenesis, 
whereas recurrent gain of Chr 6p suggests the presence of putative oncogenes on 
this arm [268, 269]. Loss/of heterozygosity and translocation rearrangements are 
more prevalent in Chr 10q than in Chr 10p [270, 271]. Moreover, some studies 
suggest early occurrence of Chr 10 deletion in tumorigenesis [168]. According to 
the AJCC109, ulceration is considered a powerful predictor of survival in melanoma 
patients [272]. Rakosy and colleagues showed a significant association between 
the loss of Chr 6q and Chr 10q, and down-regulation of 36 genes involved in 
tumor ulceration of the primary tumors provided the worse prognosis; these genes 
were involved in apoptosis and cell-cell or cell-matrix adhesion [273]. Cytogenetic 
studies showed the prevalence of Chr 7 gain mostly in thicker tumors, indicating 
its occurrence in later stages of tumor progression [198, 265, 274]. Chr 8q 
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harboring the myc oncogene shows frequent gains in melanoma. C-myc 
expression is shown to be up-regulated in 96% of melanomas [198]. It has been 
suggested that c-myc can down-regulate the HLA antigens required for T cell 
recognition, resulting in tumor evasion from the immune response [275]. In the 
UFM, we observed recurrent gain in Chr 1q, consistent with other studies; 
although deletion of Chr 1p was also reported in most of those studies. Metastatic 
tissues harbor more frequent copy number changes in Chr 1 than in primary 
samples, suggesting the occurrence of Chr 1 changes later in progression [198, 
264-266]. 
In this study, I observed a similar correlation between Chr 9p and Chr 10 (both 
harboring deletion), between Chr 11 and Chr 6 (both harboring deletion), between 
Chr 7 and Chr 20 (both harboring gain), between Chr 10 loss and Chr 7 gain, and 
between Chr 9 loss and Chr 7 gain. Similarly, the gain of Chr 6p was strongly 
correlated with the loss of Chr 6q. Large cytogenetic studies on both primary and 
metastatic melanoma have shown the concurrent occurrence of Chr 1q gain with 
Chr 6p gain and Chr 10 loss; moreover, based on previous observations obtained 
from 32 primary melanomas, Chr 7 gain occurs only if Chr 9 loss exits [198, 264]. 
In silico analysis of the TCGA metastatic melanoma samples showed a significant 
enrichment of BRAF or NRAF damaging mutations in tumors with loss of Chr 10, 
suggestive of cooperation between the MAPK signalling pathways and TSGs on 
Chr 10 [263].  
The enrichment of the UFM with several chromosomes harboring recurrent copy 
number aberrations with direct impact on transcriptional landscape suggests that 
these chromosomal segments may harbor blocks of hardwired and functionally 
related oncogenes and/or TSGs. Moreover, a combination of these mutated 
cancer genes can be fundamentally responsible for tumor survival and 
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progression. As I functionally confirmed the presence of synergy between 
components of the maintenance functional module in Patient7PoC, my validation list 
overlapped with AGK, EZH2, TRIM24, NUB1, and PDIA4 in the UFM. The 
synergistic effect between AGK, EZH2, and TRIM24 with BRAF was shown in 
both cell lines; whereas NUB1 and PDIA4 had synergy only in LNM-CL3P7 and 
LNM-CL4P7, respectively. AGK, BRAF, EZH2, TRIM24, and NUB1 belong to 
GRP3; the presence of these synergistic genes in the same GRP suggest the 
importance of the combinatory impact of maintenance genes on the tumor’s 
functional maintenance, and confirms the necessity of searching for all possible 
synergistic effects between maintenance components within the UFM.  
The seven GRPs showed two distinct tumor types within the TCGA database. TT1 
and TT2 were clustered based on the distinct expressional pattern of GRP3 and 
GRP4. GRP1 was up-regulated in both pathways. Based on the prominent 
components, GRPs were renamed ‘pro-invasion’, ‘pro-proliferation’, and ‘pro-
survival’ (GRP1, 3 and 4, respectively). For instance, ADCK2 and PRKAR2B (with 
up-gain status in GRP1 and GRP3, respectively) have been shown to be involved 
in cancer cell proliferation and motility. Studies of prostate cancer and 
osteosarcoma cell lines have revealed that ADCK2 and PRKAR2B have a 
significant effect on TNFα-mediated HIF-1α accumulation and stability in nucleus. 
TNFα, as a major pro-inflammatory cytokine, can stimulate HIF-1α activity under 
normoxia conditions. This observation suggests that ADCK2 and PRKAR2B may 
be involved in tumor survival by regulating inflammatory cytokines [182, 183].  
DNA replication and the DNA repair pathways have been shown to be the most 
significant pathways associated with metastasis. Kauffmann and colleagues 
showed that DNA repair genes were differentially over-expressed in primary 
melanomas associated with poor prognosis. DNA Repair genes such as PPIA and 
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RPA3 provide genetic stability for distant metastasis [180]. Vacuolar H+-ATPases 
(V-ATPases) such as ATP6V0E2 (present in GRP1) are highly active in metastatic 
breast cancer cells compared with less metastatic ones. These V-ATPases 
provide a dynamic cytosolic pH regulatory system to help tumor cells survive in an 
acidic extracellular pH, and to aggravate the migratory and invasive potential of 
metastatic cells [184]. Nuclear localization and activation of GLI1 can be enhanced 
by the activated MAPK pathway, AKT signaling, or loss of PTEN leading to tumor 
progression, as shown in pancreas and prostate cancers [186, 276, 277].  
GRP4 contains genes with down-loss status; PTEN with a possible prognostic 
value in melanoma also shows down-loss. CCDC6110 – as a proapoptotic protein 
– sustains DNA damage checkpoints when genotoxic events occur and maintains 
genome integrity. During tumorigenesis, DNA damage response (DDR) plays a 
pivotal role as an anti-cancer barrier. Staibano and colleagues showed that 
testicular germ cell tumors can overcome the barrier of a DDR as a result of 
CCDC6 deficiency, which provides a pro-survival pathway with impaired apoptosis 
[187, 188]. SIRT1111 is involved in several cellular functions, including stress 
resistance and apoptosis, by deacetylating proteins such as PTEN, p53, and 
FOXO112 [189, 190]. Under severe stress, SIRT1 inhibits AKT through PTEN 
deacetylation and activates FOXO1, which in turn increases the expression of 
BIM, GADD45, MnSOD, and p27 (involved in apoptosis, DNA repair, ROS 
resistance, and cell cycle arrest, respectively) [278, 279]. In SIRT1−/− cells, FOXO1 
is inhibited and AKT is activated to protect the cell from intracellular ROS113 and to 
block the nuclear PTEN-mediated apoptotic pathway [190, 280, 281]. LEF1 and β-
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catenin, as co-factors in Wnt signalling, play a critical role in tumor proliferation via 
expressional regulation of critical genes such as MITF. BTRC and CTBP1 are 
negative regulators of the Wnt signaling pathway through ubiquitin-mediated 
degradation of β-catenin and transcriptional repression of LEF1 [191-194].  
The expressional pattern of the GRPs in TT1 and TT2 suggests the importance of 
combinatory therapy in samples with activated BRAF, as the pro-invasion network 
seems to be up-regulated in these tumors as well. On the other hand, even in the 
absence of BRAF mutation, the pro-invasion network is up-regulated. Highly 
expressed inflammatory cytokine regulators (ADCK2 and PRKAR2B), V-ATPases, 
repair genes (PPIA and RPA3), and GLI1 represent interesting targets for therapy. 
Moreover, considering the crosstalk between the MAPK/AKT/HH-GLI pathways, 
the combinatory inhibition of several targets within these pathways may provide 
optimistic results. 
In summary, considering the highly heterogeneous mutational signature of 
melanoma and its role in therapy resistance, it is vital for the development of 
successful therapies to identify cooperating oncogenes and to reconstitute the 
genomic architecture that drives their synergistic effects. In this study, I 
investigated the systems biology of tumor maintenance in melanoma as defined 
by hardwired somatic mutations. I experimentally validated the presence of the 
maintenance functional module harboring components potentiated for co-
expression via hardwired somatic aberrations, with ultimately an additive or 
synergistic effect on tumor proliferation. I showed that the clustering of cancer-
promoting genes (defined as positive hits) augments tumor proliferation, as 
evidenced by the combined effects of these genes on tumor proliferation in vitro.  
I introduced novel synergistic (nine genes) and additive (eleven genes) effects to 
vemurafenib, raising the possibility of a successful combinatory therapy by 
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targeting cooperating oncogenes. To further investigate the combinatory 
therapeutic outcome of these novel targets in melanoma, the combinatory effect of 
these candidate genes needs to be studied in in vivo model systems.  
The UFM was revealed as core sets of somatic mutations persisting throughout 
the tumor evolution of any given melanoma patient, with the highest frequency in a 
larger cohort of patients. I believe that components of the UFM perform in a 
cooperative manner, with significant effect on tumor phenotype, and ultimately 
with profound impact on clinical outcomes and the efficacy of therapy. I believe 
that my systematic platform has provided a valuable gene set crucially implicated 
in the tumor’s functional maintenance. To further investigate the individual and 
combinatory therapeutic outcome of these novel targets in melanoma 
(components of the UFM), the individual, and combinatory impact of components 
of the UFM need to be studied in future.  
Finally, in this study, I have generated a noticeable amount of sequencing data for 
a unique set of samples (tissues and their matched cell lines); these data can be 
used for further processing and analyses in future. For example, working with Dr. 
Niranjan Nagarajan and his group at the GIS, I helped develop a data integration 
framework (OncoIMPACT) that acts to nominate patient-specific driver genes from 
a panel of mutations based on their phenotypic impact. The results obtained from 
this study provided strong evidence that the computational approach, combined 
with clinical genome sequencing, could serve as a means to identify personalized 
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ABSTRACT
Extensive and multi-dimensional data sets generated
from recent cancer omics profiling projects have pre-
sented new challenges and opportunities for unravel-
ing the complexity of cancer genome landscapes. In
particular, distinguishing the unique complement of
genes that drive tumorigenesis in each patient from
a sea of passenger mutations is necessary for trans-
lating the full benefit of cancer genome sequencing
into the clinic. We address this need by presenting
a data integration framework (OncoIMPACT) to nomi-
nate patient-specific driver genes based on their phe-
notypic impact. Extensive in silico and in vitro vali-
dation helped establish OncoIMPACT’s robustness,
improved precision over competing approaches and
verifiable patient and cell line specific predictions
(2/2 and 6/7 true positives and negatives, respec-
tively). In particular, we computationally predicted
and experimentally validated the gene TRIM24 as a
putative novel amplified driver in a melanoma patient.
Applying OncoIMPACT to more than 1000 tumor sam-
ples, we generated patient-specific driver gene lists
in five different cancer types to identify modes of
synergistic action. We also provide the first demon-
stration that computationally derived driver mutation
signatures can be overall superior to single gene and
gene expression based signatures in enabling pa-
tient stratification and prognostication. Source code
and executables for OncoIMPACT are freely available
from http://sourceforge.net/projects/oncoimpact.
INTRODUCTION
In recent years, advances in genomic technologies have en-
abled the systematic generation of clinical cancer omics data
at an unprecedented scale and rate, interrogating tumor bi-
ology at multiple levels––genomic, transcriptomic as well as
epigenomic (1,2). Integrativemining of these clinically char-
acterized, information-rich data sets is expected to provide
deep insights into tumor biology and guide new efforts to
develop cancer diagnostics and therapeutics (3,4). Recent
studies have, however, highlighted the complexity of can-
cer genome landscapes in terms of somatic mutations, tran-
scriptomic changes and epigenetic alterations, potentially
confounding modeling, mining and integrative analysis of
cancer omics data (5,6). While the complexity of cellular
processes that link the different levels of changes in can-
cer cells may suggest the use of sophisticated systems biol-
ogy (mechanistic or probabilistic) models for data integra-
tion, their utility can be hampered by the need to learn a
large number of parameters from a limited number of pa-
tient samples (7). On the other hand, it is unclear if sim-
pler models can adequately capture key features of the data
and be used to obtain biologically relevant insights. Corre-
spondingly, despite its importance, relatively few methods
have been proposed that can model and integrate cancer
omics data (8–11) and limitations in mining and interpre-
tation continue to be a major barrier for their exploitation
in clinical applications (3,12).
One of the fundamental challenges in the analysis and in-
terpretation of cancer genomic data is to identify and distin-
guish functional (driver)mutations from the numerous non-
functional (passenger) mutations that are found to popu-
late cancer genomes (13,14). This problem has relevance
not only for an understanding of tumor biology (in terms
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of characterizing oncogenes and tumor suppressors) but
also from a clinical perspective where patient-specific driver
genes hold significant value for defining therapeutic tar-
gets. While recent studies that have cataloged the frequency
of mutations in genes based on a large number of patient
samples have been quite successful in identifying the ma-
jor oncogenes and tumor suppressors in a cancer subtype
(15,16), these approaches are not well-suited for identify-
ing rare drivers or patient-specific driver genes (14,17), even
with the use of more sophisticated statistical approaches
(18,19). An orthogonal approach that has been used with
some success relies on the direct evaluation of evolutionary
conservation and physiochemical properties to infer func-
tional mutations (20,21), but these methods are restricted to
point mutations and were found to lack in accuracy due to a
dependence on high-quality training data (22). Integration
of mutation data with gene interaction networks has also
been proposed as an approach to identify rare drivers, rely-
ing on the assumption that they will cluster on the network,
but limited to the analysis of point mutations (23–25).
A natural and powerful approach to assess the functional
impact of mutations is to measure changes in gene expres-
sion patterns that can be attributed to them. When done
without prior information about which genes interact, this
association analysis requires a large number of samples and
can potentially lead to many false positives (9,17). Alterna-
tively, reconstructed interaction networks based on gene co-
expression (26) or known molecular networks (8,10) have
been exploited to better define informative associations.
These methods come closer to integrative modeling of can-
cer omics data and have the potential advantage of provid-
ing biologically plausible hypotheses for candidate driver
genes. In addition, these methods can be applied to a range
of mutation classes, unlike several popular mutation-type
restricted methods (e.g. CHASM (20), OncodriveFM (18)
and PARADIGM-SHIFT (11)), thus allowing for a joint
assessment of driver events and genes. They are, however,
currently still limited to making aggregate predictions for a
data set and are not designed to support the sample-specific
analysis that would be key for defining personalized can-
cer management and therapy. An additional limitation in
the field is that existing methods have not been shown to
robustly analyze data from cancer cell lines, which are fre-
quently used as in vitromodels for pharmacological investi-
gations (3) and can form the basis of a framework for per-
sonalized cancer therapy.
Tumor stratification and prognostication is another im-
portant end-goal for cancer genomic profiling and analy-
sis (27) that is often considered independent of driver gene
prediction, despite being potentially related objectives. A
commonly used approach for tumor stratification is based
on the clustering of gene expression profiles, even though
its prognostic value has appeared limited at times and de-
pends greatly on the adopted gene signature (28). Improved
driver gene prediction should, in principle, be informative
for tumor stratification as the identified mutated genes are
likely causative events for carcinogenesis and metastasis.
However, to our knowledge, this application has yet to be
demonstrated by driver gene prediction algorithms, despite
a report on whole-exome mutation profiles being useful for
tumor stratification (29).
Advances in the capability to identify oncogenic drivers
and to stratify tumors can potentially revolutionize person-
alized cancer therapy (3,27). To address existing method-
ological limitations, we developed a first-in-class algorith-
mic framework (OncoIMPACT) that nominates patient-
specific driver genes by integratively modeling genomic mu-
tations (point, structural and copy-number) and the result-
ing perturbations in transcriptional programs via defined
molecular networks. Our benchmark analysis on large pub-
licly available data sets from The Cancer Genome Atlas
(TCGA) for several cancer subtypes revealed notable im-
provements over existing approaches in terms of precision
and robustness for identifying driver genes. Furthermore,
OncoIMPACT’s robustness on cell line data sets was con-
firmed using data from the Cancer Cell Line Encyclope-
dia (CCLE) (30) and we additionally provide direct exper-
imental evidence using a patient-derived cancer cell line to
showcase its potential in personalized medicine. Finally, we
present the first demonstration for the use of a set of com-
putationally identified driver genes as a mutational-status-
based signature for tumor stratification and prognostica-
tion. Taken together, our results highlight the potential of
computational methods in integrative modeling of cancer
omics data for uncovering new insights into tumor biology,
and their application in a clinical setting for stratification
and personalized therapy.
MATERIALS AND METHODS
Design of a robust framework for patient-specific data inte-
gration
A natural framework to assess the impact of candidate
driver mutations (genomic and epigenomic) is to use gene
interaction networks to associate mutations with changes
in cell state (e.g. transcriptome (8), proteome, epigenome or
metabolome) and this is the approach adopted in the design
of OncoIMPACT. For the sake of simplicity and due to its
wide availability, we consider only transcriptomic changes
in this study, though similar ideas as proposed here apply
to other omics information as well. A key consideration in
the design of OncoIMPACT is the ability to characterize the
impact of mutations (non-synonymous Single Nucleotide
Variantions (SNV), indels and Copy Number Variations
(CNV)) at a patient-specific level and for that purpose we
propose an approach that associates mutations with mod-
ules of patient-specific deregulated genes on the network.
Specifically, given a mutation in a patient we consider a
deregulated gene in the patient as being explained if there is
a small path (length less than a parameter L) of deregulated
genes in the patient that connect it to the mutated gene in
the interaction network. To account for promiscuous asso-
ciations, we disallow paths that go through hub genes (with
degree greater than a parameterD) in the network and iden-
tify deregulated genes as those that are significantly differ-
entially expressed in cancer versus normal cells (false dis-
covery rate corrected P-value< 0.05) and with a strong fold
change (greater than a parameter F). The parameters in this
framework (L,D and F) are directly determined using a sta-
tistical approach based on the interaction network and data
sets used, as discussed in the next section. In order to clus-
ter mutations and deregulated genes into relevant modules,
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we then define the notion of a phenotype gene as frequently
explained (default ≥5% of patients) deregulated genes for
a cancer subtype, where the phenotype genes serve to rep-
resent and nucleate modules as described in a later section.
Finally, OncoIMPACT distinguishes passenger mutations
from potential driver mutations by identifying those that
explain phenotype genes and thus have a significant impact
on the associated modules.
A systematic approach to determine model parameters
While the parameters L and D are largely determined by
the properties of the network, the fold-change parame-
ter F could potentially interact with them to increase the
number of spurious associations to a mutation. Under the
assumption that with a suitable set of parameters, real
data sets should have many more associations than ran-
dom data sets, we use the following permutation-based ap-
proach to set parameters: (i) We generate random data sets
by permuting gene labels for mutation and transcriptome
data sets independently. Note that this procedure main-
tains the frequency distributions of mutated and deregu-
lated genes across patients and within a patient, while de-
stroying the association between mutated and deregulated
genes. (ii) For each random data set (which contains the
same number of patients as the real data set), we identify
explained genes on the network and compute the distri-
bution of the frequency with which a gene is explained.
(iii) Aggregating this information across data sets, we com-
pare it to the distribution for the real data set using the
Jensen–Shannon divergence metric. (iv) A grid search over
suitable ranges of parameter values is then used to set
the parameters based on the choice that maximizes the
Jensen–Shannon divergence from random data sets (default
settings: L ∈ {2, 4, . . . , 20}, D ∈ {10, 15, . . . , 100} and F ∈
{1, 1.5, . . . , 3}). To avoid extreme parameter choices, we ig-
nore choices for which the median number of deregulated
genes (across samples) is more than half the genes in the net-
work or less than 300 genes. Our experiments with subsets
of patients confirmed the robustness of the parameter infer-
ence procedure and the feasibility to do it with small data
sets to reduce overall running time (Supplementary Figure
S1).
Assessing the significance of phenotype genes
In order to identify statistically significant phenotype genes,
we adopted a permutation-based testing framework to test
each candidate. Specifically, we permuted gene labels for the
mutations for each sample independently. The random data
sets were then used to obtain an empirical null distribution
(default= 500 data sets) for the frequencywithwhich a gene
is explained and computeP-values for observed frequencies
(= probability of observing frequencies that exceed the ob-
served frequency by chance). Corrections for multiple hy-
pothesis testing were done using the method of Benjamini
and Hochberg and a significance threshold of 0.1 was used
in addition to the frequency threshold (default = 5%) to
identify significant andmeaningful phenotype genes for nu-
cleating modules.
Distinguishing driver mutations from back-seat driver muta-
tions
While the approach to individually assess the impact of mu-
tations and to use their association with phenotype genes
for distinguishing potential drivers from passengers works
reasonably well, in situations where a strong driver deregu-
lates many genes in the network, extraneous mutated genes
in the neighborhood can get associated with a module. In
order to distinguish such back-seat driver mutations, we
applied a parsimony principle to identify a minimal set
of drivers associated with phenotype genes. Encoding the
patient-specific association of mutations with phenotype
genes as set (also implicitly defining a bipartite graph), this
problem can be formulated as the classical Minimum Set
Cover problem, a well-known NP-complete problem with
a greedy O(log n) approximation algorithm. In OncoIM-
PACT, we implemented a version of this algorithm that iter-
atively selects the gene covering the most number of uncov-
ered phenotype genes, breaking ties by choosing the gene
predicted as a driver in the most number of patients. In
the patient-specific mode, a mutated gene is considered as
a driver in a patient only if it aided in covering a patient-
specific phenotype gene (stringent mode), while in amore re-
laxed setting (sensitive mode; default) OncoIMPACTmarks
a potential driver gene as a back-seat driver only if it is so
in all patients. Note that the stringent mode is particularly
well suited for analyzing data sets where there is a high rate
of false-positive mutations.
Construction of patient-specific gene modules for assessing
mutational impact
The construction of patient-specific gene modules in On-
coIMPACT allows us to obtain amore comprehensivemea-
sure of the impact/importance of a putative driver gene.
To coalesce mutated genes and phenotype genes into mod-
ules we employ the following steps: (i) For each patient a
driver gene defines a module composed of the set of ex-
plained genes associated with it. (ii) Modules of the same
patient that share a phenotype gene are merged together.
(iii) Deregulated genes that do not belong to paths between
driver and phenotype genes are trimmed from modules.
(iv) The patient-specific impact of a driver gene is com-
puted as the sum of fold change of genes that belong to
its module and the overall impact is defined as the average
patient-specific impact. Finally, OncoIMPACT orders pre-
dicted driver genes based on their impact value.
Use of pre-computed information from large public data sets
OncoIMPACT is configured to run in two modes: (i) a
database mode that allows it to determine parameter set-
tings (L,D and F) and significant phenotype genes from the
data sets provided and (ii) a discoverymode where informa-
tion in the provided database is used to predict driver genes
for each sample in an additional data set (which can be the
same as the one used to create the database). In the discov-
erymode, identification of back-seat drivers is done by com-
bining the database data sets with discovery data sets. Note
that OncoIMPACT can be run by default in a combined
database-plus-discovery setting on an input data set, while
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the discovery mode is useful to avoid computations when a
pre-computed database is available. As part of the OncoIM-
PACT package, we provide databases constructed from all
the TCGA data sets analyzed in this study, to enable easy
integration with custom, in-house data sets for these cancer
subtypes. New releases of OncoIMPACT will include addi-
tional subtype databases as well.
Patient stratification and survival analysis
Clusterings of driver gene profiles (binary 1–0 vectors) were
computed using non-negative matrix factorization (NMF)
based on consensus clustering using the R package ‘nmf’
(31). In order to produce robust clustering the consensus
clustering was obtain using 200 random runs of the NMF
optimization algorithm. Kaplan–Meier curves were drawn
for the clusters and log rank P-values computed using the
R package ‘survival’ (29).
Data sets and networks
All TCGA data sets were downloaded from the TCGA
data portal (https://tcga-data.nci.nih.gov/tcga/). OncoIM-
PACT analysis was restricted to samples for which infor-
mation on point mutations, copy-number alterations and
gene expression was available. Cell line data sets (47 ovar-
ian and 41 glioma lines) were downloaded from the CCLE
data portal (http://www.broadinstitute.org/ccle/home) and
shRNA data from the Achilles data portal (http://www.
broadinstitute.org/achilles; 24 ovarian cell lines with ge-
nomic and shRNA data). A detailed description of data
parsing and pre-processing steps can be found in the Sup-
plementary Text.
By default, OncoIMPACT uses the gene interaction net-
work constructed by Wu et al. (32) (covering nearly 50%
of the human proteome) for its analysis. This interaction
network integrates information from known pathways (e.g.
KEGG, NCI-Nature) as well as interactions derived from
computational predictions (e.g. gene co-expression, protein
domain interactions and shared gene ontology (GO) bio-
logical process). However, OncoIMPACT can use other net-
works as input as well and our experiments with a manually
curated network (33) suggest that while a less complete net-
work can reduce its predictive power, its predictions are still
typically better than a frequency-based approach (Supple-
mentary Figure S2).
Genomic analysis of melanoma sample and functional valida-
tion using patient-derived cell line
Distant metastasis melanoma samples and the correspond-
ing patient-derived cancer cell line were provided and estab-
lished by the JohnWayne Cancer Institute as previously de-
scribed (34). Details of genome and transcriptome sequenc-
ing and analysis of the melanoma samples can be found in
the Supplementary Text. Driver genes in the cell line de-
rived from distant metastasis were validated using siRNA-
mediated knockdown. Briefly, the patient-derived cell line
was cultured in complete RPMI culture medium containing
10% fetal bovine serum and was kept at 37◦C with 5% CO2.
For the knockdown experiment, cells were incubated with
25 nM siRNA and lipofectamine RNAimax (Life Tech-
nologies) at 37◦C for 72 h. Active cell proliferation was
detected using Click-iT EdU Alexa Fluor 488 HTS Assay
(Life Technologies). Fixation and staining of cells was per-
formed according to manufacturer’s instructions. The siR-
NAs used are tabulated in Supplementary Table S1. Dhar-
maconON-TARGETplusNon-TargetingControl Pool was
used as a negative control. The TaqMan primers for quan-
titative polymerase chain reaction are designed by and or-
dered comerically from Life Technologies.
RESULTS
An overview of OncoIMPACT’s algorithmic framework
OncoIMPACT is designed to integrate information re-
garding mutations (genomic and epigenomic), changes
in cell state (e.g. transcriptome, proteome, epigenome or
metabolome) and gene interaction networks to nominate
and rank driver cancer mutations in a patient-specific man-
ner (i.e. driver predictions are made for each patient; Figure
1a andMaterials andMethods). Briefly, it does so by evalu-
ating the impact of a mutation by associating them to mod-
ules of patient-specific deregulated genes through the gene
interaction network (step 3 in Figure 1a). A key step in this
process is the identification of sentinel phenotype genes fre-
quently deregulated in a cancer subtype (but not typically
mutated) and serve to distinguish relevant driver mutations
from passengers (step 2 in Figure 1a). The association of
mutations to phenotype genes is controlled by three param-
eters (maximum path length L, maximum gene connectiv-
ity D and a perturbation threshold F) that are determined
in a data-driven fashion using a statistical maximization ap-
proach (step 1 in Figure 1a, b andMaterials andMethods).
To further differentiate true drivers from back-seat drivers,
OncoIMPACT employs the parsimony principle to iden-
tify a minimal set of driver mutations for each patient (Fig-
ure 1c). Finally, the nominated patient-specific drivers are
ranked based on their impact on associated modules. A de-
tailed description for each of the steps inOncoIMPACT can
be found in the Materials and Methods section.
OncoIMPACT nominates cancer drivers accurately and con-
sistently
As existing methods for identifying driver genes are based
on aggregate analysis over a large number of patients, we
begin by comparing OncoIMPACT’s performance for this
task against an aggregate network approach (DriverNet (8))
as well as a commonly used mutation frequency-based ap-
proach for ordering candidate drivers (35–39) (Frequency).
Our experiments using large TCGA data sets (328 sam-
ples for Glioblastoma multiforme or GBM (1) and 316 for
Ovarian Cancer (40)) indicate that OncoIMPACT can suc-
cessfully integrate information regarding copy-number as
well as point mutations and indels to highlight key driver
genes across categories (Supplementary Tables S2 and S3).
In contrast, a naive frequency-based approach seems to en-
rich for less known cancer driver genes (Supplementary Ta-
bles S2 and S3 and Supplementary File S1), e.g. the top
gene on the Glioblastoma list is JARID1D instead of EGFR
and both lists omit PIK3CA from the top 10. While results
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Figure 1. A schematic representation of OncoIMPACT’s algorithmic framework. (a) Overview of OncoIMPACT’s workflow involving three main stages
of data-processing. (b) Depiction of OncoIMPACT’s search through a multi-dimensional space to set network and expression parameters (F, fold change
of genes; L, length of path; D, degree of nodes). (c) Parsimony-based matching of potential driver and phenotype genes in a bipartite graph to eliminate
back-seat drivers. Solid and dashed lines indicate the association of potential driver genes to phenotype genes that were accepted and rejected, respectively.
for DriverNET were more comparable to those from On-
coIMPACT, DriverNET failed to identify several known
oncogenes, such as NF1 and RB1, in ovarian cancer (40)
and MDM4 in Glioblastoma (41) among others (Supple-
mentary Tables S4 and Supplementary File S1). To per-
form a more systematic comparison across methods, we
used genes in the cancer gene census (CGC) (42) and a
previously compiled pan-cancer driver list (43) as a proxy
for potential drivers to assess the concordance/precision
of the top driver genes reported for five different cancer
types (GBM, Melanoma, Ovarian, Prostate and Bladder)
(Figure 2a, Supplementary Figure S3). These results indi-
cate a strong enrichment for potential true positive driver
genes in OncoIMPACT’s predictions (Supplementary Fig-
ure S3b). For example, among the top 20 predictions in
Glioblastoma, OncoIMPACT’s concordance is above 60%
while the frequency-based approach and DriverNet are be-
low 40%, suggesting that it is generally more accurate and
less likely to be influenced by frequently mutated passen-
gers. This trend was seen in all cancer types, except for the
Melanoma data set where the lack of sufficient normal con-
trols likely affected OncoIMPACT’s results in relation to
DriverNet (Supplementary Figure S3).
We further tested the robustness of OncoIMPACT using
a subsampling-based approach to compare predictions to
those on the full data set of patients. Our results suggest
that OncoIMPACT’s predictions are extremely stable even
with very small sample sizes (∼20 patients), with more than
90% of reported drivers being found on the full data set
(Figure 2b). In addition, OncoIMPACT can recover a siz-
able proportion of drivers using a relatively small subset of
the data set (>70% with 50 patients; Figure 2b). Although
both common drivers (>5%mutational frequency) and rare
drivers (<5% mutational frequency) have high recovery, a
higher fraction of common drivers is generally recovered,
possibly due to the bias in the passenger filtering step in
OncoIMPACT (Figure 2b; Materials and Methods). How-
ever, the recovery rates for rare and common drivers con-
verge as the number of samples increases. The stability at-
tribute of OncoIMPACT is likely to be a useful feature in
the analysis of rare forms of cancers (e.g. cardiac tumors
(44)), where the availability of samples is limited. In partic-
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Figure 2. OncoIMPACTmakes precise and robust driver gene predictions. (a) Concordance/precision measured by the fraction of top ranked driver genes
from OncoIMPACT, DriverNet and a frequency-based approach that are included in the CGC and a pan-cancer driver gene list. (b) Stability (precision
when evaluated on predictions from the full data set) and recovery (sensitivity when evaluated on the full data set) characteristics of OncoIMPACT as a
function of the size of the data set analyzed (average of 20 simulations). (c) Common genes predicted as drivers by OncoIMPACT in both clinical tumor
samples and cell lines (cancer census genes).
ular, the naive frequency-based approach would be unsuit-
able for such data sets due to limited statistics.
To further demonstrate that OncoIMPACT is able to dis-
cern true signals from noisy data, and to establish its utility
for analyzing cell line data sets, we repeated our analysis
using data from CCLE (30). As the cell lines here do not
have normal controls, identification of somatic variants is
error-prone, but despite this we found that OncoIMPACT
results enrich for true drivers and are significantly better
than a competing approach (Supplementary Figure S4). A
significant fraction of drivers in the cell line were also fur-
ther confirmed using shRNA experiments, as detailed in the
next section. Cancer cell lines are commonly used as in vitro
models for clinical tumors with the caveat that they can de-
viate genetically from their tumor counterparts after years
of adaptation to artificial culturing conditions (45). Fur-
thermore, there is a diversity bias inherent in cell line col-
lections, where mutation frequencies in cell lines may not
be reflective of clinical tumor collections. Despite this, our
comparisons of driver genes predicted from cell lines and
patient samples suggested that the overlap between them
is significant (P-value = 2.3 × 10−9 and 3.3 × 10−9 for
Glioblastoma and Ovarian Cancer, respectively; hyperge-
ometric test, Supplementary Figure S5) and involves key
known cancer driver genes (Figure 2c). However, important
differences still exist in terms of cell line and patient-specific
drivers (Supplementary File S2), possibly due to differences
in the biological contexts in which they exist.
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OncoIMPACT makes robust and verifiable patient-specific
driver gene predictions
While the identification of patient-specific driver genes is
challenging, validating a methodology that identifies them
is even more so, given the lack of gold standards (e.g. by
their very definition patient-specific drivers are less likely to
be in CGC). We attempted to verify OncoIMPACT’s abil-
ity to call patient-specific drivers using three different ap-
proaches. First, we experimented with in silico data sets de-
rived from real TCGAdata sets by introducing randommu-
tations to test our ability to discriminate them. These exper-
iments highlight that OncoIMPACT shows a high-degree of
tolerance to the introduction of decoy mutations, and can
robustly accommodate up to 10% of erroneous mutation
data (e.g. due to sequencing or variant-calling errors) (Fig-
ure 3a, Supplementary Figure S6). In doing so, it is able to
control the false positive rate (FPR) to be generally less than
10% (median FPR < 5% for 2.5% decoy mutations), sug-
gesting that a majority of patient-specific driver predictions
are likely to be true positives. To further validate the consis-
tency of patient-specific driver gene predictions, we experi-
mented with learning phenotype genes from a random sub-
set of samples, with prediction on unselected samples (cross-
validation). Our results show good predictive stability for
all drivers and good predictive recovery for both common
(>5% frequency) and rare drivers (<5% frequency) (Sup-
plementary Figure S7), further confirming OncoIMPACT’s
robustness for patient-specific driver gene prediction.
Second, we leveraged data from a recent genome-scale
functional screen for genes essential for survival and prolif-
eration (ESP) in 24 different ovarian cancer cell lines (46),
to evaluate our cell line-specific predictions. We noted a
significant overlap (P-value = 9.5 × 10−4; hypergeomet-
ric test, Figure 3b) between predicted drivers and validated
ESP genes, including several that are rarelymutated in ovar-
ian cancer (e.g.MAPK1 (1.6%) and JUN (2.2%)) and with
functions consistent with cancer driver genes (Supplemen-
tary Tables S5). As control, we evaluated overlap with the
frequency-based approach and found it to be not significant
(P-value = 0.96 at frequency cutoff of 5%; hypergeometric
test). Furthermore, increasing the stringency for ESP genes
(validated by 4 shRNAs), increased the enrichment in On-
coIMPACT predictions (5 out of 7; P-value = 2.5 × 10−6;
hypergeometric test) suggesting that most strong prolifera-
tion drivers are identified byOncoIMPACT. Further valida-
tion would be needed to characterize drivers that play a role
in other cancer processes, such as invasion, genome stability
and angiogenesis.
Finally, to showcase OncoIMPACT’s ability to combine
large publicly available data sets with data from custom
sample collections, we analyzed data from a clinical dis-
tant metastasis sample (paired tumor-normal exome se-
quencing, mate-pair sequencing-based copy-number profil-
ing and RNA-seq) in combination with a data set of 160
melanoma samples from TCGA (see Materials and Meth-
ods). Despite the presence of a large number of mutations
and amplifications in the sample, OncoIMPACTnominated
a concise list of driver mutations (Figure 3c). As proof of
principle, a patient-derived cell line from the patient was
used for experimental validation (see Materials and Meth-
ods). Using siRNAs, we attempted to knock-down the ex-
pression of the two amplified, predicted driver genes in
the cell line (BRAF and TRIM24, Supplementary Figure
S8) and noted a substantial reduction in the proliferation
rate of cancer cells for both genes (Figure 3d, Supplemen-
tary Figure S9). BRAF is a well-known frequently mu-
tated and amplified driver in melanoma (47). On the other
hand, even though TRIM24-BRAF fusion gene was previ-
ously reported to be present in a subset of melanomas (48),
TRIM24 on its own has not been characterized as a driver
andwas ranked 671 in the list of frequentlymutated genes in
the TCGAmelanoma data set. Interestingly, whileTRIM24
was initially identified as a transcriptional co-regulator, it
has been recently shown to ubiquitinate TP53 for degrada-
tion in breast cancer (49) and could play a similar role in
melanoma. We further performed an experimental assess-
ment of our false-negative rate by silencing seven selected
amplified genes (CASP2, CNOT4, CUL1, EZH2, HIPK2,
SSBP1 and ZYX) with known functions in oncogenic pro-
cesses that were not predicted as drivers by OncoIMPACT
(Supplementary Figure S8). Strikingly, despite our enrich-
ment for potential false negatives, we observed a reduction
in the proliferation of cancer cells in only one (EZH2) out
of seven selected genes (Supplementary Figure S10). To-
gether, these results provide evidence that a computational
approach, combined with clinical genome sequencing could
serve as a means to reliably identify personalized therapeu-
tic targets in cancer.
Distributional properties of driver genes and associated
deregulated modules
The ability to generate patient-specific lists of driver genes
allowed us to analyze the distributional properties of driver
genes without having to resort to an aggregate analysis that
may obscure its interpretation. For example, using all pre-
dicted drivers, we readily observed that driver genes tend
to cluster on the gene interaction network, similar to what
was observed by others (50), and distances between them
were significantly lower than between all mutated genes and
between random genes (Supplementary Figure S11). How-
ever, this observation has several potential explanations in-
cluding, but not limited to: (i) tumors share driver mu-
tations that affect the same functional network (29) and
(ii) biases in the data (50). Analysis using patient-specific
driver gene lists avoids some of these issues and our analy-
sis using OncoIMPACT revealed a similar pattern of clus-
tering at a sample-specific level (Figure 4a and Supplemen-
tary Figure S12), that is not explained by mutation fre-
quency or network structure (i.e. hub genes), suggesting that
an alternative explanation––that the occurrence of multi-
ple mutations in a network module is necessary for path-
way deregulation in a tumor––may be valid here.We further
investigated such synergistic interactions between drivers
by using an unbiased search and statistical testing to iden-
tify potential co-drivers and compared our patient-specific
results with a non-patient-specific approach (Supplemen-
tary Figure S13, Supplementary File S3). Our results show
that the patient-specific analysis likely identifiesmoremean-
ingful co-driver gene pairs (i) identifying a smaller subset
of potential gene-pairs as co-drivers (Supplementary Fig-
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Figure 3. Validation of sample-specific driver gene predictions. (a) Box plots depicting the distribution across samples of FPR for driver gene predictions
in OncoIMPACT (average of 20 simulations). Decoy mutations were introduced in random genes as proxy for non-drivers in this assessment. (b) Overlap
between predicted unique cell line-specific drivers and shRNA validated genes (using at least 2 shRNAs) ESP in 24 ovarian cancer cell lines. Number in
parenthesis represent the number of unique genes. The P-value is computed using hypergeometric test. (c) Frequency in TCGA samples and mutation
type for driver gene predictions from a melanoma sample. (d) Cell proliferation assay in a patient-derived melanoma cell line treated with control siRNA
or siRNA targeting BRAF and TRIM24. Error bars represent SEM of three independent repeats. Statistical significance was assessed by using student’s
t-test.
ure S13a), (ii) that are less likely to be enriched in false-
positives due to genomic proximity (Supplementary Figure
S13b) and (iii) are more enriched in genes that are likely to
have similar functional roles (Supplementary Figure S13c).
In addition, we identified several gene-pairs as co-drivers
that were not necessarily correlated in their mutation occur-
rences and were not therefore detectable without a patient-
specific analysis as provided byOncoIMPACT (Supplemen-
tary File S3). Interestingly, in comparison to glioblastoma,
ovarian and prostate cancer, we noted only a handful of co-
drivers in melanoma and bladder cancer (Supplementary
Figure S13a) and we discuss this observation further in a
following section (see Discussion).
An intrinsic feature of OncoIMPACT is that it ‘anno-
tates’ candidate driver genes with an associated module of
deregulated genes and phenotype genes in the network that
can provide hints to the mechanism by which the putative
driver acts as one (see Materials and Methods). For exam-
ple, in our analysis of the TCGA Ovarian Cancer data set,
amplification of the c-MYC oncogene was frequently asso-
ciated (in 58% of mutated tumors) with an increase in the
expression of the phenotype gene BCAT1, an amino acid
transaminase that produces branched-chain L-amino acids
required for cell proliferation. This suggests that BCAT1
may be a direct transcriptional target of c-MYC and an ef-
fector through which c-MYC exerts its oncogenic influence,
a relationship that has previously been demonstrated in na-
sopharyngeal carcinoma (51), but needs to be explored in
ovarian cancers. As another notable example, we observed
that the amplification ofDVL3was associated in 81% of tu-
mors by a corresponding down-regulation in the expression
of the phenotype gene CXXC4.DVL3 is a human homolog
of the Drosophila dishevelled gene and to our knowledge,
not yet directly implicated as a driver in ovarian cancers.
CXXC4 is known to negatively regulate the Wnt signaling
pathway by binding and inhibitingDvl (52). Thus, our anal-
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Figure 4. Clustering of driver genes and GO enrichment of associated modules. (a) Violin plots showing the distribution of average distance in the gene
interaction network (computed at a sample-specific level) between all pairs of genes in each class (mutated genes, predicted driver genes and random hub
genes (degree ≥ 20)). The blue line represents the average distance between genes on the interaction network. The P-values are computed using Wilcoxon
rank sum test. (b) Box plots depicting the distribution of the number of genes in the largest module and all other modules. The P-values are computed
using Wilcoxon rank sum test. (c) Bar chart showing the frequency at which GO terms are enriched in the largest module for each patient. Enrichment
analysis was done using DAVID (53) (http://david.abcc.ncifcrf.gov/) and a q-value threshold of 0.05 was used to identify enriched terms.
ysis suggests the hypothesis that DVL3 amplifications, cou-
pled with decrease in CXXC4 expression, could drive ovar-
ian cancer progression through enhanced activation of the
Wnt signaling pathway. These and other novel driver gene
predictions fromOncoIMPACT can be further investigated
based on downstream analysis (e.g. GO enrichment) and in
vitro testing of the phenotype genes andmodules associated
with them.
We further analyzed the patient-specific deregulated
modules from OncoIMPACT and observed that multiple
distinct deregulated modules exist in most patients (Supple-
mentary Figure S14). Despite this, a single dominant mod-
ule comprising of multiple driver genes was also frequently
observed (Figure 4b and Supplementary Figure S15), sug-
gestive of the existence of a core deregulatedmodule driving
cancer progression in each tumor sample. Furthermore,GO
enrichment analysis (53) of the dominant modules showed
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that they are frequently enriched for genes that regulate cel-
lular processes contributing to the hallmarks of cancer (54)
(e.g. regulation of cell proliferation, apoptosis and cell mi-
gration; Figure 4c). The functional enrichment of deregu-
lated modules in these processes further demonstrates their
utility for guiding validation (e.g. distinguishing prolifer-
ation drivers from angiogenesis drivers) and mechanism-
informed therapy from patient-specific predictions in On-
coIMPACT.
Tumor stratification using personalized driver mutation pro-
files
Patient-specific driver mutational profiles are potentially
promising inputs for tumor stratification since by defini-
tion, they are likely causative events for carcinogenesis and
metastasis. However, while the mutational status of selected
single genes has been shown to be of value in various cancers
(16,55–56), unsupervised stratification using whole-exome
mutation profiles is significantly more challenging (29), and
the use of a small, computationally derived driver gene list
for this purpose has not been demonstrated before. As a
first, pilot exploration of this concept, we tested the utility of
OncoIMPACT’s predictions for stratifying patients accord-
ing to their survival outcomes. Specifically, we used unsu-
pervised consensus clustering usingNMF to cluster patient-
specific driver mutational profiles. Despite the sparseness of
mutational profiles and the use of only a subset of genes
containing predicted driver mutations (307 and 183 genes
for Glioblastoma and Ovarian Cancer, respectively), we ob-
tained robust clustering of patients (Figure 5a). In addition,
we found that most clusters are defined by a few key driver
genes that are predominantly mutated in tumors belonging
to that cluster and serve to distinguish them from tumors in
other clusters (Figure 5a).
Evaluation of survival outcomes for patients in these clus-
ters using Kaplan–Meier statistics suggested that the clus-
ters carry significant prognostic value for survival (Figure
5b). For example, for Glioblastoma, cluster 4 has a mean
survival time of 7.3 months compared to cluster 5 with
a mean survival time of 18.4 months. Further analysis of
these prognostic driver mutation signatures suggested that
a smaller subset of them (using as few as the top 47 and top
6 genes for Glioblastoma and Ovarian Cancer, respectively)
could contribute to the development of clinical grade signa-
tures (Supplementary Figure S16). Overall, gene signatures
selected based on driver genes also showed significantly bet-
ter prognostic value compared to similar sized subsets of
genes selected from all mutated genes, as well as single gene
classifiers (Figure 5c). Comparison with mRNA expression
profiles suggested that driver mutation-based stratification
could provide better patient survival predictive value over-
all (Supplementary Figure S17). This could also extend to
other attributes, e.g. in prostate cancer this approach suc-
cessfully clustered patients into subgroups with differential
prostate-specific antigen expression, themain biomarker for
prostate cancer (Supplementary Figure S18). In all, these
results not only highlight the promise of driver mutation
profiles to stratify patients in an unsupervised fashion, but
also indirectly confirm the quality of driver gene predictions
from OncoIMPACT.
DISCUSSION
In recent years, as the generation of high-dimensional
molecular profiling data sets has become easier, the chal-
lenge has naturally shifted toward better mining of this in-
formation. While, in principle, these data sets represent a
rich resource, their high-dimensionality entails that correla-
tions and associations are easy to find, but validating them
may not be so. In particular, cancer genomics is an area that
has benefitted from the facility of data generation and the
focus has now rightly shifted toward integrative analysis,
with driver gene identification being a key focus (57). In this
work, we show that a simple, model-based approach can re-
liably sort through the sea of passenger mutations that dot
cancer genomes (13) to nominate patient-specific drivers,
outperforming competing approaches to do so. Our bench-
marking analysis suggests that this approach is robust to
noise andworkswith small data sets, making it applicable to
a wider array of sample collections, including cell lines and
xenograft models. By being model based, our approach dis-
tinguishes itself from others in that it can (i) provide insights
into the mechanisms by which putative drivers act and (ii)
enable integration of diverse molecular profiles. For exam-
ple, phospho-proteomic, microRNA and methylation pro-
filing can provide valuable additional information about tu-
mor biology and can naturally be integrated into OncoIM-
PACT’s model as new perturbations, genes and mutations,
respectively.
The ability to make patient-specific driver predictions
open up new avenues in personalized medicine and targeted
cancer therapy.Our validation results suggest thatOncoIM-
PACT is the first method to make robust and verifiable
patient-specific driver gene predictions. As a proof of prin-
ciple, using genomic profiling of melanoma samples and a
patient-derived cell line, we provide evidence that a compu-
tational approach, such as OncoIMPACT, combined with
clinical genome sequencing can help identify personalized
therapeutic targets. This is an exciting area for further work,
including in the development of gold standard data sets for
benchmarking, and further validation to bring this vision
closer to clinical practice.
Additionally, our analysis of OncoIMPACT’s patient-
specific driver predictions revealed new biological insights,
including the clustering of driver mutations on the network
for each patient, suggesting that multiple hits may be re-
quired to significantly deregulate a pathway for oncogene-
sis. These observations support a model where there is sub-
stantial functional redundancy between genes, giving rise to
robust cellular networks. They also suggest an additional
aspect to the multiple-mutation theory of carcinogenesis
(58), where the functional relationship of potential driver
genes (reflected by their proximity in the molecular net-
work) may be another determining factor for progression
to cancer. Further work will be needed to explore and con-
firm this hypothesis, particularly through single tumor cell
profiling to eliminate the caveat that the identified drivers
mutations may not have occurred in the same cell.
A surprising observation from our co-driver analysis
was the lower number of co-drivers found in melanoma
and bladder cancer compared to glioblastoma, ovarian and
prostate cancer. As our statistical analysis is influenced by
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Figure 5. Tumor stratification using predicted driver gene profiles. (a)Heatmaps depicting consistency of clustering (fraction of bootstrap replicates inwhich
patients clustered together) for predicted driver gene mutational profiles (binary 0–1 vectors) using NMF. (b) Survival profiles of glioblastoma and ovarian
cancer patients stratified by consensus clustering in (a). (c) Box plots showing the distribution of P-values (log rank test) for survival profiles of random
subsets of glioblastoma (sample size 275) and ovarian cancer (sample size 250) patients, clustered into the same number of groups using different gene
signatures (OncoIMPACT predicted driver genes; DriverNET predicted driver genes; Randomly selected sets of genes of the same size as OncoIMPACT
predicted drivers; Randomly selected single genes).
the frequency of driver genes, it is not clear if this obser-
vation can be solely attributed to the biological differences
in specific cancer types. In addition, as co-drivers can more
easily emerge from a single CNV event, this could partially
explain the imbalance in the number of co-drivers observed
in various cancer types. This question deserves further in-
vestigation through the analysis of additional cancer types.
Given that mutations in driver genes are the putative
underlying causes for tumorigenesis and have been shown
to hold strong prognostic value individually (59), driver
gene prediction-based tumor stratification has been sur-
prisingly difficult and elusive. While individual genes are
useful for prognostication, a more comprehensive panel of
driver genes for a cancer type can help capture relevant in-
teractions between drivers, without sequencing the whole
genome. In this study, we directly confirmed that tumors
can be robustly stratified into subgroups through standard
consensus clustering of digital mutational profiles restricted
to driver genes predicted by OncoIMPACT. Moreover, the
subgroups obtained exhibited significantly different sur-
vival outcomes, establishing the clinical relevance for such
a stratification and indirect validation for OncoIMPACT’s
predictions. Given that DNA-based assays can be easier to
work with, refinement of the mutational signatures identi-
fied here and validation using large, independent cohorts
can help complement the ongoing efforts to develop RNA-
based prognostic signatures (60,61).
SUPPLEMENTARY DATA
Supplementary Data are available at NAR Online.
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